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ABSTRACT 
Asthma  is  a  chronic  disease  characterised  by  variable  airflow  obstruction, 
bronchial hyperresponsiveness and airways inflammation. At an immunological 
level Th2 inflammation and the presence of activated eosinophils and mast cells 
are key features of asthma. ST2, the receptor for the novel cytokine IL-33, is 
expressed  upon  Th2  lymphocytes  and  mast  cells  but  its  role  in  clinical  and 
experimental asthma remains unclear. IL-33 has been shown to induce local and 
systemic  eosinophilia  when  administered  to  the  peritoneum  of  mice.  In  this 
thesis I have set out to test the hypothesis that the activation of mast cells by 
IL-33  acting  on  cell  surface  ST2  plays  a  critical  role  in  allergic  airways 
inflammation. 
I began by studying the function of ST2 on mast cells in vitro. I found that ST2 
was expressed at an early stage of development, and correlated closely with the 
expression of the stem cell factor receptor (c-kit), a marker present on mast 
cells from a progenitor stage. Despite this mast cells generated form ST2 gene 
deleted  mice  proliferated  and  matured  normally.  When  mast  cells  were 
activated  by  IL-33,  acting  in  an  ST2-dependent  manner,  pro-inflammatory 
cytokines and chemokines were released that have potential roles in asthma, 
specifically IL-6, IL-13, MIP-1α and MCP-1. 
To  extend  these  findings  I  looked  at  the  role  of  ST2  in  allergic  airways 
inflammation. I first optimised and validated an ovalbumin and adjuvant based 
„short‟  twelve day model of murine asthma and demonstrated that ST2 gene 
deletion results  in  attenuated eosinophilic  inflammation.  In addition  to being 
ST2 dependent it is possible that this adjuvant based short model is mast cell 
dependent, unlike longer adjuvant based models which are mast cell and ST2 
independent. Therefore I went on to study an adjuvant-free model of asthma 
which has been demonstrated to be mast cell dependent. In this adjuvant-free 
model of asthma the airway inflammation was attenuated in ST2 gene deficient 
mice compared with wild type mice, while AHR was unaffected. There was an 
associated  reduction  in  IgE  production  and  thoracic  lymph  node  recall  Th2 
cytokine responses. 3 
I  then  examined  the  effect  of  ST2  activation  in  the  lungs.  When  IL-33  was 
administered directly to the airways  of naïve mice it induced the features of 
experimental asthma. There was extensive eosinophilic inflammation within the 
lung tissue and airspaces. The Th2 cytokines IL-5 and IL-13, and the eosinophil 
chemoattractant  chemokines  eotaxin-1  and  eotaxin-2  were  detected  at 
increased  concentrations.  Significant  airways  hyperresponsiveness  was  also 
generated. Using ST2 gene deleted mice I demonstrated that these effects were 
ST2 specific. Although I have shown that mast cells are activated by IL-33 in 
vitro,  I  used  mast  cell  deficient  mice  to  demonstrate  that  the  eosinophilic 
inflammation generated by IL-33 is unaffected by the absence of mast cells. 
These data show that IL-33 can induce in the lungs the cardinal pathological 
characteristics  of  asthma,  and  that  it  appears  to  act  upstream  of  other 
important  mediators  such  as  IL-13  and  the  eotaxins.  Furthermore  the  IL-33 
receptor ST2 is required in an adjuvant free model of asthma, which is more akin 
to human disease. Placing these findings in the context of recent evidence that 
IL-33 is released by structural cells in response to damage or injury suggests that 
IL-33  may  play  a  key  role  in initiating  the  immunological  features  of  clinical 
asthma. As a consequence of this position in the hierarchy of inflammation IL-33 
offers a promising direct target for novel biological therapies in asthma. 4 
ACKNOWLEDGEMENTS 
There are a great many people who have helped and supported me during this 
work. While it is not possible to name them all I would like to extend my thanks 
to everyone no matter how small their contribution may seem.  There are of 
course some people who deserve a specific mention. 
I would like to thank Professor Eddy Liew and Professor Neil Thomson for giving 
me  the  opportunity  to  undertake  this  research  and  for  their  excellent 
supervision, providing me with advice, direction and encouragement throughout. 
I would also like to thank Dr Charles McSharry who has been like a supervisor in 
all  but  name,  from  his  support  and  guidance  on  my  first  arrival  in  the  lab, 
through  to  his  thorough  reviewing  of  my  thesis  in  the  final  days  before 
submission. I am indebted to Dr Malcolm Shepherd who played an important role 
in directing my research during the crucial final years and was always a source 
intellectual  stimulation  and  debate.  This  work  was  kindly  supported  by  a 
Research Fellowship from the Medical Research Council. 
All those working within the Immunology laboratory who have helped me during 
my time there deserve a mention.  Special thanks go  to those I  worked most 
closely  with  for  their  social  and  psychological  support,  their  many  hours  of 
physical labour, their tuition and advice, and their friendship. They are Manish 
Patel, Brian Choo-Kang, Pete Kewin and Grace Murphy. Although not forced to 
spend quite so many hours working with me, Ashley Miller, Iona Donnelly and 
Mousa Komai-Komia also deserve thanks for the same reasons. 
I  am  grateful  to  Mr.  Roderick  Ferrier  (Department  of  Pathology,  Western 
Infirmary, Glasgow) for assistance in the preparation of lung histology and to 
Professor Sarah Howie who demonstrated the intratracheal technique to us. All 
the staff within Biological Services, University of Glasgow have provided valuable 
assistance and advice throughout this work. 
I would like to thank my parents for helping me to get to a position where I had 
the opportunity and the desire to carry out this research. A very special thanks 
goes to my wife, Emma who has supported me throughout this work, particularly 
the  difficult  writing  up  phase.  She  has  shouldered  the  enormous  burden  of 5 
looking after me and our children during this time and I would not have managed 
without her help. 6 
DECLARATION 
The work presented in this thesis represents original work carried out by the 
author.  Some  of  the  work  in  this  thesis  was  performed  equally  and  in 
collaboration with Dr Peter Kewin (4.3.2 to 4.5.1 inclusive) and Dr Grace Murphy 
(5.2.1 to 5.3.3 inclusive). This thesis has not been submitted in any form to any 
other  University.  Where  reagents,  materials  or  practical  support  has  been 
provided by others, due acknowledgement has been made in the text. 7 
TABLE OF CONTENTS     
ABSTRACT ..................................................................... 2 
ACKNOWLEDGEMENTS ....................................................... 4 
DECLARATION ................................................................. 6 
TABLE OF CONTENTS ........................................................ 7 
LIST OF FIGURES............................................................ 11 
LIST OF TABLES  ............................................................. 15 
ABBREVIATIONS  ............................................................. 16 
CHAPTER 1  INTRODUCTION ............................................. 19 
1.1  Asthma  ..............................................................................  20 
1.1.1  Clinical asthma ............................................................... 20 
1.1.2  Animal models of asthma ................................................... 21 
1.1.2.1  Features of animal models  ............................................... 21 
1.1.2.2  Protocols  .................................................................... 23 
1.1.2.3  Genetic background  ....................................................... 24 
1.1.3  Cellular components of asthma ............................................ 25 
1.1.3.1  Eosinophils and IL-5 ....................................................... 25 
1.1.3.2  B lymphocytes and IgE  .................................................... 30 
1.1.3.3  Mast cells ................................................................... 31 
1.1.3.4  T lymphocytes ............................................................. 34 
Th2 inflammation ......................................................... 35 
Th2 cytokines .............................................................. 36 
Other cytokines in asthma ............................................... 38 
Regulatory T lymphocytes ............................................... 40 
1.1.3.5  Macrophages and dendritic cells ........................................ 41 
1.1.3.6  Stromal cells ............................................................... 42 
1.1.3.7  Neutrophils ................................................................. 43 
1.2  ST2 ..................................................................................  44 
1.2.1  ST2 gene and protein  ........................................................ 44 
1.2.1.1  The discovery of ST2  ...................................................... 44 
1.2.1.2  The ST2 gene and its products .......................................... 45 
1.2.1.3  ST2 regulation and expression  ........................................... 47 
T lymphocytes ............................................................. 49 
Mast cells ................................................................... 50 
1.2.2  ST2 function .................................................................. 50 
1.2.2.1  The function of ST2 in vitro ............................................. 50 8 
1.2.2.2  The function of ST2 in vivo .............................................. 51 
ST2 in asthma .............................................................. 53 
1.2.2.3  ST2 in clinical disease .................................................... 55 
ST2 in heart disease ...................................................... 55 
1.2.2.4  The search for a ligand for ST2 ......................................... 56 
1.3  Interleukin-33  .....................................................................  57 
1.3.1  IL-33 gene and protein ...................................................... 57 
1.3.1.1  IL-33 expression ........................................................... 57 
1.3.1.2  IL-33 processing ........................................................... 58 
1.3.2  IL-33 function  ................................................................. 58 
1.3.2.1  IL-33 signalling  ............................................................. 58 
1.3.2.2  IL-33 function .............................................................. 59 
1.4  Objectives .........................................................................  59 
CHAPTER 2  MATERIALS AND METHODS ............................... 61 
2.1  Reagents and buffers ............................................................  62 
2.2  Animals .............................................................................  63 
2.3  In vivo procedures ...............................................................  64 
2.3.1  Antigen dosing procedures.................................................. 64 
2.3.1.1  Intranasal dosing .......................................................... 64 
2.3.1.2  Intratracheal dosing ...................................................... 64 
2.3.2  Induction of allergic airways inflammation .............................. 64 
2.3.3  IL-33 administration ......................................................... 65 
2.3.4  Measure of airways hyperresponsiveness ................................. 65 
2.3.5  Sample collection and preparation  ........................................ 66 
2.3.5.1  Serum ....................................................................... 66 
2.3.5.2  Bronchoalveolar lavage  ................................................... 66 
2.3.5.3  Lung and lymph node collection ........................................ 67 
2.3.5.4  Bone marrow collection .................................................. 67 
2.3.6  In vitro culture ............................................................... 67 
2.3.7  Cell lines ...................................................................... 68 
2.3.8  Bone marrow mast cell culture ............................................ 68 
2.3.9  IL-33 stimulation ............................................................. 68 
2.3.10  Lymph node culture ......................................................... 69 
2.4  Assays and analysis  ...............................................................  69 
2.4.1  Flow cytometry [FACS] ...................................................... 69 
2.4.2  Cytokine immunoassay ...................................................... 71 
2.4.3  Ovalbumin-specific immunoassay.......................................... 72 
2.4.4  Multiplexed immunoassay .................................................. 73 
2.4.5  Mast cell degranulation assay .............................................. 74 
2.4.6  Lung lavage analysis ......................................................... 74 
2.4.7  Lung histology ................................................................ 76 
2.5  Statistics............................................................................  76 9 
CHAPTER 3  THE ROLE OF MAST CELL ST2 AND THE EFFECT OF 
ACTIVATION BY IL-33 ................................................. 78 
3.1  Introduction .......................................................................  79 
3.2  The role of ST2 on human and murine mast cell lines ....................  79 
3.2.1  IL-33 induces cytokine production by human HMC-1 cells ............. 80 
3.2.2  IL-33 induces cytokine production by murine P815 cells  ............... 85 
3.3  Bone marrow derived mast cell culture .....................................  89 
3.3.1  Bone marrow mast cell maturation ....................................... 89 
3.3.2  Expression of ST2 on bone marrow mast cells ........................... 92 
3.4  ST2 deficient bone marrow mast cells .......................................  97 
3.4.1  Growth and maturation of mast cells lacking ST2 ...................... 97 
3.4.2  Function of mast cells lacking ST2 .......................................  101 
3.5  The effect of IL-33 on bone marrow mast cells .......................... 103 
3.5.1  The effect of IL-33 on wild type mast cells .............................  103 
3.5.2  The need for ST2 in the mast cell response to IL-33 ..................  105 
3.6  Conclusions ...................................................................... 107 
CHAPTER 4  THE ROLE OF ST2 IN  MURINE MODELS OF ASTHMA 112 
4.1  Introduction ..................................................................... 113 
4.2  Developing a murine model of asthma ..................................... 114 
4.2.1  Induction of allergic airways inflammation in a 28 day model .......  114 
4.2.2  Intranasal versus intratracheal dosing ...................................  119 
4.2.3  Validation of BAL differential cell counts ...............................  121 
4.2.4  Pooled versus individual LN culture ......................................  123 
4.2.5  Establishing a method to measure airways hyperresponsiveness ....  125 
4.3  Establishing a twelve day model of asthma ............................... 127 
4.3.1  Features of asthma can be induced using a twelve day model ......  127 
4.3.2  Dose response to ovalbumin challenge in the twelve day model ....  130 
4.3.3  Validation of a twelve day model ........................................  132 
4.4  Cytokines and chemokines in the twelve day model .................... 139 
4.4.1  Kinetics of airways inflammation following multiple challenges ....  139 
4.4.2  Kinetics of airways inflammation following a single challenge ......  149 
4.5  The role of ST2 in murine asthma models  ................................. 153 
4.5.1  The effect of ST2 gene knock-out in the twelve day model  ..........  153 
4.5.2  Establishing an alum-free model of asthma  .............................  158 
4.5.3  The role of ST2 in an alum-free model of asthma .....................  165 
4.6  Conclusions ...................................................................... 174 
CHAPTER 5  THE EFFECT OF IL-33 IN THE AIRWAYS  ...............  180 
5.1  Introduction ..................................................................... 181 10 
5.2  The effect of IL-33 on airways inflammation ............................. 181 
5.2.1  The effect of intranasal IL-33 .............................................  182 
5.2.2  Kinetics during serial IL-33 administration ..............................  185 
5.2.3  Kinetics following IL-33 administration ..................................  191 
5.2.4  A three dose protocol for the study of IL-33 in C57Bl/6 mice  ........  196 
5.2.5  The effect of IL-33 in BALB/c mice ......................................  199 
5.2.6  The role of ST2 in IL-33 induced inflammation .........................  201 
5.3  The effect of IL-33 on airways hyperresponsiveness  .................... 204 
5.3.1  Airways hyperresponsiveness following three doses of IL-33 .........  204 
5.3.2  Airways hyperresponsiveness following seven doses of    IL-33 ......  206 
5.3.3  Study of the seven day protocol in BALB/c and C57Bl/6 mice .......  208 
5.4  The role of mast cells in the response to IL-33  ........................... 210 
5.4.1  Strain differences in bone marrow mast cell development  ...........  210 
5.4.2  Strain differences in the effect of IL-33 on mast cells ................  212 
5.4.3  The role of mast cells in the response to intranasal IL-33 ............  214 
5.5  Conclusion ....................................................................... 216 
CHAPTER 6  GENERAL DISCUSSION ....................................  219 
6.1  Summary of results  ............................................................. 220 
6.2  The cellular source of IL-33 .................................................. 221 
6.3  Cellular targets of IL-33 ....................................................... 224 
6.4  The role of IL-33 in airways inflammation................................. 226 
6.4.1  IL-33 at sensitisation .......................................................  226 
6.4.2  IL-33 at challenge  ...........................................................  228 
6.5  IL-33 in clinical asthma  ........................................................ 230 
6.6  Future work ..................................................................... 231 
6.7  Conclusions ...................................................................... 233 
REFERENCES  ................................................................  234 
 11 
LIST OF FIGURES 
Chapter 1 
Figure 1.1 - Schematic representation of the human ST2 gene .................... 46 
Chapter 2 
Figure 2.1 – Cytospin preparation of murine bronchoalveolar lavage ............. 75 
Figure 2.2 – Power calculation for the sample size required in experimental 
asthma  ........................................................................ 77 
Chapter 3 
Figure 3.1 – IL-33 induces TNFα production by HMC-1 cells  ......................... 82 
Figure 3.2 – IL-33 does not induce IL-5 or eotaxin production by HMC-1 cells ... 83 
Figure 3.3 – IL-33 induced TNFα production by HMC-1 cells is dose dependent  .. 83 
Figure 3.4 - IL-33 induces the production of cytokines and chemokines by HMC-1 
cells  ........................................................................... 84 
Figure 3.5 - IL-33 induced MIP-1α production by HMC-1 cells is dose dependent 84 
Figure 3.6 – P815 cells are ST2 positive ................................................ 87 
Figure 3.7 – IL-33 induces the release of TNFα and IL-6 from P815 cells ......... 88 
Figure 3.8 - Mature mast cells express FcεRIα and c-kit  ............................. 91 
Figure 3.9 - The expression of FcεRIα and c-kit on mast cells increase with 
culture time ................................................................. 91 
Figure 3.10 – The expression of ST2 on mast cells increases with culture time  .. 93 
Figure 3.11 – The expression of c-kit and FcεRIα differs according to the 
expression of ST2 ........................................................... 94 
Figure 3.12 - The expression of ST2 differs according to the expression of c-kit 
and FcεRIα ................................................................... 95 
Figure 3.13 – The expression of ST2 correlates with the expression of c-kit ..... 96 
Figure 3.14 - FcεRIα and c-kit expression is unaffected by the absence of ST2.. 99 
Figure 3.15 - ST2 gene knockout does not affect BMMC numbers .................  100 
Figure 3.16 - ST2 gene knockout does not affect mast cell degranulation ......  102 
Figure 3.17 - IL-33 induces cytokine and chemokine release from BMMCs  .......  104 
Figure 3.18 - IL-33 induced cytokine and chemokine production by BMMCs is ST2 
dependent ..................................................................  106 12 
Chapter 4 
Figure 4.1 – A 28 day model of asthma induces pulmonary eosinophilia .........  116 
Figure 4.2 – A 28 day model of asthma induces antigen specific immunoglobulins
 ...............................................................................  117 
Figure 4.3 - A 28 day model of asthma induces antigen specific Th2 lymphocytes
 ...............................................................................  118 
Figure 4.4 – Intratracheal OVA administration is not superior to intranasal 
administration  ..............................................................  120 
Figure 4.5 – BAL differential cell counts are reproducible .........................  122 
Figure 4.6 – Individual lymph node culture provides additional information ....  124 
Figure 4.7 - Airways hyperresponsiveness can be measured by Penh  .............  126 
Figure 4.8 - The twelve day model of asthma........................................  128 
Figure 4.9 – BAL eosinophilia is induced by a twelve day asthma protocol ......  129 
Figure 4.10 - BAL cell content related to OVA challenge dose ....................  131 
Figure 4.11 – The twelve day model of asthma induces airways 
hyperresponsiveness  .......................................................  134 
Figure 4.12 - The twelve day model of asthma induces lung eosinophilia .......  135 
Figure 4.13 - The twelve day model of asthma induces lung eosinophilia .......  136 
Figure 4.14 - The twelve day model of asthma induces antigen specific 
immunoglobulins ...........................................................  137 
Figure 4.15 - The twelve day model of asthma induces antigen specific Th2 
lymphocytes ................................................................  138 
Figure 4.16 – A time course study of the twelve day asthma model ..............  142 
Figure 4.17 - Eosinophil numbers increase with time during challenge ..........  143 
Figure 4.18 – BAL cytokine and chemokine concentrations change throughout the 
challenge period ...........................................................  144 
Figure 4.19 - Airways eosinophilia correlates with local eotaxin-2 concentrations
 ...............................................................................  145 
Figure 4.20 – Serum cytokine and chemokine concentrations change throughout 
the challenge period ......................................................  146 
Figure 4.21 - Serum IgE titres are unaffected by intranasal antigen challenge .  147 
Figure 4.22 – Th2 cytokines and eotaxins are produced by draining lymph node 
cells  ..........................................................................  148 
Figure 4.23 – A time course study of the twelve day asthma model ..............  151 
Figure 4.24 – A single airways challenge induces eosinophilia and Th2 cytokines
 ...............................................................................  152 13 
Figure 4.25 - ST2 gene knockout attenuates airways inflammation ..............  155 
Figure 4.26 –ST2 gene knockout does not affect BAL and serum cytokine and 
chemokines .................................................................  156 
Figure 4.27 - ST2 gene knockout does not affect draining lymph node responses
 ...............................................................................  157 
Figure 4.28 – Two alum-free models of asthma  ......................................  161 
Figure 4.29 – BAL eosinophilia is generated in the absence of alum  ..............  162 
Figure 4.30 – Airways hyperresponsiveness is generated in the absence of alum
 ...............................................................................  163 
Figure 4.31 – Antigen specific IgE is generated in the absence of alum  ..........  163 
Figure 4.32 - Histological inflammation is induced in the absence of alum .....  164 
Figure 4.33 - BAL eosinophils are reduced in ST2
-/- mice in the absence of alum
 ...............................................................................  167 
Figure 4.34 – Tissue eosinophilia is reduced in ST2
-/- mice in the absence of alum
 ...............................................................................  168 
Figure 4.35 - Airways hyperresponsiveness is preserved in ST2
-/- mice ..........  169 
Figure 4.36 – BAL cytokines and chemokines are not significantly altered in ST2
-/- 
mice .........................................................................  170 
Figure 4.37 – Serum cytokines and chemokines are not significantly altered in 
ST2
-/- mice ..................................................................  171 
Figure 4.38 – Antigen specific IgE is reduced in ST2
-/- mice in the absence of alum
 ...............................................................................  172 
Figure 4.39 – Lymph node Th2 cytokines are reduced in ST2
-/- mice in the 
absence of alum ...........................................................  173 
Chapter 5 
Figure 5.1 – Intranasal IL-33 induces BAL eosinophilia ..............................  183 
Figure 5.2 – Intranasal IL-33 induces inflammation within the lung ..............  184 
Figure 5.3 – Intranasal IL-33 induces BAL cytokines and chemokines  .............  184 
Figure 5.4 – Protocol for studying the kinetics of the response to IL-33 .........  187 
Figure 5.5 - Eosinophils rise with successive IL-33 doses ...........................  188 
Figure 5.6 - Change in BAL cytokines and chemokines with repeated IL-33 dosing
 ...............................................................................  189 
Figure 5.7 - Change in serum cytokines and chemokines with repeated IL-33 
dosing  ........................................................................  190 
Figure 5.8 – Protocol for studying the kinetics following four doses of IL-33  ....  193 14 
Figure 5.9 – Change in BAL cell numbers with repeated IL-33 dosing ............  193 
Figure 5.10 - Change in BAL cytokines and chemokines with repeated IL-33 
dosing  ........................................................................  194 
Figure 5.11 - Change in serum cytokines and chemokines with repeated IL-33 
dosing  ........................................................................  195 
Figure 5.12 – Final protocol for intranasal IL-33 administration  ...................  197 
Figure 5.13 – BAL eosinophilia is induced by the modified IL-33 administration 
protocol .....................................................................  197 
Figure 5.14 –Lung Inflammation is induced by the modified IL-33 administration 
protocol .....................................................................  198 
Figure 5.15 – IL-33 induces airways eosinophilia in BALB/c mice .................  200 
Figure 5.16 – IL-33 induced BAL eosinophilia is ST2 specific .......................  202 
Figure 5.17 – IL-33 induced lung inflammation is ST2 specific  .....................  203 
Figure 5.18 – IL-33 induces a trend towards AHR in BALB/c but not C57Bl/6 mice
 ...............................................................................  205 
Figure 5.19 – IL-33 induces significant AHR in BALB/c but not C57Bl/6 mice ...  207 
Figure 5.20 – IL-33 induced inflammation is equal in BALB/c and C57Bl/6 mice209 
Figure 5.21 – C57Bl/6 BMMCs mature more rapidly than those from BALB/c mice
 ...............................................................................  211 
Figure 5.22 – C57Bl/6 BMMCs are more responsive to IL-33 than those from 
BALB/c mice ................................................................  213 
Figure 5.23 – IL-33 induced inflammation is unaffected by mast cell deficiency.
 ...............................................................................  215 
Chapter 6 
Figure 6.1 – Two pathways of pathogen-associated molecular pattern (PAMP) 
activation ...................................................................  227 
Figure 6.2 – The release of IL-33 as an „alarmin‟ inducing the features of asthma
 ...............................................................................  230 
 15 
LIST OF TABLES 
Chapter 1 
Table 1.1 - Studies on the requirement for IL-5 in experimental asthma  ......... 27 
Table 1.2 – The effect of mast cell deficiency on the outcomes of experimental 
asthma.  ....................................................................... 34 
Table 1.3 – Studies on the requirement for IL-4 in experimental asthma  ......... 37 
Table 1.4 - Studies on the requirement for IL-13 in experimental asthma ....... 38 
Table 1.5 – Tissues and cells in which ST2 expression has been detected ........ 48 
Chapter 2 
Table 2.1 – List of commonly used buffers and solutions  ............................ 62 
Table 2.2 – FACS antibodies  .............................................................. 70 
Table 2.3 – Samples used in FACS compensation ..................................... 70 
Table 2.4 – ELISA antibodies and concentrations ..................................... 71 
Chapter 3 
Table 3.1 – Mediators released by IL-33 treated mast cells: comparison with 
published data .............................................................  109 
Chapter 4 
Table 4.1 – The effect of ST2 gene deletion in experimental asthma ............  158 
 16 
ABBREVIATIONS 
-/-  gene deleted mouse 
7-AAD  7-amino-actinomycin D 
AHR  airways hyperresponsiveness 
alum  aluminium hydroxide  
ANP  atrial natriuretic peptide 
AP-1  activator protein-1 
APC  allophycocyanin 
BAL  bronchoalveolar lavage 
BMMC  bone marrow derived mast cell 
BNP  brain natriuretic peptide 
Bq  becquerel 
BSA  bovine serum albumin 
CBMCs  cord blood derived mast cell 
CD  clusters of differentiation 
(c)DNA  (complementary) deoxyribonucleic acid 
CCL  CC chemokine ligand 
CCR  CC chemokine receptor 
CSF  cerebrospinal fluid 
CXCL  CXC chemokine ligand 
DAMP  damage-associated molecular patterns 
DC  dendritic cell 
ECP  eosinophil cationic protein  
EDN  eosinophil-derived neurotoxin  
ELISA  enzyme linked immunosorbant assay 
EPO  eosinophil peroxidase 
FACS  fluorescence-activated cell sorting 
Fc  fragment crystallizable [region] 
FCS  foetal calf serum 
FEV1  forced expiratory volume in 1 second 
FGF  fibroblast growth factor 
FITC  fluorescein isothiocyanate 
GFP  green fluorescent protein 
GM-CSF  granulocyte-macrophage colony-stimulating factor 
HDM  house dust mite 
HEV  high endothelial venule 17 
HMGB1  high mobility group box 1 
HRP  horseradish peroxidase 
HTH  helix-turn-helix 
IFN  interferon 
Ig  immunoglobulin 
IL  interleukin 
IMDM  Iscove's modified Dulbecco's medium 
IN  intranasal 
iNKT  invariant natural killer T [cell] 
IP  intraperitoneal  
IP-10  interferon-gamma-induced protein (CXCL10) 
IRAK  IL1 receptor-associated kinase 
IT  intratracheal 
IV  intravenous 
JNK  c-Jun N-terminal kinase 
KC  keratinocyte chemoattractant (CXCL1) 
LPS  lipopolysaccharide 
MAP  mitogen-activated protein 
MBP  major basic protein  
MCP-1  monocyte chemotactic protein-1 (CCL2) 
MI  myocardial infarction 
MIG  monokine induced by gamma interferon (CXCL9) 
m/hIL-33  murine/human recombinant IL-33 
MIP-1  macrophage inflammatory protein-1 (CCL3) 
(m)RNA  (messenger) ribonucleic acid 
MyD88  myeloid differentiation primary response gene (88) 
NAG  N-acetyl-β-d-glucosamine  
NBF  neutral buffered formalin  
NF-HEV  nuclear factor from high endothelial  
NFκB  nuclear factor kappa-light-chain-enhancer of activated B 
cells 
Ni-NTA  nickel-nitrilotriacetic acid 
NK  natural killer [cell] 
NLR  NOD-like receptor 
NOD  nucleotide-binding oligomerization domain 
OVA  ovalbumin 
PaCO2  partial pressure (arterial) of carbon dioxide 
PAMP  pathogen-associated molecular pattern 18 
PBS  phosphate buffered saline 
PE  phycoerythrin 
Penh  enhanced pause 
PMA  phorbol 12-myristate 13-acetate 
RAG  recombinase-activating gene 
RAGE  receptor for advanced glycation end products 
RANTES  regulated upon activation normal T cell expressed and 
secreted (CCL5) 
RPE  R-phycoerythrin 
RPMI  Roswell Park Memorial Institute 
RT-PCR  reverse transcription polymerase chain reaction 
SCF  stem cell factor 
SCID  severe combined immunodeficiency 
SEM  standard error of the mean 
SLE  systemic lupus erythematosus 
SNP  single-nucleotide polymorphism 
sST2  soluble ST2 
ST2L  membrane bound 'long' ST2 
STAT  signal transducers and activator of transcription 
TARC  thymus- and activation-regulated chemokine (CCL17) 
TCA3  T-cell activation-3 (CCL1) 
TcR  T cell receptor 
TGFβ  transforming growth factor beta 
Th  T helper [cell] 
TLR  toll-like receptor 
TMB  tetramethylbenzidine 
TNFα  tumor necrosis factor alpha 
Tr1  T regulatory cell type 1 
TReg  regulatory T cell 
VEGF  vascular endothelial growth factor 
WT  wild type 
w/v  weight/volume 
 
  
 
 
 
 
 
 
Chapter 1   
 
Introduction 
 Chapter 1:  20 
1.1 Asthma 
1.1.1 Clinical asthma 
Asthma  is  a  cause  of  significant  morbidity  and  mortality  and  is  estimated  to 
affect 300 million people worldwide, with increasing prevalence(1). Asthma is 
defined clinically by the presence of variable airflow obstruction and symptoms, 
namely wheeze, breathlessness, chest tightness or cough. Physiologically airways 
hyperresponsiveness (AHR) and airway inflammation are cardinal features(2,3). 
The nature of the immune response in asthma will be discussed in more detail 
later, but is generally characterised by eosinophilic inflammation. The mainstay 
of  treatment  is  with  bronchodilators  plus  inhaled,  and  in  more  refractory 
asthma, oral corticosteroids. 
While  some  patients  have  chronic  stable  disease  of  varying  severity, 
exacerbations can also be a feature. Clinically exacerbations present as an acute 
worsening of symptoms and airflow obstruction for a period of hours or days and 
represent the commonest reason for hospital admission in asthmatic patients. 
This airflow obstruction is a result of smooth muscle contraction, airway oedema 
and mucus plugging(4). While exacerbations can be triggered  by a number of 
factors  including allergens,  irritants  and  stress,  the commonest  cause is  viral 
infection(5).  Despite  this  association,  studies  have  shown  that  in  those  with 
eosinophilic inflammation targeting asthma treatment based on the extent of 
eosinophilia rather than symptoms reduces exacerbation rates(6). 
Asthma  can  be  associated  with  structural  airway  changes  including  smooth 
muscle hypertrophy and thickening of the epithelial basement membrane(7) and 
some  patients  with  asthma  develop  gradually  worsening  lung  function  over 
time(8,9). While it is assumed that the latter is a consequence of the former this 
is not yet conclusively proven, as disease severity does not always correlate with 
measures of remodelling(10-14). 
Although defined clinically by the presence of variable airflow obstruction and 
appropriate  symptoms,  asthma  is  a  heterogeneous  disease  and  there  is 
increasing interest in characterising different phenotypes. There is a wide range 
of overlapping descriptions, many of which are based on the clinical course and Chapter 1:  21 
response  to  treatment.  They  include  the  most  widely  used  severity 
classifications(2,3) and other subgroups such as difficult asthma, severe asthma, 
refractory asthma, brittle asthma and steroid-resistant asthma(2,15,16). Another 
way of classifying asthma is according to pathophysiology, one of the oldest such 
distinctions being that of atopic (extrinsic) or non-atopic (intrinsic) asthma first 
described in the 19
th century(17). Atopic asthma is characterised by positive skin 
testing or elevated serum IgE antibody for common allergens. The age of onset is 
usually earlier than in non-atopic asthma and there is often a positive family 
history as well as other co-existing atopic disease such as hay fever or eczema. It 
is thought that 70-90% of asthmatic patients have atopic asthma(18,19). While 
originally  considered  as  two  distinct  entities  the  nature  of  the  airway 
inflammation in both atopic and non-atopic asthma is almost identical and there 
is  evidence  of  elevated total  serum  IgE or  local  IgE  production  in  non-atopic 
asthma.  This  has  led  to  the  hypothesis  that  there  may  be  no  fundamental 
immunopathological  distinction  between  the  two  subsets(18,19).  At  present 
there is considerable clinical interest in the distinction between eosinophilic and 
non-eosinophilic asthma, the later being characterised by a high proportion of 
neutrophils in the airways, histological differences and a relative resistance to 
steroid therapy(20). 
1.1.2 Animal models of asthma 
In parallel with human studies animal models provide an important tool in the 
study  of  mechanisms  of  asthma(21-23).  It  is  necessary  to  recognise  the 
limitations of such models and to use them for hypothesis-generating and testing 
with the clear intention of translational purposes. 
Mice [Mus musculus] are the species used most frequently to model asthma for a 
number  of  reasons  including  the  extensive  knowledge  of  the  murine  immune 
system, the availability of reagents and genetically manipulated animals as well 
as the practical advantages of working with small mammals. 
1.1.2.1  Features of animal models 
It is generally accepted that the cardinal features required of a model of asthma 
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The simplest method of measuring eosinophilic inflammation is to quantify the 
number  of  eosinophils  within  the  airway  lumen,  which  can  be  sampled  by 
performing  a  bronchoalveolar  lavage  (BAL).  Although  investigators  have  used 
flow cytometry to quantify eosinophils(24), using standard microscopy to identify 
and count Romanovsky stained cells remains the gold standard. It can also be 
useful  to  measure  the  changes  that  occur  within  the  lung  parenchyma.  Most 
commonly histological lung sections are stained and examined by microscopy. 
This  allows  inflammation  to  be  assessed  and  can  demonstrate  other 
abnormalities, such as early perivascular changes and one of the other major 
features of asthma, mucus productions and associated goblet cell hyperplasia. 
The study of lung sections remains subjective and can be misleading when the 
changes are not homogenously distributed throughout the lungs. Scoring systems 
reduce the subjectivity but can be very labour intensive(25). One alternative is 
to  quantify  the  eosinophils  within  the  lung  tissue  by  performing  digests  and 
counting individual stained cells counted by microscopy(26), however this results 
in the loss of the other information available on histology and is therefore rarely 
undertaken. 
More problematic than the assessment of inflammation is the measurement of 
AHR, which relies on assessing bronchoconstriction in response to a provoking 
agent.  The  currently  accepted  best  parameter  in  humans  is  FEV1  which  is  a 
measure  of  airflow  during  a  forced  expiratory  manoeuvre.  This  is  effort 
dependent  and  requires  patient  co-operation  and  the  use  of  a  tight  fitting 
mouthpiece,  neither  of  which  are  possible  in  mice.  The  classical  solution, 
developed in 1988, has been to intubate anaesthetised mice via tracheostomy, 
artificially ventilate them and then measure pulmonary resistance (RL) to airflow 
and dynamic compliance (Cdyn), a measure of lung stiffness(27). This method is 
accepted as the gold standard and gives very reproducible results, but requires 
considerable time and technical expertise(28). Alternatively lung function can be 
measured non-invasively using whole body plethysmography(29). Although there 
have been some reservations regarding this technique(28,30) it remains widely 
used by those working with asthma models and correlates well with the more 
technically demanding invasive measurements(29,31-34). 
Airway remodelling is a feature of asthma models that becomes evident with 
increasing  duration  of  antigen  challenge.  In  models  of  chronic  asthma,  using Chapter 1:  23 
more sustained challenge protocols, it is possible to induce features of airway 
remodelling,  specifically  extra-cellular  matrix  deposition  and  an  increase  in 
airway smooth muscle mass(35-38). 
1.1.2.2  Protocols 
The most common way of inducing experimental asthma is to employ a method 
of antigen sensitisation followed by local antigen challenge, although protocols 
which utilise cell transfer, gene manipulation or viral infection do exist. 
The  antigen  used  can  range  from  complex  microorganisms,  such  as 
Aspergillus(39) and Schistosoma(40), to simple proteins. However, due to the 
problems  with  consistency  of  dosing,  handling  and  preparation  of  complex 
micro-organisms  most  investigators  choose  to  use  soluble  purified  proteins  or 
extracts. 
The majority of antigen based models use chicken egg ovalbumin (OVA), which is 
a useful experimental antigen available in a highly purified form, with a known 
epitope structure and available antibody and T cell receptor transgenic mice. 
Sensitising mice using OVA and alum adjuvant can induce IgE and Th2 responses 
and  has  been  demonstrated  to  induce  pulmonary  eosinophilia  and  AHR  upon 
subsequent airways challenge with OVA. While less well studied there is also 
interest in antigens with direct relevance to clinical asthma, such as cockroach 
antigen(41) and house dust mite extract(38,42). House dust mite antigens have 
specific properties which may be important in their pathophysiology, including 
intrinsic  protease  activity(43)  and  possibly  an  ability  to  modulate  TLR 
signalling(44). 
Even among the models that utilise OVA there is considerable variation in the 
exact protocol used, with differences in dose, timing, route of administration 
and use of adjuvants(21). While subcutaneous, transcutaneous, intrapulmonary 
and intravenous sensitisations have been used, generally an intraperitoneal (IP) 
administration is employed. This is felt to deliver a systemic dose of antigen in a 
convenient and reproducible manner. The most popular methods of challenge 
are  via  direct  intratracheal  or  intranasal  administration  or  via  nebulisation. 
While there are likely to be differences in the actual dose delivered they will all 
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evidence that any method is superior and consequently the choice often falls to 
investigator experience and preference. 
Human vaccines generally employ adjuvants to boost the immune response to 
administered antigens, and the same technique is often used in a wide variety of 
animal models of allergic and autoimmune disease. Aluminium salts (alum) have 
been used in human vaccines since 1926(45), and remain by far the most widely 
used(46). Alum is also the most commonly used adjuvant in murine models of 
asthma,  in  part  due  to  the  fact  that  it  is  a  strong  inducer  of  Th2 
responses(47,48). 
The number of challenges employed and the duration of the model can also have 
an impact on the pathological changes seen. Models as short as 12 days(49) or 
models utilising only a single airways challenge(42) have been shown to induce 
IgE  production,  pulmonary  eosinophilia  and  AHR.  Models  designed  to 
demonstrate  the  features  of  airway  remodelling  tend  to  require  multiple 
repeated challenges over a period of around two months(35-37). 
While the various different models used all generate the required features of 
experimental  asthma,  these  protocol  differences  can  affect  the  apparent 
contribution  of  different cells,  cytokines  and  pathways,  as  will  become  clear 
later in this introduction. It is generally accepted that the best protocols for 
achieving  a  robust  Th2  dependent  model  in  which  pulmonary  eosinophilia, 
antigen-specific  IgE  and  AHR  are  generated  are  those  using  BALB/c  mice 
sensitised with antigen in adjuvant followed by multiple airways challenges over 
a total period of around four weeks(21). 
1.1.2.3  Genetic background 
While  the  majority  of  investigators  use  BALB/c  mice  in  the  study  of  asthma 
others strains are also used, most frequently C57Bl/6 mice which are often the 
background on which gene knock-out and transgenic animals are generated. It is 
well established that while experimental asthma can be induced in BALB/c and 
C57Bl/6 mice there are differences between the strains. While the extent of 
pulmonary eosinophilia generated does not vary greatly, the magnitude of the 
IgE  is  response  is  reduced  in  C57Bl/6  mice(50-52).  AHR  also  varies  between 
different  strains  of  mice,  with  airways  responsiveness  in  naïve  BALB/c  mice Chapter 1:  25 
greater  than  in  C57Bl/6  mice(50,53).  There  is  a  similar  trend  in  models  of 
asthma, with some protocols unable to generate AHR in C57Bl/6 mice(21,50,54). 
It has been suggested that these two strains may rely on different pathways for 
the generation of AHR, possibly due to functional differences in mast cells(55), 
including a deficiency in mast cell protease 7 in C57Bl/6 mice(56). 
1.1.3 Cellular components of asthma 
As  early  as  1864  Henry  Salter  recognised  the  importance  of  inflammation  in 
asthma; “The inflammation or congestion of the mucous surface appears to be 
the stimulus that, through the nerves of the air tubes, excites the muscular wall 
to contract”, as well as ascribing a role to extrinsic “irritants”(17). Since then a 
great  deal  has  been  learnt  about  immunology  and  asthma,  but  the  role  of 
different  inflammatory  cells  and  mediators  in  the  pathogenesis  of  asthma 
remains hotly debated. 
1.1.3.1  Eosinophils and IL-5 
The eosinophil was one of the first cells to be implicated in the pathophysiology 
of asthma. Early post-mortem reports identified eosinophils and Charcot-Leyden 
crystals, later discovered to be eosinophil granule crystals, in the airway lumen 
of asthmatic patients and in some cases elevated sputum or peripheral blood 
eosinophil counts were reported(57). A century later the eosinophil remains a 
focus of interest in the study of asthma, but just how central a role it plays is 
still unresolved. 
The primary evidence implicating eosinophils in the pathogenesis of asthma is 
the association between increased eosinophil numbers and asthma. Eosinophils 
in peripheral blood are readily measured and the level of eosinophilia correlates 
with  AHR  in  response  to  methacholine(58,59)  and  in  some  cases  with 
measurements  of  airflow  resistance(59,60).  Sputum  eosinophilia  is  also  easily 
assessed and correlates with asthma severity to the extent that it can be used to 
direct treatment with corticosteroids(6,61). As initial fears over the safety of 
bronchoscopy  in  asthmatics  were  allayed(62)  reports  were  published  showing 
elevated  BAL  eosinophils  in  asthmatic  patients(63,64)  that  correlated  with 
AHR(65-67), lung function(67) and severity(68). Using bronchoscopy it was also 
possible  to  take  airway  wall  biopsies  for  histological  studies(69).  These Chapter 1:  26 
demonstrated  increased  eosinophil  numbers  within  the  airways(70,71)  which 
correlated  with  AHR  in  some  asthmatics(72)  and  showed  evidence  of 
degranulation  and  a  unique  distribution  in  asthmatics,  with  intraepithelial 
eosinophils  only  found  in  asthma(68).  Despite  this  close  association  between 
airway eosinophilia and asthma it is important to note that this finding is not 
unique to asthma. Most notably sputum eosinophilia also occurs in eosinophilic 
bronchitis,  a  condition  which  shares  the  symptom  of  cough  with  asthma  but 
without bronchoconstriction or AHR(73). 
Not only are eosinophils present in the airways of asthmatics, but they have the 
potential to contribute to the pathophysiology. Eosinophil granules contain the 
cytotoxic granule proteins major basic protein (MBP), eosinophil cationic protein 
(ECP), eosinophil peroxidase (EPO), and eosinophil-derived neurotoxin (EDN)(74). 
MBP is the most studied of the granule products in asthma and there is increased 
MBP  in  the  sputum(75)  and  lungs(76)  of  asthmatics.  Not  only  is  MBP  directly 
cytotoxic  to  respiratory  epithelial  cells(77),  but  it  can  also  induce 
bronchoconstriction in vitro(78). Eosinophil granule products can stimulate mast 
cells and basophils to release histamine(79-82). Although when the role of MBP-1 
was studied in vivo using MBP-1 gene knock-out mice there was no difference in 
eosinophilic inflammation or AHR(83). In addition to granule products eosinophils 
are also a potential source of Th2 cytokines(84-86) and may be able to drive Th2 
responses by other means(87,88). 
Despite the circumstantial evidence implicating eosinophils in the pathology of 
asthma the definitive proof is lacking. In an attempt to answer the question 
investigators have tried to study asthma in the absence of eosinophils. Since the 
discovery of IL-5 in 1985, initially named eosinophil differentiation factor(89), it 
has  been  closely  linked  with  eosinophil  function,  driving  differentiation, 
proliferation,  activation  and  recruitment(90,91).  Transgenic  mice  over-
expressing  IL-5  display  a  profound  blood  eosinophilia  with  evidence  of 
accumulation in the lungs(92). When IL-5 over-expression is induced in the lungs 
there  is  marked  eosinophilic  inflammation  with  associated  goblet  cell 
hyperplasia  and  collagen  deposition  in  addition  to  a  degree  of  spontaneous 
AHR(93). Consequently IL-5 had been targeted in models of asthma, either by 
using antibodies against IL-5 or by selective gene deletion (IL-5
-/-). The results of 
these experiments are summarised in Table 1.1. Chapter 1:  27 
Mice  Model  Method  EØ  AHR  Ref 
C57Bl/6  OVA + Alum  IL-5
-/-      (94) 
C57Bl/6  Aspergillus  α-IL-5
1    NC  (95) 
C57Bl/6  Aspergillus  IL-5
-/-    NC  (95) 
C57Bl/6  S.mansoni  α-IL-5    NC  (96) 
C57Bl/6  OVA + Alum  α-IL-5      (97) 
C57Bl/6  OVA + Alum  IL-5
-/-    
2  (97) 
BALB/c  OVA + Alum  α-IL-5    NC  (54) 
BALB/c  OVA + Alum  α-IL-5      (98) 
BALB/c  airways OVA
3  α-IL-5      (99) 
BALB/c  OVA + Alum  α-IL-5
4    NC  (100) 
BALB/c  OVA + Alum  IL-5
-/-    NC  (100) 
BALB/c  OVA + Alum  α-IL-5      (101) 
BALB/c  OVA  α-IL-5    NC  (102) 
BALB/c  OVA + Alum  IL-5
-/-    NC  (103) 
B10.BR  OVA + Alum  α-IL-5      (104) 
Table 1.1 - Studies on the requirement for IL-5 in experimental asthma 
Key –   EØ: effect on lung eosinophil numbers. AHR: effect on airways hyperresponsiveness. α-IL-
5: anti-IL-5. : reduced. NC: no change. 
Notes - (1) Mice were also B cell deficient. (2) Eosinophil transfer restored AHR. (3) Protocol 
utilising repeated antigen challenge of naïve mice. (4) Mice were also IL-4-/- 
 
While blocking the function of IL-5 by either method consistently resulted in a 
significant reduction in lung eosinophils, although notably often not complete 
loss, the effect on AHR was more variable. All models which utilised systemic 
sensitisation with OVA alone, or an alternative antigen failed to demonstrate any 
reduction  in  AHR.  In  C57Bl/6  mice  blocking  IL-5  function  in  models  utilising 
sensitisation with both OVA and alum invariably resulted in a reduction in AHR. 
The use of OVA and alum models of asthma in BALB/c mice gave more variable 
results  with  AHR  unchanged  in  some  and  completely  abrogated  in  others, 
although when IL-5 was targeted in BALB/c mice by gene deletion rather than 
antibody,  AHR  was  consistently  preserved.  In  the  few  studies  which  assessed 
other  changes  in  lung  such  as  mucus  production(97)  and  subepithelial 
fibrosis(102), these were shown to be attenuated by blocking IL-5. 
In human asthma IL-5 was among the first cytokines to be specifically targeted. 
The  value  of  this  as  an  immuno-therapeutic  target  was  due  not  only  to  the 
relationship between IL-5, eosinophils and asthma already discussed, but also 
the  finding  that  IL-5  inhalation  induced  sputum  eosinophilia  and  AHR  in 
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In 2000 a randomised double-blind placebo controlled trial of anti-IL-5 involving 
24 atopic asthmatics was published(106). Patients were given a single dose of 
anti-IL-5 antibody and were challenged with antigen one and four weeks later. 
Treatment resulted in a significant and sustained reduction in blood and sputum 
eosinophils but failed to demonstrate a difference in pre-challenge AHR or late 
asthmatic response, as measured by delayed bronchoconstriction in response to 
allergen  challenge.  On  face  value  this  suggests  a  dissociation  between 
eosinophilia and AHR. However there have been criticisms of the study, including 
concerns over the interpretation of the late asthmatic response data and the 
small number of patients studied(107). Although a subsequent similarly powered 
study  confirmed  the  reduction  of  blood  eosinophils  with  no  change  in 
measurements of AHR and lung function, it raised questions by demonstrating 
that anti-IL-5 treatment only reduced eosinophil numbers in the airway wall and 
bone  marrow  by  around  50%(108).  In  this  study  there  was  a  reduction  in 
deposition of extra-cellular matrix proteins and BAL TGFβ(109), both features 
associated with airways remodelling. 
It was not until 2007 that a larger study was conducted in which 362 patients 
with moderate asthma received 3 monthly doses of anti-IL-5(110).  Treatment 
failed  to  produce  any  clinically  relevant  improvement  in  measures  of  airflow 
obstruction  or  symptom  scores  but  did  show  a  trend  towards  a  reduction  in 
exacerbations. In light of this trend combined with an increasing understanding 
of the relationship between eosinophil levels and asthma control two further 
studies  were  carried  out,  the  results  of  which  have  just  been 
published(111,112).  Both  recruited  subjects  with  very  severe  asthma,  the 
majority  of  whom  were  on  regular  oral  steroids,  and  both  demonstrated  a 
significant  reduction  in  the  primary  end-point  of  exacerbations.  Not  only  do 
these studies suggest a role for anti-IL-5 therapy in a select group of patients, 
but they also support a pathophysiological role for IL-5 and eosinophils in asthma 
exacerbations. 
One of the caveats when drawing conclusions regarding the role of eosinophils 
from any study is the failure to completely eliminate eosinophils from the lung. 
As  discussed  above  this  has  been  a  criticism  of  the  interpretation  of  clinical 
studies of anti-IL-5 therapy, but is also a problem in the murine studies with a 
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In  an  attempt  to  address  the  role  of  eosinophils  more  directly  eosinophil 
deficient  mice  were  generated  by  two  different  groups  using  different 
approaches. The first group genetically engineered C57Bl/6 mice with diphtheria 
toxin linked to the promoter for the eosinophil granule protein EPO (PHIL mice) 
which resulted in mice in which eosinophils were almost completely absent(113). 
When  allergic  airways  inflammation  was  generated  using  OVA/Alum  in  these 
mice less than 0.5% of BAL cells were eosinophils and no eosinophils were seen in 
lung sections. Other histological changes, including goblet cell hyperplasia, were 
attenuated but not lost. AHR however was completely absent in PHIL mice. 
The  second  group,  in  a  paper  published  simultaneously,  used  the  previously 
described(114)  ΔdblGATA  mice  on  a  BALB/c  background  in  OVA/alum  driven 
acute and chronic models of asthma(115). These mice have a deletion in the 
high affinity GATA-binding site of the GATA-1 transcription factor which results 
in slightly impaired red cell production and a complete absence of circulating 
eosinophils, even if an IL-5 transgene is introduced(114). In both the acute and 
chronic models of asthma there was a complete absence of eosinophils in BAL 
and  lung  tissue  with  goblet  cell  hyperplasia  unaffected(115).  Using  these 
ΔdblGATA mice for the chronic asthma model resulted in a reduction in both 
collagen deposition and airway smooth muscle hypertrophy. In contrast to the 
findings in PHIL mice, AHR was preserved in ΔdblGATA mice. 
These  two  papers  reached  contradictory  conclusions  regarding  the  role  of 
eosinophils in AHR. In order to reconcile this discrepancy it is necessary to look 
at the different mice used. As AHR was preserved in the mice that appeared to 
have the most complete ablation of eosinophils such a difference seems unlikely 
to be responsible. One possible explanation is the genetic background, the PHIL 
mice were on a C57Bl/6 background, which appears to be more dependent on 
eosinophils  for  AHR  in  IL-5
-/-  experiments  as  discussed  above,  whereas  the 
ΔdblGATA mice were on a BALB/c background where the effect of eosinophil 
depletion on AHR is more variable. This is supported by a recent paper in which 
BALB/c and C57Bl/6 ΔdblGATA mice were compared(116). The BALB/c ΔdblGATA 
mice  had  preserved  AHR  and  histological  changes  as  previously  reported, 
whereas  the  C57Bl/6  ΔdblGATA  mice  failed  to  develop  AHR  or  show  any 
histological changes. Chapter 1:  30 
Ultimately the role of eosinophils in asthma remains unclear. In mice it appears 
that, depending on the strain and protocol, AHR can be induced in an eosinophil 
dependent or independent manner. In humans it appears that eosinophils play a 
key role in exacerbations of asthma. In addition both murine and human data 
also suggest a role for eosinophils in airway remodelling. 
1.1.3.2  B lymphocytes and IgE 
The role of external agents in provoking asthma was identified as far back as the 
nineteenth century when “extrinsic” asthma was first described (17) and many 
years  later  associations  were  made  between  asthma  and  allergy  or 
anaphylaxis(117).  Extrinsic  asthma  came  to  be  viewed  as  a  form  of  Type  I 
hypersensitivity reaction, which were later found to be mediated by a serum 
component  (118)  ultimately  identified  as  a  novel  immunoglobulin  isotype; 
IgE(119).  Mast  cells  express  the  high  affinity  IgE  receptor  (FcεRI)  and  Type  I 
hypersensitivity reactions are recognised as being mediated by the degranulation 
of  mast  cells  due  to  the  cross-linking  of  surface  bound  IgE  by  allergen(120). 
Following  the  association  between  IgE  and  hypersensitivity  elevated  levels  of 
serum IgE were detected in some asthmatic patients(121), and atopic asthma is 
now defined as being associated with elevated serum IgE antibody to common 
inhaled  allergens.  Consequently  questions  have  been  asked  regarding  the 
potential role of IgE in the pathogenesis of asthma. 
Initial  animal  studies  showed  that  the  administration  of  anti-IgE  antibodies, 
which  mimicked  allergens  by  cross-linking  surface  bound  IgE,  resulted  in 
AHR(122). Similarly the transfer of OVA-specific IgE followed by intranasal OVA 
challenge  also  resulted  in  AHR,  in  addition  to  a  modest  airways 
eosinophilia(123). When blocking anti-IgE antibodies were used in a house dust 
mite antigen model of asthma eosinophil accumulation was attenuated, although 
AHR was not measured(42). More recent studies using mice with a selective IgE 
deficiency have reached differing conclusions. In an OVA/Alum based model of 
asthma AHR and inflammation were preserved in IgE deficient mice(124), while 
in a model where naïve mice were repeatedly challenged with OVA alone IgE 
deficiency resulted in the loss of AHR and reduced inflammation(125).  Taken 
together these observations fail to provide a clear picture regarding the role of 
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In clinical asthma the use of the anti-IgE monoclonal antibody omalizumab has 
provided good evidence for the importance of IgE. Initial studies in asthmatics 
showed that as well as reducing serum IgE concentrations, omalizumab inhibited 
bronchoconstriction  in  response  to  allergen  challenge(126,127).  Subsequent 
clinical trials demonstrated that in patients with moderate to severe allergic 
asthma, treatment resulted in reduced exacerbations and symptoms and allowed 
inhaled steroid doses to be reduced(128-130). The greatest benefit appeared to 
be  in  patients  with  the  most  severe  and  poorly  controlled  asthma(131,132). 
Consequently  omalizumab  is  now  recommended  for  use  in  patients  with 
uncontrolled atopic asthma both in the UK(133) and elsewhere. 
While the need for B cells in asthma is generally considered to be as a source of 
IgE,  their  role  could  potentially  include  the  production  of  other 
immunoglobulins, antigen presentation and cytokine production. By using B cell 
deficient mice it has been possible to study the contribution of these cells to 
asthma.  As  expected  these  mice  consistently  fail  to  generate  any 
immunoglobulins, but no study has shown any difference in the development of 
typical inflammation and eosinophil accumulation within the lungs(104,134-136). 
As in IgE deficient mice, the requirement for B cells in the generation of AHR 
depends on the model used. AHR in response to OVA challenge was unaffected in 
B cell deficient mice immunised with OVA and alum(104,136). However, when 
allergic airways inflammation was generated by the repeated challenge of naïve 
mice with OVA, AHR was B cell dependent and restored by the transfer of OVA-
sepcific  IgE,  although  it  is  important  to  note  that  in  this  report  AHR  was 
measured by studying tracheal segments ex vivo(134). 
1.1.3.3  Mast cells 
While  mast  cells  were  first  identified  by  Ehrlich  in  his  doctoral  thesis  in 
1878(137) their function remained unclear for many years, although they were 
described as sentinel cells because of their location in mucosal surfaces of the 
gut, lung and skin. Since histamine was already associated with anaphylaxis(138) 
and AHR(139), the mast cell began to attract attention in the study of allergy 
and  asthma  with  the  discovery  in  1952  that  mast  cells  could  release 
histamine(140,141).  By  the  early  1970s  this  had  led  to  the  hypothesis  that 
asthma  was  a  form  of  Type  I  hypersensitivity  reaction,  with  inflammation  a Chapter 1:  32 
result of allergen triggered release of mast cell mediators via surface IgE. While 
the importance of IgE in atopic asthma discussed earlier lends support to this 
theory, IgE can interact with a number of other cells, for example to mediate 
antigen  presentation  by  dendritic  cells  and  B  cells,  or  to  activate 
eosinophils(120). Therefore more direct evidence is required for a pathogenic 
role of mast cells in asthma. 
Bronchoscopic lavage has consistently found elevated mast cell numbers from 
the airway lumen of asthmatic patients(66,70,142-144), with some evidence of 
correlation  with  airflow  obstruction(64).  Biopsy  studies  of  mast  cell  numbers 
within the wall of the airways themselves have sometimes yielded conflicting 
data.  Within  the  epithelium  there  are  reports  of  increased(145-147)  or 
unaltered(143,148) mast cells numbers, while within the submucosa mast cell 
numbers have been found to be unchanged(72,148,149) or reduced(150). Within 
the airway smooth muscle mast cell numbers are consistently elevated(151,152). 
The number of mast cells within the smooth muscle layer correlates with AHR in 
both asthmatic(151) and allergic non-asthmatic patients(153). Further evidence 
for  the  importance  of  mast  cells  in  smooth  muscle  bundles  in  asthma  is  the 
comparison  with  eosinophilic  bronchitis.  In  this  disease  there  is  eosinophilic 
inflammation and cough as in asthma but no AHR, and mast cells are not found 
within the smooth muscle bundles(151).  
Support for mast cell activation comes from the findings there is histological 
evidence  of  mast  cell  degranulation  in  the  airways  of  asthmatic 
patients(70,145,148,150,152)  and  that  BAL  histamine  levels  are  elevated  in 
symptomatic asthmatics(154). 
These reports that mast cells, which are capable of releasing a wide array of 
pro-inflammatory mediators, are present in increased numbers within asthmatic 
airways and show evidence of degranulation suggests they may play a role in 
asthma. Using W/W
v or W-sh mast cell deficient mice investigators have tried to 
establish whether or not there is a requirement for mast cells in allergic airways 
inflammation. 
While  there  had  been  a  previous  experiment  showing  no  change  in  Ascaris 
induced pulmonary eosinophilia in W/W
v mice(155), the earliest report on the 
requirement for mast cells in experimental asthma was published in 1994. Wild Chapter 1:  33 
type and W/W
v mice were immunised with OVA and alum on day 0 before being 
challenged  with  nebulised  OVA  on  days  14  to  21.  There  was  no  change  in 
histological  inflammation  but  a  small,  non-significant  reduction  in  BAL 
eosinophils(156). Three subsequent papers also failed to show any requirement 
for mast cells in the generation of airways eosinophilia. All three models utilised 
alum at sensitisation, with house dust mite(42) or OVA(157,158) as the antigen, 
and  used  protocols  between  20  and  30  days  long.    When  AHR  was  assessed 
results were inconsistent with one study demonstrating no requirement for mast 
cells(157) and another mast cell dependence(158). 
Contrasting results were obtained utilising protocols which differed from these 
more traditional models of asthma. In a short model utilising OVA and alum with 
the final challenge on day 12, BAL and histological eosinophilia was significantly 
reduced in W/W
v mice and was restored when these mice were reconstituted 
with mast cells(159). When mice were immunised with OVA and alum on days 0 
and  14  before  receiving  a  single  nebulised  OVA  challenge  on  day  28,  lung 
eosinophil accumulation was significantly reduced in W/W
v mice 48 hours later, 
although  not  at  any  of  the  four  other  time  points  studied(160).  In  another 
variant of the model mice were immunised with OVA and alum on day 0 followed 
by OVA alone on day 10 after which they were challenge with nebulised OVA on 
days  17  and  24,  resulting  in  a  significant  reduction  in  eosinophilia  in  W/W
v 
mice(161).  Once  again  the  effect  on  AHR  was  variable  with  some  showin 
depence on mast cells(161) and others independence(160). 
In 2000 Williams and Galli made a significant contribution to our understanding 
of  the  role  of  mast  cells  in  experimental  asthma  when  they  compared  the 
requirement for mast cells of two different models(162). As with most previous 
studies  they  found  that  when  mice  immunised  with  OVA  and  alum  were 
challenged lung eosinophilia was generated equally well in wild type and W/W
v 
mice.  However  when  immunised  with  OVA  without  adjuvant  eosinophilic 
inflammation was significantly reduced in W/W
v mice. The same was also true of 
AHR, which was attenuated in mast cell deficient mice only when immunised 
with OVA alone. Subsequent studies have confirmed the requirement for mast 
cells  in  alum-free  models  of  asthma  using  W-sh  as  well  as  in  W/W
v 
mice(33,37,163). Interestingly in mast cell reconstitution experiments one of the 
essential roles of mast cells in these models is as a source of TNFα (33,163). The Chapter 1:  34 
data regarding experimental asthma in mast cell deficient mice is summarised in 
Table 1.2. 
Mice  Model  Length  EØ  AHR  Ref 
W/W
v  OVA + Alum  21 days  NC  -  (156) 
W/W
v  OVA + Alum  12 days    -  (159) 
W/W
v  HDM + Alum  21 days  NC  -  (42) 
W/W
v  OVA + Alum  30 days  NC  NC  (157) 
W/W
v  OVA + Alum  20 days  NC   (158) 
W/W
v  OVA + Alum  30 days  NC  NC  (162) 
W/W
v  OVA  46 days    (162) 
W/W
v  OVA + Alum  28 days  
1  NC  (160) 
W/W
v + W-sh  OVA  75 days    (37) 
W/W
v  OVA + Alum
2  24 days    (161) 
W-sh  OVA  46 days    (33) 
W/W
v + W-sh  OVA  30 days    (163) 
Table 1.2 – The effect of mast cell deficiency on the outcomes of experimental asthma. 
Key –   Length: duration of model used. EØ: effect on lung eosinophil numbers. AHR: effect on 
airways hyperresponsiveness. : reduced. NC: no change. HDM: house dust mite antigen 
Notes - (1) Of five timepoints studied eosinophils only reduced at 48 hours. (2) Alum was used 
with first sensitisation only. 
 
The  clinical  data  certainly  suggest  a  role  for  mast  cells  in  asthma,  perhaps 
related  to  smooth  muscle  function.  The  data  from  asthma  models  is  more 
difficult  to  interpret,  with  a  clear  requirement  for  mast  cells  when  alum  is 
omitted, although the exact role they play is not clear. 
1.1.3.4  T lymphocytes 
Initial  histological  studies  in  asthma  focused  on  the  eosinophils  and  mast 
cells(57,150) and T cells were not much studied until their central role in the 
immune response became understood. In particular their capacity to recruit cells 
of the innate immune system, including eosinophils, and their ability to provide 
help to B cells in antibody production and isotype switching(164). It was also at 
this time that T cell biology was revolutionised by the discovery of the Th1 and 
Th2 subsets of helper T cells(165). 
In  humans  there  are  reports  of  increased  T  cell  numbers  within  the  airway 
wall(166) and lumen(67,167), but not peripheral blood(167,168) of asthmatics. 
Regardless  of  the  location  sampled,  the  proportion  of  activated  T  cells  is 
consistently  elevated(71,168-171)  and  this  rise  correlates  with  eosinophil Chapter 1:  35 
numbers(67,166,172)  and  AHR(67).  A  study  using  anti-CD4  to  target  helper  T 
cells in severe asthma demonstrated an improvement in peak expiratory flow 
but  no  significant  change  in  FEV1  or  symptoms(173).  While  this  raised  the 
possibility that T cells could be targeted in asthma there has been no further 
progress in this area. 
Antibodies against CD4 have also been used in murine studies of allergic airways 
inflammation, showing that helper T cell depletion before or after sensitisation 
results in markedly reduced eosinophilia, AHR and remodelling(100,174-176), but 
has no effect on AHR or remodelling when given after challenge in a chronic 
model(177,178).  Similarly  B  and  T  cell  deficient  SCID  or  RAG
-/-  mice  fail  to 
develop airways eosinophilia and AHR(54,95,179,180). In RAG
-/- mice both could 
be restored by reconstitution with CD4 cells(95). The corollary of this is that 
eosinophilic inflammation and AHR can be induced in naïve mice by the transfer 
of antigen-specific helper T cells(180,181). The requirement for CD8 cells is less 
clearly defined; two adjuvant free models have found conflicting results with 
one  showing  that  CD8  cells  were  required  for  eosinophilic  inflammation  and 
AHR(182)  and  another  that  eosinophilic  inflammation  was  unaffected  in  CD8 
deficient mice(179). 
Th2 inflammation 
Shortly after the identification of Th1 and Th2 lymphocyte subsets investigators 
began to look for a link between Th2 cells and atopy due to the established role 
of  the  Th2  cytokine  IL-4  in  IgE  synthesis(183).  BAL  obtained  from  asthmatic 
patients contains elevated levels of Th2 cytokines(170,171) and cells expressing 
Th2  cytokines(184,185).  Similar  results  have  been  obtained  from  bronchial 
biopsies (184,186-188), sputum(189,190) and peripheral blood(170). In one study 
there was a direct correlation between the number of IL-5+ cells within the BAL 
and clinical measures of bronchoconstriction(191), and while expression of IL-5 is 
not  necessarily  restricted  to  T  cells,  other  have  shown  that  in  asthma  the 
majority of IL-4 and IL-5 positive cells are T cells(184). 
Further support for Th2 inflammation in asthma comes from studies looking at 
the Th2 associated transcription factors STAT6(192) and GATA-3(193) which are 
expressed  at  elevated  levels  in  BAL  and  biopsy  samples  from Chapter 1:  36 
asthmatics(194,195).  Conversely  the  Th1  associated  transcription  factor  T-
bet(196) is expressed at significantly reduced levels(197). 
Data from murine models concur with those from humans. Transfer of polarised 
antigen-specific Th1 cells followed by airways challenge results in neutrophilic 
rather  than  eosinophilic  inflammation  and  fails  to  induce  AHR(180,198,199). 
However when antigen-specific Th2 cells are transferred into naïve wild type or 
SCID  mice  then  airways  challenge  induces  eosinophilic  inflammation,  mucus 
hyper-secretion and AHR(180,198,199). 
Th2 cytokines 
The defining cytokines of the Th2 subset are IL-4, IL-5, IL-13 and variably IL-
9(165,200,201).  The  contribution  of  IL-5  has  already  been  discussed  when 
considering the role of eosinophils in asthma.  
In  1986  the  name  IL-4  was  proposed  for  what  had  previously  been  variously 
known  as  B-cell  stimulating  factor  1,  B-cell  growth  factor  1,  B-cell  IgG 
differentiation factor and IgG1 induction factor(202). As the names imply, IL-4 
was  already  recognised  for  being  able  to  induce  B  cell  growth  and  isotype 
switching to the Th2 associated isotypes IgG1(203) and IgE(204).  Two months 
later  IL-4  was  associated  with  the  Th2  subset  of  T  cells(165)  and  was 
subsequently shown to be a crucial factor in driving Th2 development(205). 
When IL-13 was discovered in 1993 it was found to be closely linked to the IL-4 
gene on chromosome 5 and expressed by Th2 but not Th1 cells(206,207). The 
association with Th2 inflammation and atopy was strengthened by the finding 
that IL-13 could induce IgE production, independently of IL-4. The functional 
overlap between IL-4 and IL-13 is due to the fact that they share a common 
receptor subunit. The Type I IL-4R consists of the IL-4Rα and γc subunits and the 
Type II IL-4R consists of the same IL-4Rα subunit plus an IL-13Rα1 subunit. IL-4 
signals through both receptors whereas IL-13 signals only through  the Type II 
receptor(208). 
The  finding  that  IL-4  can  induce  the  features  of  asthma  in  mice,  including 
eosinophilia, AHR and goblet cell hyperplasia(209,210), is perhaps not surprising 
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order  to  assess  whether  or  not  experimental  asthma  is  IL-4  dependent  IL-4 
deficient mice have been used, which have impaired Th2 responses(211) and are 
unable  to  produce  IgG1  or  IgE(212).  As  summarised  in  Table  1.3  these  have 
consistently  shown  a  requirement  for  IL-4  in  the  development  of  airways 
eosinophilia, regardless of strain, model or adjuvant use. The only exception was 
the finding that epicutaneous sensitisation with OVA results in IL-4 independent 
BAL eosinophilia in response to OVA challenge(213). Also shown in Table 1.3 are 
the effects of using anti-IL-4 antibodies on airways eosinophilia, which are less 
consistent, perhaps due to an inability to completely block IL-4 signalling. AHR is 
also variable with the suggestion of a strain effect, being preserved in IL-4
-/- 
BALB/c mice but reduced in C57Bl/6 IL-4
-/- mice, similar to the strain difference 
seen in IL-5
-/- mice. 
 
Mice  Model  Method  EØ  AHR  Ref 
C57Bl/6  OVA + Alum  IL-4
-/-    -  (156) 
C57Bl/6  OVA + Alum  IL-4
-/-    -  (214) 
C57Bl/6  OVA + Alum  α-IL-4    -  (214) 
C57Bl/6  OVA + Alum  IL-4
-/-      (215) 
C57Bl/6  OVA + Alum  IL-4
-/-      (216) 
BALB/c  OVA + Alum  α-IL-4  NC    (54) 
C57Bl/6  OVA + Alum  IL-4
-/-    NC  (217) 
BALB/c  OVA + Alum  IL-4
-/-    NC  (100) 
BALB/c  TF-OVA  IL-4
-/-    NC  (198,199) 
C57Bl/6  airways OVA
1  IL-4
-/-      (213) 
C57Bl/6  epicutaneous OVA
2  IL-4
-/-  NC    (213) 
BALB/c  GM-CSF + OVA
3  IL-4
-/-      (218) 
Table 1.3 – Studies on the requirement for IL-4 in experimental asthma 
Key –   EØ: effect on lung eosinophil numbers. AHR: effect on airways hyperresponsiveness. α-IL-
4: anti-IL-4. : reduced. NC: no change. TF-OVA: model employing adoptive transfer of 
OVA-specific T cells followed by antigen challenge. 
Notes  (1)  Protocol  utilising  repeated  antigen  challenge  of  naïve  mice.  (2)  Protocol  utilising 
epicutaneous sensitisation followed by airways challenge. (3) Protocol utilising airways 
GM-CSF over-expression and OVA challenge. 
 
A number of studies have also been carried out in mice deficient in STAT-6, an 
essential element in both IL-4 and IL-13 signalling. These have shown loss of AHR 
and  mucus  production  with  reduced  or  absent  airways  eosinophilia(219-221). 
Studies in mice deficient in the common IL-4Rα chain used for both IL-4 and IL-
13 signalling have shown that eosinophilic inflammation and mucus production Chapter 1:  38 
are attenuated while AHR is preserved(209,221), perhaps due to the existence of 
an IL-4Rα independent signalling pathway for IL-13(222). 
A number of approaches have been applied to address the specific role of IL-13, 
independently of IL-4. When IL-13 is administered to, or expressed in, the lungs 
IgE  production,  AHR  and  local  eosinophilia  and  goblet  cell  hyperplasia  are 
induced(209,221,223-225). Blocking the function of IL-13 has been achieved with 
soluble anti-IL-13 and IL-13Rα2 (IL-13Rα2-Fc) or by generating mice lacking IL-13 
or IL-13Rα1. Results of these experiments are summarised in Table 1.4 and show 
a  fairly  consistent  failure  to  generate  AHR  or  goblet  cell  hyperplasia  with 
preserved airways eosinophilia. 
 
Mice  Model  Method  EØ  AHR  Goblet  Ref 
A/J  OVA  IL-13Rα2-Fc  NC      (223) 
BALB/c  OVA + Alum  IL-13Rα2-Fc        (209) 
BALB/c  OVA + Alum  IL-13
-/-  NC  NC    (226) 
BALB/c  OVA + Alum  IL-13
-/-  NC      (225) 
BALB/c  TF-OVA  IL-13
-/-  NC      (225) 
BALB/c  OVA + Alum  α-IL-13  NC    -  (227) 
BALB/c  S. mansoni  IL-13Rα1
-/-  NC      (228) 
NS  OVA + Alum  IL-13Rα1
-/-        (229) 
Table 1.4 - Studies on the requirement for IL-13 in experimental asthma 
KEY –   EØ:  effect  on  lung  eosinophil  numbers.  AHR:  effect  on  airways  hyperresponsiveness. 
Goblet: goblet cell hyperplasia. : reduced. : absent. NC: no change. NS: Not stated. 
 
Overall  it  would  appear  that  IL-4  is  crucial  in  the  generation of  IgE  and  the 
development of Th2 inflammation and consequent eosinophil accumulation, IL-5 
plays a key role in eosinophilic inflammation and IL-13 is responsible for AHR and 
goblet cell hyperplasia. 
Other cytokines in asthma 
While  evidence  of  Th2  inflammation  is  consistently  found  in  clinical  asthma 
there are reports of increased IFNγ producing cells within the airways(230-232), 
particularly in those with more severe disease(233,234). As discussed above the 
transfer of Th1 cells alone fails to generate experimental asthma in mice, but 
when  co-transferred  with  Th2  cells  results  have  been  conflicting.  Two 
independent groups found that when polarised antigen-specific Th1 and Th2 cells 
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attenuated as compared with the transfer of Th2 cells alone(180,235), although 
histological  inflammation  and  AHR  were  unaffected(180).  However  another 
group utilising a similar model, but with only a single antigen challenge, found 
that BAL eosinophilia was not generated following the transfer of Th1  or Th2 
cells alone, but only with the co-transfer of both populations(236). While it is 
hard to draw firm conclusions it would certainly seem that asthma is not simply 
due to changes in the Th1-Th2 balance. 
Drugs targeting TNFα are now widely used in Crohn‟s disease and rheumatoid 
arthritis,  and  are  the  only  anti-cytokine  therapies  in  regular  clinical  use  for 
inflammatory  disease.  TNFα  is  found  at  elevated  levels  in  the  airways  of 
asthmatics,  particularly  in  mast  cells(237,238).  Murine  models  also  support  a 
role for mast cell derived TNFα(33,163). Following on from the apparent efficacy 
of anti-TNFα for severe asthma in a small uncontrolled study(239) there have 
been a number of studies addressing the use of anti-TNFα therapy in asthma. An 
initial randomised controlled study of 10 patients with severe asthma also looked 
promising  with  improvements  in  AHR,  lung  function  and  quality  of  life(240). 
Unfortunately subsequent small trials in both patients with severe(241) and more 
mild(242,243) asthma failed to show any convincing benefit. A much larger trial 
of 309 patients with severe asthma also failed to demonstrate any benefit(244). 
In light of these results and concerns over safety it seems unlikely that anti-
TNFα  therapies  will  become  widely  used  in  asthma,  although  the  possibility 
remains that a specific subset of patients may be identified who will benefit. 
There has recently been considerable interest in the novel Th17 subset of helper 
T cells. They are characterised by the production of IL-17 and play a key role in 
certain  autoimmune  diseases(245,246).  While  IL-17  has  been  detected  at 
elevated levels in the sputum and BAL of asthmatic patients(247,248), the role it 
plays in disease is unclear. In rodent models IL-17 expression or administration 
to  the  lungs  results  in  non-eosinophilic  inflammation(249-251).  However  in 
murine models of asthma IL-17 deficiency attenuates eosinophil accumulation in 
some studies(251,252) but not others(253), and IL-17 administered at challenge 
blocks  AHR  and  eosinophil  recruitment(252).  Antibody  studies  with  anti-IL-17 
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The subset of chemotactic cytokines, or chemokines, play an important role in 
asthma due to their function as inducers of leucocyte migration and activation. 
In asthma there has been particular interest in the chemokines which act on Th2 
cells and eosinophils. Th2 cells preferentially express the chemokine receptors 
CCR3  and  CCR4(256,257),  the  ligands  for  which  include  eotaxin-1  (CCL11), 
eotaxin-2 (CCL24), RANTES (CCL5) and TARC (CCL17). While RANTES and TARC 
are both elevated in asthma (258,259), the eotaxin chemokines have attracted 
particular interest due their potent and relatively selective effect on eosinophil 
migration(260), mediated via CCR3. In clinical asthma CCR3 and eotaxin-1 are 
detected at increased levels within the lungs and serum(261-264), and increased 
pulmonary  or  serum  eotaxin-1  correlates  increased  AHR  and  airflow 
obstruction(263,264). Epithelial cells, fibroblasts and macrophages appear to be 
the source of eotaxin-1 in asthma(261,262,265). Murine models have shown that 
blocking eotaxin-1 or eotaxin-2 alone by antibodies or gene deletion partially 
reduces  eosinophil  recruitment(179,260,266-268),  whereas  elimination  of  all 
eotaxin signalling by CCR3 knock-out or eotaxin-1/eotaxin-2 double knock-out, 
has a much more dramatic effect on lung eosinophilia(268-270). Effects on AHR 
have been much more variable(266,269,270), in keeping with the dissociation 
between eosinophilic inflammation and AHR discussed earlier. CCR3 antagonists 
have yielded promising results in animal studies(271,272) and there is currently 
interest  from  pharmaceutical  companies  in  developing  such  molecules  for 
therapeutic use in asthma. 
Regulatory T lymphocytes 
There are at least three major types of regulatory T (TReg) cells: CD4
+CD25
+, Tr1 
and Th3 cells with overlapping functions(273-275). CD25
+ T cells are arguably the 
best characterized so far. This subset of CD4+ T cells constitutively express the 
IL-2R α-chain (CD25) and a role in immune regulation was postulated following 
the observation that depletion of CD25
+ T cells results in the development of 
organ-specific auto-immunity and the production of auto-antibodies (275,275). 
CD25
+ T cells can suppress both Th1 and Th2 cell development and the effector 
functions of committed Th1/Th2 cells (276,276). In humans CD25+ TReg numbers 
are  reduced  in  asthma(277),  and  may  be  functionally  impaired  (277,278).  In 
experimental  asthma  there  is  evidence  that  CD25
+(26,279-282)  and  Tr1(283) 
cells can suppress IgE production, pulmonary eosinophilia and AHR. Chapter 1:  41 
1.1.3.5  Macrophages and dendritic cells 
While  there  is  some  debate  as  to  the  relationship  between  them(284), 
macrophages  and  dendritic  cells  (DCs)  are  derived  from  circulating 
monocytes(285,286)  and  are  both  involved  in  the  uptake  of  foreign  material 
within the lung, although probably have distinct functions. 
Macrophages are the most abundant inflammatory cells within the lung, making 
up the majority of cells within the normal BAL(285). There are both interstitial 
macrophages within the lung parenchyma, and alveolar macrophages that line 
the  alveoli  and  airways  and  are  therefore  directly  exposed  to  the  air.  While 
traditionally  considered  as  phagocytic  effector  cells,  macrophages  can  also 
direct  the  immune  response  by  antigen  presentation  and  cytokine  release. 
Despite the presence of high numbers of macrophages at the interface between 
the  lung  and  the  environment,  little  is  known  about  the  role  they  play  in 
asthma. When macrophages are adoptively transferred into murine lungs they 
attenuate  models  of  allergic  airways  disease(287,288).  Initial  studies  using 
macrophage depletion demonstrated a worsening of experimental asthma, with 
the  suggestion  that  the  mechanism  is  the  promotion  of  a  protective  Th1 
response(289,290). However more recent studies have been contradictory, with 
a subset of CD11b
+ CD11c
int macrophages capable of inducing allergic airways 
inflammation(291),  and  a  macrophage  depletion  model  showing  abrogated 
eosinophilia and AHR(255). All these results must be interpreted with caution as 
adoptively transferred macrophages may not be representative of the normal 
lung macrophage population, and depletion techniques are incomplete and not 
necessarily clearly targeted. 
DCs are professional antigen presenting cells and play a key role in directing the 
adaptive  immune  response.  Within  the  lungs  immature  mucosal  DCs  sitting 
beneath  the  epithelium,  as  well  as  alveolar  DCs  within  the  air-spaces,  are 
constantly  sampling  inhaled  antigens(292).  In  the  context  of  inflammation, 
particularly associated with TLR ligands(293), DCs are activated and migrate to 
the draining lymph nodes to present their antigens, thereby activating helper T 
cells(292). Under other circumstances DCs can promote tolerance(294) and the 
generation of regulatory T cells(295). The development of Th cells into a Th1, 
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presentation by DCs and is strongly influenced by co-stimulatory molecules and 
the cytokine milieu present(296). In addition to the role DCs play at sensitisation 
they are also found at increased numbers following antigen challenge in both 
mice  and  humans(297).  Evidence  for  the  importance  of  DCs  in  experimental 
asthma  comes  from  the  findings  that  challenge  of  mice  which  have  received 
antigen  pulsed  DCs  results  in  eosinophilic  airways  inflammation(298,299)  and 
depletion  of  DCs  attenuates  the  inflammation  and  AHR  in  models  of 
asthma(300,301). 
1.1.3.6  Stromal cells 
The most important structural cells in the lung are epithelial cells, endothelial 
cells, fibroblasts and smooth muscle cells. While initially considered as target 
cells in asthma which were bystanders affected by the inflammatory process, it 
is now becoming clear that they are active participants in the immune response. 
Epithelial  abnormalities,  particularly  shedding,  have  long  been  recognised  as 
features  of  asthma  (57,69)  and  were  thought  to  be  an  end  result  of 
inflammation. It is now accepted that epithelial cells are far from inert and can 
release  a  number  of  mediators  including  TGFβ,  eotaxin,  IL-5  and  IL-13  in 
response to pathogens, toxins or direct injury(302). There is also evidence that 
epithelial cells can drive myofibroblast proliferation, and collagen deposition, 
thereby contributing to airway remodelling. TGFβ appears to be central in this 
process(303) and can be induced in epithelial cells in response to IL-4 and IL-
13(304). 
While the function of smooth muscle in healthy lungs is debated(305), the role it 
plays in bronchoconstriction and AHR is well established. Smooth muscle cells 
also  contribute  to  remodelling,  both  in  terms  of  increased  smooth  muscle 
mass(306) and influences on the extracellular matrix(307,308). Some of these 
effects  may  be  due  to  fundamental  differences  in  smooth  muscle  cells  of 
asthmatics, while others may be due to the response of smooth muscle cells to 
inflammatory mediators(308). In addition to these downstream effects, it is now 
becoming  clear  that  smooth  muscle  cells  play  a  role  in  the  inflammatory 
response by releasing a number of pro-inflammatory mediators including IL-6, IL-
8, TGFβ and eotaxin(308,309).  Chapter 1:  43 
1.1.3.7  Neutrophils 
In healthy controls the cellular content of sputum is comprised of around two 
thirds macrophages and one third neutrophils,  with eosinophils makingup less 
than 1%(310-312). As discussed previously, clinical asthma is characterised by an 
increase  in  eosinophil  numbers  within  the  sputum,  BAL  and  airway  walls. 
However  reports  began  to  emerge  in  the  1990s  suggesting  that  airways 
eosinophilia  is  not  universal  in  asthmatic  patients.  Not  only  did  a  significant 
proportion  of  patients  experiencing  a  mild  exacerbation  have  a  normal 
eosinophil count(313), but patients with sudden onset fatal asthma(314), severe 
exacerbations(315),  and  severe  asthma  on  oral  corticosteroids(316)  often  had 
significantly elevated numbers of neutrophils within the airways and lung tissue. 
Since then there has been considerable interest in trying to characterise this 
subgroup of patients. While around 70-80% of asthmatic patients have elevated 
sputum eosinophil numbers the remainder have “non-eosinophilic” asthma, with 
either  normal  or  elevated  neutrophils(20).  Not  only  is  a  neutrophilic  asthma 
associated  with  more  severe  asthma,  but  also  with  a  failure  to  respond  to 
corticosteroids(317). Interestingly mast cells are also present within the smooth 
muscle  bundles  in  neutrophilic  asthma(318),  a  characteristic  finding  in 
eosinophilic asthma(151).  One of the histological features that appears to be 
unique to eosinophilic asthma is basement membrane thickening, suggesting that 
airway remodelling may not be a feature of neutrophilic asthma. 
The role of neutrophils in the pathophysiology of asthma remains unknown. In 
patients with neutrophilic asthma there is evidence of activation of the innate 
immune system, with elevated sputum IL-8,  TLR mRNA and LPS as compared 
with eosinophilic asthma(319). The role of neutrophils in experimental asthma 
has  not  been  addressed  and  almost  all  current  animal  models  reproduce 
eosinophilic asthma. There is one report describing a model of non-eosinophilic 
asthma  in  which  AHR  was  generated(320).  However  neutrophils  were  only 
modestly elevated within the BAL at 8% with eosinophils still detectable at 1%, 
and within the lung tissue eosinophils were more abundant than neutrophils.  
---oOo--- 
Despite significant advances in our understanding of asthma over the past one 
hundred years the exact role of different cells and cytokines remains unclear. Chapter 1:  44 
While  eosinophils  are  perhaps  not  as  central  as  once  thought,  particularly  in 
AHR,  they  appear  to  be  important  in  asthma  exacerbations  and  airways 
remodelling. This implicates IL-5 and the eotaxins, which are key mediators in 
the  activation  and  recruitment  of eosinophils,  in  these  processes.  IL-4  and T 
cells  are  likely  to  be  crucial  in  the  development  of  Th2  inflammation  which 
results in the production of IL-5 as well as IL-13, which appears to be important 
for AHR and mucus production. B and T lymphocytes as well as IL-4 are essential 
for the generation of IgE which is central in atopic asthma and may play a role in 
non-atopic  asthma.  The  function  of  mast  cells  remains  undefined,  and  while 
animal models suggest they are an essential source of TNFα, in clinical asthma 
TNFα  does  not  appear  to  be  an  important  therapeutic  target.  However  the 
location  of  mast  cells  within  the  smooth  muscle  bundles  in  asthma  but  not 
eosinophilic bronchitis suggests they may play a role in AHR. Macrophages, DCs 
and neutrophils are also likely to have their roles to play. In addition to the cells 
of the immune system stromal cells are increasingly recognised as contributing 
to the inflammatory process. 
By studying novel cytokines which fit into this network of cells and mediators we 
can not only improve our understanding of the pathophysiology of asthma, but 
may also discover new therapeutic targets. IL-33 and the receptor ST2 represent 
one such cytokine. 
 
1.2 ST2 
1.2.1 ST2 gene and protein 
1.2.1.1  The discovery of ST2 
The gene for the protein referred to herein as ST2 was first described in 1989 by 
two  independent  groups.  Initially  referred  to  as  T1,  it  was  identified  by 
screening of a cDNA library obtained from the murine 3T3 fibroblast cell line 
under  mitogenic  stimulation  by  over-expression  of  the  ras  oncogene(321).  In 
these cells the T1 gene was also induced by dexamethasone and by re-feeding 
following  serum  starvation(321).  At  around  the  same  time  an  identical  gene, Chapter 1:  45 
referred to as ST2, was identified in 3T3 fibroblasts following serum re-feeding, 
which was absent in serum starved fibroblasts(322).  
Although ST2 would remain an orphan receptor until the discovery of the ligand 
IL-33  in  2005(323),  a  great  deal  was  learnt  about  the  biology  of  ST2  in  the 
intervening sixteen years. 
1.2.1.2  The ST2 gene and its products 
The first described sequence for ST2 was 2.7kb long with two potential initiation 
sites encoding  a 337 amino acid protein with a predicted size of 37.7 or 38.5 
kDa(322,324). It has significant homology to the IL-1 receptor (IL-1R1) and is a 
member  of  the  immunoglobulin  superfamily,  although  it  appears  to  lack 
transmembrane or cytoplasmic domains(322,324). Consequently it is referred to 
as soluble ST2 or sST2(325). The human cDNA for sST2 was then isolated from a 
granulocyte  DNA  library  by  screening  with  a  probe  from  the  murine  sST2 
sequence  before  being  sequenced  from  a  helper  T  cell  clone(326),  the  final 
protein  having  68%  homology  to  murine  sST2(327).  The  murine  St2  gene  is 
located on chromosome 1 and is closely related to the  IL-1r1 locus(328). The 
human St2 gene is also found closely related to Il-1r, in this case on chromosome 
2q12-13(329). Cells transfected with soluble ST2 produce an intracellular protein 
of 45-60  kDa  and an extracellular protein of 60-70  kDa  when glycosylation is 
permitted, the differences in size presumably representing different degrees of 
glycosylation (330,331). 
A third ST2 gene product has been described in human cells, referred to as ST2V, 
which was initially identified in a helper T-cell line(332). It resembles sST2, but 
due  to  alternative  splicing,  one  of  the  three  extracellular  immunoglobulin 
domains is replaced by a hydrophobic tail. Although a homolog exists in chickens 
there is no evidence for the existence of ST2V in mice. In chickens there also 
exists a fourth product, ST2LV, which is identical to ST2L but due to alternative 
splicing lacks the exon encoding the transmembrane domain(333). No data exists 
regarding their function. Figure 1.1 shows the three transcription products from 
the human ST2 gene. 
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Figure 1.1 - Schematic representation of the human ST2 gene 
(A) The top line shows the location of ST2 in the human genome. The bottom line indicates the 
expanded region for the human ST2 gene. Exons are shown as boxes and numbered from 1a to 11 
with coding regions in red, and non-coding regions in white except for exon 5E in orange, which 
is specific to ST2V. (B) The exon usage starting from exon 5 for three spliced isoforms is shown. 
All the spliced isoforms thus far found commonly utilize from exon 2 to exon 5. The entire exon 8 
is integrated for ST2 or ST2V cDNA, while part of exon 8 is utilized for ST2L cDNA. Adapted from 
Li et al (334) 
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1.2.1.3  ST2 regulation and expression 
As previously discussed ST2 was initially identified in murine fibroblast lines and 
much  of  the  understanding  of  ST2  gene  regulation  is  from  early  studies  in 
fibroblasts. Due to the fact that ST2 was induced by oncongene transfection or 
feeding  following  serum  starvation(321,322),  it  was  associated  with  the 
transition between the G0 and G1 state. 
Immediate early  genes,  many of  which  are  transcription  factors,  are induced 
rapidly in resting cells without the need for synthesis of other proteins. Delayed 
early  genes  require  the  synthesis  of  other  proteins,  such  as  immediate  early 
transcription factors, for activation and therefore such activation occurs later. 
The  initial  finding  that  ST2  induction  peaked  at  6-10  hours  after  serum 
stimulation  of  fibroblasts  suggested  that  it  might  be  a  delayed  early 
gene(321,322,335,336). 
Activator  Protein-1  (AP-1)  is  a  prototypical  transcription  factor  and  is  a 
heterodimer made up of two variable immediate early gene products, often Jun 
and Fos proteins(337). Support for ST2 as a delayed early gene comes from the 
finding that the expression of AP-1 subunits can drive sST2, and to some extent 
ST2L, in both mouse and rat fibroblasts(335,338-340). Further evidence for ST2 
as a delayed early response gene is the finding that ST2 could not be induced by 
serum stimulation of fibroblasts in the presence of the protein synthesis inhibitor 
cycloheximide(335,336,339),  although  there  is  one  report  contradicting 
this(325). 
Ultimately it appears that ST2 can be induced via Fos/AP-1 as a protein synthesis 
dependent delayed early response gene (as is the case with serum stimulation), 
or  via  activation  of  p38  MAP  kinase  as  a  protein  synthesis  independent 
immediate early gene(341). 
Two  potential  promoter  regions  for  ST2  have  been  identified  in  fibroblasts 
(342,343),  one  of  which  was  found  to  be activated  by  AP-1  and  contained a 
classical  AP-1  site(343).  Subsequently  it  has  been  shown  that  inflammatory 
stimuli can also upregulate ST2. In human fibroblasts sST2, and to a much lesser 
degree ST2L, are induced by PMA, TNF, IL-1α and IL-1β(344).  Chapter 1:  48 
Since  the  initial  identification  of  ST2  in  fibroblasts  ST2  expression  has  been 
detected in a number of other cells types under different conditions as shown in 
Table  1.5.  These  studies  highlighted  that  sST2  is  predominantly  found  in 
structural cells such as epithelial cells and fibroblasts while ST2L expression is 
more restricted to lympoid tissue and inflammatory cells, with particularly good 
evidence  of  expression  by  T  cells  and  mast  cells  as  discussed  below.  As  in 
fibroblasts  ST2  can  be  upregulated  by  inflammatory  stimuli.  TNFα  similarly 
upregulates  sST2  and  ST2L  in  human  vascular  endothelial  cells(341,344).  In 
macrophages and monocytes ST2 expression is induced by LPS (345), and other 
TLR ligands can upregulate ST2 in spleen preparations(346). 
 
  murine  human   
Tissues  sST2  ST2L  sST2  ST2L  Ref 
Liver    R, P  R  R  (339,344,347,348) 
Spleen    R      (334,339,344,347) 
Lung    R  R  R  (334,339,344) 
Lymph node    R      (339) 
Bone marrow  R  R, P      (339,347,348)  
Bone  R, P        (347,349,350) 
Skin  R, P        (344,347) 
Bowel      R    (334) 
Placenta      R  R  (334,344) 
Kidney      R  R  (334,344) 
Cells           
Fibroblasts  R, P  R, P  R
1, P
1    (324,327,331,344,348,351-354) 
Epithelial   R    R
1, P  R
1  (339,353-356) 
Endothelial       R, P  R  (344,351,353) 
Smooth muscle      R  R  (353,357) 
Mast cell    R, P    R, P  (347,348,350,352,358)  
T cells
2    R, P  R  R, P  (344,347,348,359-364) 
B cells    P      (348,360) 
PBMCs      R  P  (365,366) 
Mono/MO    R, P  R
1  R
1  (339,348,353) 
Erythroid  R  R  R    (339,344,347,350) 
 
Table 1.5 – Tissues and cells in which ST2 expression has been detected 
Whole tissues or cells, including cell lines, where sST2 or ST2L have been identified at the RNA 
(R) or protein (P) level. PBMCs = Peripheral blood mononuclear cells. Mono/MO = monocytes and 
macrophages. (1) Includes detection in cells specifically of lung origin (2) Preferentially detected 
in Th2 cells(359,360,362,364,365). Chapter 1:  49 
The  expression  of  ST2  in  different  cells  is  controlled  by  the  use  of  differing 
promoters. Mice and rat fibroblasts use a 4kb upstream promoter for both forms 
of ST2(339,343,350). While ST2 and ST2L from mast cells have an alternative 
exon 1 which is 10.5kb(367) upstream of the transcription start site in fibroblasts 
and has a separate promoter which is independent of serum growth factors(350) 
and  contains  several  GATA  elements,  with  GATA-1  over-expression  enhancing 
ST2 expression (367,368). Like mast cells, Th2 cells utilise the distal promoter 
for  sST2  and  ST2L(368,369)  and  GATA-3  can  bind  to  the  distal  promoter  and 
activate  ST2  in  these  cells(368).  In  humans  the  situation  is  less  clear  cut, 
although fibroblasts predominantly use the proximal promoter and leucocytes 
the distal promoter for both ST2 and ST2L(357,370). There is once again a GATA-
1 site in the distal promoter(370). However in human mast cells while ST2L is 
expressed utilising the distal promoter, sST2 appears to utilise both(357). 
T lymphocytes 
The report that ST2L RNA was expressed in T cell lines(347) was followed by the 
finding that this expression was limited to Th0 and Th2 lines and was enhanced 
under  conditions  favouring  Th2  development(365).  Subsequently  two 
independent  groups  identified  ST2L  by  differential  display  PCR  as  being 
expressed by murine Th2 and not Th1 cells(359,360), with similar findings from 
human Th2 cells(362,364).  
The  frequency  of  ST2+  cells  in  naïve  mice(360)  and  human  peripheral 
blood(364,371) is low, at around 1-3% of CD4+ cells. However surface ST2L is 
upregulated under Th2 polarising conditions in vitro and in vivo. When naïve T 
cells are driven towards a Th2 phenotype in vitro 41-77% have been reported to 
express  ST2(359,372,373).  This  upregulation  of  ST2  under  Th2  polarising 
conditions is further enhanced by the addition of IL-6(373). Established Th2 cells 
also upregulate surface ST2L in response to TcR stimulation in the presence of 
co-stimulation(369). While IL-4 enhances ST2L expression IFNγ results in a net 
reduction in ST2L(369). In the context of disease ST2 can also be significantly 
upregulated, with expression on between 10% and 60% of murine CD4+ cells in 
Schistomsoma  mansoni  egg  responses(374,375),  Leishmania  major 
infection(375,376) and experimental asthma(218,298,377,378). Although ST2L is 
restricted  to  Th2  T  cells,  IL-4  is  not  required  for  the  expression  of  ST2L  in 
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by  ST2+  T  cells,  while  the  absence  of  IL-5  results  in  reduced ST2  expression 
(360). As would be expected ST2L+ T cells produce Th2 cytokines and are IL-4+ 
and IL-5+ on intra-cellular staining(359,360,373,374), and while under conditions 
favouring Th2 cells development CD4+ST2- cells expressed IL-4 and IL-10, albeit 
at lower levels than the CD4+ST2+ cells, none of them expressed IL-5(379). 
Mast cells 
The other main cell line of the haematopoetic lineage found to express ST2L are 
mast cells. Not only are they strong expressers of ST2L RNA(347,350,367), but 
they also express the protein on the cell surface(347,350). When compared with 
other leukocytes mast cells are all ST2L
+ and have the highest concentration of 
surface ST2L(348). Following the finding that ST2L is expressed on foetal mast 
cell progenitors(348), a search for mast cell lineage cells in adults using an in 
vitro culture system found that ST2 appeared to be a marker of committed mast 
cell progenitors(380). Whereas the β7+CD27-ST2- fraction of bone marrow cells 
was  able  to  generate  mast  cells,  macrophages,  erythrocytes  and 
megakaryocytes, the β7+CD27-ST2+ fraction gave rise to mast cells alone. This 
fraction was the only one able to generate significant numbers of mast cells and 
also  reconstituted  irradiated  W-sh  mice  with  mast  cells  but  not  B  cells, 
macrophages or granulocytes. 
Despite this, ST2 is not essential for mast cell production as ST2
-/- mice have 
normal  mast  cell  numbers  in  the  skin  and  stomach  and  mast  cells  can  be 
cultured from the bone marrow of these mice(381). These cultured ST2
-/- mast 
cells degranulate normally in response to IgE cross-linking(381). 
1.2.2 ST2 function 
1.2.2.1  The function of ST2 in vitro 
The  first  studies  investigating  the  role of ST2  in  vitro used either antibodies 
against ST2 or recombinant sST2, often fused with the Fc portion of human IgG1 
(sST2-Fc) as experimental blocking agents. In the presence of ST2-Fc there is a 
reduction in IL-4 and IL-5 and an increase in IFNγ production by CD4+ T cells 
under both neutral and Th2 polarising conditions(372). When measuring Th2 cell 
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enhance  the  effect  of  TcR  signalling,  but  anti-ST2  alone  can  mediate  these 
effects.  This  is  dependent  on  the anti-ST2  being plate bound,  presumably  to 
mediate ST2 crosslinking, and is blocked by recombinant sST2(373). 
The development of ST2 gene knockout mice made it possible to study the effect 
of ST2 deficiency on T cells. ST2
-/- and wild type T cells stimulated with anti-CD3 
produce  identical  levels  of  IL-4,  IL-5  and  IL-10  or  IFNγ  under  Th2  or  Th1 
polarising conditions respectively(381-383). However when ST2
-/- OVA-specific T 
cells are activated by OVA peptide they produce significantly more IL-5 than wild 
type cells(383). 
When murine macrophages were studied it was shown that pre-treatment with 
sST2-Fc attenuates LPS mediated release of IL-6, IL-12 and TNFα(353,384-386). 
Similarly, sST2 was shown to inhibit LPS induced IL-1β, IL-6 and TNFα production 
by a human monocytic cell line and was associated with reduced IκB degradation 
and  reduced  binding  of  NFκB  to  the  IL-6  promoter(387).  In  addition  sST2-Fc 
induces  macrophage  NFκB(384,388)  and  down-regulates  TLR-4  and  TLR-1 
mRNA(384). Conversely ST2
-/- macrophages produce increased quantities of IL-6 
and IL-12 in response to treatment with TLR ligands or IL-1(345).  
ST2 also appeared to be inhibitory in mast cells, with transfection reducing IL-1 
or LPS mediated NFκB activation and anti-ST2 antibody inhibiting IL-1 mediated 
NFκB activation in an ST2+ mast cell line(345). One possible mechanism for these 
inhibitory effects is the downregulation of NFκB by ST2 sequestration of MyD88 
and Mal(345).  
1.2.2.2  The function of ST2 in vivo 
The first studies investigating the role of ST2 in vivo used antibodies against ST2. 
One  such  polyclonal  anti-ST2  antibody  was  shown  to  induce  complement 
mediated lysis in vitro. When administered to Leishmania major susceptible Th2 
prone BALB/c mice they developed less severe disease with a reduced parasite 
load and evidence of switching to a protective Th1 response(359). However a 
later study using a different, non-lytic antibody or ST2-Fc found no difference in 
the  course  of  L.  major  infection  in  BALB/c  mice(385).  In  collagen  induced 
arthritis  the  use  of  depleting  anti-ST2  antibody  exacerbated  disease  with 
evidence of enhanced Th1 responses(359). Conversely blocking ST2 function with Chapter 1:  52 
ST2-Fc at the time of disease onset reduces the severity of collagen-induced 
arthritis(389). 
sST2-Fc  reduces  mortality  and  cytokine  production  in  LPS  induced  shock, 
whereas blocking anti-ST2 antibody has the opposite effect(384). While ST2
-/- 
mice are as susceptible to LPS induced shock as wild type mice, pre-treatment 
with LPS protects wild type but not ST2
-/- mice from subsequent challenge with a 
lethal  dose  of  LPS(345).  This  effect  may  be  mediated  by  LPS  induced 
upregulation  of  ST2  on  macrophages  and  subsequent  MyD88  sequestration 
inhibiting TLR-4 signalling, phenomena which have been observed in vitro(345). 
Transfection with sST2-Fc results in reduced liver damage in a liver ischaemia-
reperfusion  model.  This  was  associated  with  a  reduction  in  liver  macrophage 
number and serum IL-6 and TNFα(386). Similar results were seen in an intestinal 
ischaemia-reperfusion model where treatment with sST2-Fc reduced neutrophil 
influx,  histological  damage  and  vascular  permeability  with  an  associated 
reduction in TNFα, CCL2(MCP-1) and CXCL1. Interestingly this effect was IL-10 
dependent, not only was there a rise in local IL-10, but the protective effect of 
sST2-Fc  was  lost  in  IL-10
-/-  mice(390).  In  a  model  of  hepatic  injury  sST2-Fc 
treatment did not alter the extent of liver damage, but did enhance subsequent 
fibrosis  with  an  associated  increase  in  ex  vivo  Th2  cytokine  production.  This 
effect  was  abrogated  by  CD4  depletion  and  attenuated  in  IL-4
-/-  mice(388). 
Taken together these data suggest that ST2 can play a role the inflammatory 
response to tissue injury. 
The development of ST2 gene knockout mice(381,382,391) made it possible to 
ask further questions regarding the role of ST2. Initial phenotyping showed that 
naïve  ST2
-/-  mice  have  normal  serum  immunoglobulin  levels  and  a  normal 
population of immune cells(382). 
In ST2
-/- mice infected with Nippostrongylus brasiliensis serum immunoglobulin 
levels and ex vivo IL-4 and IFNγ production by CD4 T cells are unaffected(381). 
Although a later study suggested that T cell IL-5 was reduced in the lungs of ST2
-
/-  and  ST2-Fc  transgenic  mice  during  N.  brasiliensis  infection,  peripheral  and 
lung eosinophilia, serum immunoglobulin induction and parasite clearance was 
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A  study  of  Schistosoma  mansoni  egg  induced  granuloma  formation,  a  Th2 
dominated response(392), yielded intriguing results(382). When S. mansoni eggs 
were  administered  intravenously  (IV)  to  naïve  mice  there  was  a  dramatic 
impairment of eosinophil accumulation and pulmonary granuloma formation in 
ST2
-/- mice. Conversely, when the eggs were administered IV to mice that were 
first immunised IP with eggs, granuloma formation and antibody production was 
unaffected in ST2
-/- mice, although there was a reduction in ex vivo Th2 cytokine 
production(382). 
ST2
-/- mice developed more severe pancreatic inflammation in a streptozotocin 
induced diabetes model(393). Observational studies have also reported elevated 
ST2 in models such as LPS induced acute lung injury, where BAL sST2 protein was 
elevated(353),  an  allergic  model  of  contact  dermatitis,  where  ST2  RNA  was 
elevated in the skin(394) and bleomycin induced pulmonary fibrosis where ST2 
RNA was induced locally(354), 
ST2 in asthma 
Given the expression of ST2 on mast cells and Th2 cells it seemed reasonable 
that ST2 may be involved in the pathophysiology of asthma. A hypothesis that 
was later strengthened by the finding that lung ST2 RNA and serum sST2 protein 
were elevated during an OVA/Alum driven murine model of asthma(395). 
Initial studies into the role of ST2 in allergic airways inflammation relied on the 
administration of antibodies or exogenous sST2, and consistently favoured a role 
for ST2 in asthma models. The first of these studies used anti-ST2 or sST2-Fc, 
both at a dose of 20 to 100 µg per mouse. Allergic airways inflammation was 
induced  by  the  adoptive  transfer  of  OVA  specific  T  cells  which  had  been 
polarised  to  a  Th2  phenotype,  followed  one  day  later  by  two  challenges  of 
nebulised  OVA  on  two  consecutive  days.  When  anti-ST2  or  sST2-Fc  was 
administered  one  hour  prior  to  antigen  challenge  there  was  a  substantial 
reduction in BAL eosinophils and Th2 cytokines, histological inflammation in the 
lung and AHR(360,372). A similar effect was seen in a 21 day OVA sensitisation 
and  challenge  model  where  mice  were  sensitised  with  IP  OVA/Alum  on  two 
occasions before being twice challenged with nebulised OVA. Administration of 
the  same  anti-ST2  antibody  1  hour  before  each  sensitisation  and  challenge 
resulted in a significant reduction in BAL eosinophils and IL-5 as well as serum Chapter 1:  54 
OVA-specific IgE(372). In a model of asthma mediated by the adoptive transfer 
of OVA pulsed DCs followed by seven nebulised doses of OVA, treatment with 
anti-ST2  or  ST2-Fc  at  the  time  of  DC  transfer  reduced  BAL  eosinophilia  and 
histological inflammation(298). In respiratory syncytial (RSV) virus induced Th2 
mediated eosinophilic lung disease in mice administration of anti-ST2 around the 
time  of  RSV  challenge  attenuated  disease  severity,  as  measured  by  BAL 
eosinophilia and weight loss, although viral clearance was delayed(396). Using 
the alternative technique of intravenous ST2 gene transfer resulted in reduced 
BAL eosinophils, IL-4 and IL-5 in a 14 day OVA/Alum model of asthma(395).  
Subsequent studies in ST2 gene knockout mice yielded results contrary to the 
data from anti-ST2 and sST2 experiments. In a 35 day model of asthma with 
OVA/Alum sensitisation followed by OVA challenge C57Bl/6 wild type and ST2
-/- 
mice showed identical levels of BAL eosinophilia, histological inflammation and 
serum  immunoglobulins(381).  There  were  comparable  results  in  BALB/c  mice 
using a similar OVA/Alum model, this time over 30 days(383). Wild type and ST2
-
/- mice had a similar of degree of AHR, histological inflammation and ex vivo 
cytokine production. However BAL eosinophils were elevated and macrophages 
were reduced in ST2
-/- mice. An adoptive transfer model was then used to focus 
on the role of T cells. OVA specific wild type or ST2
-/- Th2 cells were generated 
in  vitro  and  transferred  into  wild  type  mice  which  had  been  primed  with 
OVA/Alum, mice were challenged daily with nebulised OVA over the following 
five days. When compared with mice that received wild type Th2 cells those that 
received  ST2
-/-  Th2  cells  had  elevated  BAL  and  lung  eosinophilia,  increased 
inflammation and mucus production on lung histology and dramatically enhanced 
AHR,  leading  to  increased  mortality.  The  BAL,  lungs  and  lymph  nodes  were 
enriched for antigen specific T cells, but total macrophage numbers in the BAL 
were reduced. BAL and lung cytokine and chemokine levels were all low and 
there was no difference between groups. There was no evidence of a mast cell 
or  basophil  contribution  as  serum  mast  cell  protease-1  and  lung  mast  cell 
numbers were unaffected.   Allergic inflammation was also independent of B-
cells or recipient T cells as lung and BAL inflammation was unaffected if RAG
-/- 
mice were used as recipients(383). Chapter 1:  55 
1.2.2.3  ST2 in clinical disease 
Although sST2 and ST2L had been detected in human cells and samples at both 
the RNA and protein level, it was the development of an ELISA for sST2(397) 
which made it possible to identify and study the role of ST2 in clinical disease. 
The first of these studies suggested that serum sST2 was elevated in a  small 
cohort of six asthmatics as compared with patients with lung cancer or healthy 
controls(397). A subsequent larger study of 56 patients also found that serum 
sST2  was  slightly  elevated  in  asthma,  but  was  further  elevated  during 
exacerbations  when  levels  correlated  with  severity  of  exacerbation,  peak 
expiratory flow rate and PaCO2(398). 
While  sample  sizes  were  often  very  small,  serum  sST2  was  also  found  to  be 
elevated in a number of other conditions including eosinophilic pneumonia(399), 
autoimmune  diseases  such  as  rheumatoid  arthritis,  SLE,  Wegener‟s 
granulomatosis and Bechet‟s disease (400), idiopathic pulmonary fibrosis (401), 
sepsis and trauma where ST2 correlated with mortality (402), in patients treated 
with  H2  antagonists(403,404),  and  in  the  CSF  of  patients  with  subarachnoid 
haemorrhage(405). 
A  large  Japanese  cohort  study  found  a  number  of  Single-nucleotide 
polymorphisms (SNPs) in the ST2 gene and went on to study seven of them in 
patients with atopic dermatitis and normal controls. One SNP, located in exon 
1a, showed a significant association with atopic dermatitis, and among patients 
with atopic dermatitis those with the associated genotype had higher levels of 
serum  sST2  and  IgE.  Of  the  haplotypes  incorporating  all  seven  loci  one  was 
associated  with  atopic  dermatitis  and  this  haplotype  was  associated  with 
stronger ST2 promoter activity in a reporter system(406). 
ST2 in heart disease 
The possibility that ST2 might be involved in heart disease was raised after the 
finding  that  sST2,  and  to  a  lesser  extent ST2L,  were  up-regulated  in  cardiac 
myocytes and fibroblasts under mechanical strain(406,407). This observation was 
extended to the whole organism with data showing ST2 RNA was upregulated in 
the  left  ventricle  and  sST2  was  elevated  in  the  serum  of  mice  following 
myocardial  infarction  (MI)(406).  In  a  small  cohort  of  patients  serum  ST2  was Chapter 1:  56 
elevated  immediately  post  MI  and  levels  correlated  with  creatinine  kinase,  a 
marker of cardiac damage, and with poor left ventricular function post MI(406). 
A later study of 810 patients with acute MI found that serum ST2 at presentation 
correlated with troponin, a marker of cardiac damage, and was a predictor of 
subsequent mortality or heart failure(408). However sST2 appeared to be a poor 
predictor  of  acute  coronary  syndrome  in  an  emergency  setting,  although 
measurements were made very early and there was no comparison with gold 
standard biomarkers(409). Serum sST2 was also found to rise following coronary 
artery bypass grafting(410). A study of 161 patients with severe heart failure 
found that serum sST2 was elevated, correlated with other biomarkers of heart 
failure, BNP and proANP, and was a predictor of mortality (411). A study of 593 
breathless patients, of whom 208 had acute heart failure, found that serum sST2 
was elevated in those with heart failure and correlated with NT-proBNP, left 
ventricular systolic dysfunction and mortality. Interestingly, among patients with 
elevated  sST2  without  heart  failure  the  commonest  cause  of  death  was  lung 
disease, including obstructive lung disease, pneumonia and lung cancer(412). 
1.2.2.4  The search for a ligand for ST2 
Given  the  structure  of  ST2  and  it‟s  homology  to  the  IL-1  receptor  it  was 
immediately  ascribed  the  function  of  a  receptor(347,351,365,413).  IL-1  was 
quickly excluded as a ligand given that it did not bind to,  or signal via,  ST2 
(414).  However  the  hypothesis  that  ST2  could  function  as  a  receptor  was 
supported  by  the  findings  that  IL-1  could  induce  reporter  activation,  NFΚB 
activation, kinase activity and IL-4 produvction from T cells via a fusion protein 
with  the  extracellular  portion  of  IL-1R1  and  the  intracellular  portion  of 
ST2(351,415,416).  While  a  number  of  candidate  ligands  were  proposed,  they 
failed to show any functional activity(351,415). 
 Chapter 1:  57 
1.3 Interleukin-33 
1.3.1 IL-33 gene and protein 
In late 2005 the discovery of IL-33 was reported, a novel IL-1 family cytokine and 
a  functional  ligand  for  ST2(323).  It  was  discovered  using  a  computational 
database search for IL-1 family members. Human IL-33 is found on chromosome 
9p24.1 and murine IL-33 on 19qC1. They encode proteins of 270 and 266 amino 
acids respectively, both with a molecular weight of 30kDa. Human and murine 
IL-33 share 55% homology at the amino acid level. Within the IL-1 family IL-33 
most closely resembles IL-18. It later became clear that IL-33 is identical to the 
previously reported nuclear factor from high endothelial venules (NF-HEV) which 
was found by subtractive hybridization to be preferentially expressed in  high 
endothelial venule (HEV) cells as compared with other endothelial cells(417). 
1.3.1.1  IL-33 expression 
In the mouse IL-33 RNA is detected at high levels in the stomach, lung, spinal 
cord, brain, and skin and at lower levels in lymph nodes, resting DCs, spleen, 
pancreas,  kidney,  and  heart.  In  the  human  IL-33  RNA  is  detected  in  resting 
bronchial epithelial cells and smooth muscle cells, including those from bronchi, 
pulmonary arteries and coronary arteries, and in cytokine activated fibroblasts. 
Activated  murine  bone  marrow  macrophages,  and  to  a  much  lesser  extent 
activated  human  macrophages  and  DCs  also  express  IL-33(323).  Using  in-situ 
hybridization  and  RT-PCR  IL-33  RNA  was  detected  in  endothelial  cells  from 
human tonsils, rheumatoid arthritis synovium and Crohn‟s disease intestine(418). 
As  mentioned  previously,  IL-33  protein  is  also  detected  in  endothelial  cells, 
specifically  those  of  HEVs,  and  in  a  few  scattered  cells  in  the  T-  and  B-cell 
zones, of human tonsils(417). 
In an adoptive transfer model of asthma OVA/Alum priming alone induced IL-33 
RNA in the lungs, and expression was further enhanced following challenge(383). 
Within  the  rat  heart  IL-33  RNA  and  protein  has  been  detected  from  cardiac 
fibroblasts, and to a much lesser extent cardiac myocytes, and is upregulated by 
biomechanical  strain(407).  A  similar  result  was  seen  in  vivo  where  cardiac 
overload in mice led to increased IL-33 in cardiac fibroblasts(407). Chapter 1:  58 
1.3.1.2  IL-33 processing 
In keeping with the finding that within the first 65 amino acids of IL-33 there is a 
putative Helix-Turn-Helix (HTH) DNA-Binding Domain(417), IL-33 has been found 
to  localise  to  the  nucleus(417).  In  human  tonsillar  HEV  endothelial  cells  an 
exclusively  nuclear  distribution  of  naturally  occurring  IL-33  was  seen,  and 
specifically  in  heterochromatin  (tightly  packed  transcriptionally  inactive  DNA) 
rich  areas(418).  This  association  was  demonstrated  in  other  cell  types  using 
transfection  with  GFP  tagged  IL-33(418).  Using  truncated  proteins  it  was 
confirmed that the 65 amino acids containing the HTH domain at the N-terminal 
end  of  IL-33  were  responsible  for  this  nuclear  localisation(418).  These  data 
would be in keeping with the suggestion that IL-33 has a pro-domain(323), and 
the  evidence  that  it  can  be  cleaved  from  the  30kDa  product  to  an  18kDa 
“mature” form by caspase-1(323). However IL-33 does not contain a classical 
caspase-1 cleavage site and there is no evidence of cleavage  in vivo. Nuclear 
localisation was observed with endogenous IL-33 in HEV endothelial cells, or with 
transfected IL-33 in other cells, even when specific antibodies against the IL-1 
like C-terminal end of “mature” IL-33 were used(418). 
1.3.2 IL-33 function 
1.3.2.1  IL-33 signalling 
The  binding  of  IL-33  to  ST2  was  demonstrated  by  the  fact  that  ST2  co-
precipitates IL-33, and vice versa(323,407), and that binding of anti-ST2 to the 
surface of mast cells is blocked by IL-33(323). Cells transfected with ST2 showed 
NFκB  activation  using  a  GFP  reporter  system(323).  ST2  transfected  cells 
stimulated with IL-33 were also used to show that ST2 recruits MyD88, IRAK, 
IRAK4, and to a lesser extent TRAF6 and that IκB, Erk1/2, p38, and JNK are 
phosphorylated.  This  was  confirmed  using  bone  marrow  derived  mast  cells 
(BMMCs),  previously  shown  to  express  surface  ST2L(347,350),  where  IL-33 
treatment resulted in NFΚB, Erk1/2, p38, and JNK phosphorylation, which could 
be blocked with anti-ST2 antibody(323).  Chapter 1:  59 
1.3.2.2  IL-33 function 
At the time of undertaking this research there was very little data on the effect 
of IL-33, all of which was in the paper by Schmitz et al(323). 
The only functional in vitro data was of the effect of IL-33 on T cells. In keeping 
with earlier studies which had activated ST2 by antibody cross-linking(373), IL-33 
enhanced IL-5 and IL-13 production by Th2 cells  stimulated via the TcR with 
CD28 co-stimulation, although IL-4 production was unaffected(323). While there 
was evidence of IL-33 induced signalling in mast cells there was no data on the 
functional effects of this(323). 
To study the effects in vivo, recombinant IL-33 was administered IP to C57Bl/6 
mice at a dose of 0.4 or 4  g each day for a total of seven days(323).  This 
resulted in a marked increase in peripheral blood eosinophils, and to a lesser 
extent lymphocytes and neutrophils, with elevated serum IgE and IgA. There was 
splenomegaly with increased monocytes, eosinophils and plasma cells within the 
spleen. Histological studies revealed changes within the gastro-intestinal tract 
and  lungs.  There  was  epithelial  hyperplasia  and  inflammatory  infiltrates, 
including eosinophils, in the oesophagus and goblet cell hypertrophy with excess 
mucus in the intestines. In the lungs there was epithelial hypertrophy and mucus 
hypersecretion  in  addition  to  vascular  changes,  namely  perivascular 
mononuclear  and  myeloid  infiltrates  round  medium  and  small  vessels  with 
medial hypertrophy. There was evidence of Th2 activation with elevated serum 
IL-5 and IL-13 and increased IL-4, IL-5 and IL-13 RNA in the thymus, spleen, liver 
and lung. When IL-33 was administered to IL-13
-/- mice the epithelial changes 
seen  in  the  lungs  of  wild  type  mice  were  absent,  but  the  vascular  changes 
remained. 
 
1.4 Objectives 
In the preceding Introduction I have highlighted the current understanding of the 
immunological basis of asthma and some of the key questions that remain. While 
the  importance  of  Th2  inflammation  is  well  established  the  exact  role  of 
different  cells  and  cytokines  remains  unclear.  There  is  still  uncertainty  over Chapter 1:  60 
what  mechanisms  are  involved  in  the  initiation  of  airways  inflammation,  the 
place of different cytokines within the hierarchy and sequence of events that 
occurs and the relationship between structural cells and inflammatory cells. 
IL-33 is a novel cytokine about which very little is known, but which has the 
ability to induce Th2 inflammation and eosinophilia in vivo. The receptor for IL-
33, ST2 is expressed at very high levels on mast cells, and there is a body of 
evidence  that  suggests  ST2  plays  an  important  role  in  Th2  inflammation, 
although  the  importance  of  the  IL-33  –  ST2  axis  in  experimental  asthma  is 
unresolved. 
My  hypothesis  is  that  „The  activation  of  ST2  on  mast  cells  by  IL-33  plays  an 
important role in allergic airways inflammation‟. 
To address this question I have set out three objectives. 
2.  To  establish if  mast cells  can  be  activated  by  IL-33,  acting  via  ST2  to 
produce pro-inflammatory cytokines and chemokines in vitro. 
3.  To  optimise  a  murine  model  of  experimental  asthma  and  establish 
whether there is a need for ST2 in this model. 
4.  To assess whether or not IL-33 can activate mast cells within the airways 
to induce the features of experimental asthma in vivo. 
By achieving these aims I hope to show that IL-33 is a key cytokine in asthma and 
hence potentially a novel therapeutic target.  
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2.1 Reagents and buffers 
Reagents  and  chemicals  were  purchased  from  Sigma-Aldrich  (Poole,  UK)  and 
culture  media  was  purchased  from  Invitrogen  Ltd  (Paisley,  UK)  unless  stated 
otherwise. Commonly used buffers and solutions are listed in Table 2.1. 
IL-33 used was from one of two sources. For all in vitro experiments commercial 
IL-33 (ALEXIS Corporation, Switzerland) was used. For in vivo experiments IL-33 
produced within the laboratory was used. The methods for the production of IL-
33 have been published elsewhere(419). Briefly, mouse IL-33 cDNA was cloned 
from IL-1-stimulated fibroblasts, and the cDNA sequence was transformed into 
host Escherichia coli. IL-33 protein was induced by IPTG and purified by Ni-NTA 
affinity chromatography followed by polymyxin B column to remove endotoxin. 
The purity of IL-33 was more than 95% and endotoxin levels were less than 0.01 
EU/µg of protein by the QCL-1000 pyrogen test (Bio-Whittaker). Bioactivity and 
specificity  of  recombinant  IL-33  were  confirmed  by  its  ability  to  induce  IL-5 
production from wild type but not ST2
-/- Th2 cells. 
Phosphate buffered saline (PBS)  8g  NaCl,  1.16g  Na2HPO4,  0.2g  KCl,  0.2g 
KH2PO4 in 1 litre distilled water, pH 7.4 
Avertin stock  1:1 w/v solution of 2,2,2-tribromoethanol 
in tert-amyl alcohol 
Complete medium  500 ml RPMI 1640, 50 ml inactivated FBS, 5 
ml pen / strep, 5 ml L-glutamine 
Complete IMDM  500  ml  Iscove's  Modified  Dulbecco's 
Medium (IMDM), 50 ml inactivated FBS, 5 
ml pen / strep, 5 ml L-glutamine 
FACS buffer   2% FCS in PBS 
BD ELISA Coating buffer   0.1M NaHCO3 pH 8.4 
ELISA Wash buffer   0.05% Tween-20 in PBS pH 7.4 
BD ELISA assay buffer   10% FCS in PBS 
R&D ELISA assay buffer   1% BSA in PBS 
Biousource ELISA assay buffer   0.5% BSA and 0.1% Tween in PBS 
OptEIA Coating Buffer   8.4g  NaHCO3,  3.56g  Na2CO3  in  1  litre 
distilled water, pH 9.5 
0.05M Citrate buffer   24.8 ml 0.05M citric acid 
25.2 ml 0.05M trisodium citrate 
Sodium Carbonate Buffer  25 ml 0.2M Na2CO3 
25 ml 0.2M NaHCO3 
Table 2.1 – List of commonly used buffers and solutions Chapter 2:  63 
2.2 Animals 
Wild  type  (WT)  BALB/c  and  C57Bl/6  mice  were  obtained  from  Harlan  Olac 
(Bicester, Oxon, UK). ST2 gene knockout BALB/c mice have a deletion within the 
ST2 gene which involves the majority of exons 4 and 5 (382). These mice had 
previously been obtained from Professor Andrew Mackenzie, BBRC, University of 
Cambridge  and  were  bred  in  in-house  by  Biological  Services,  University  of 
Glasgow.  
W-sh mice are among the mice which have a mutation of the white spotting (W) 
locus. This locus was first described nearly a century ago when a mutation was 
found to result in abnormal haematopoiesis and pigmentation(420) and the gene 
responsible was subsequently identified as the Kit gene which encodes the stem 
cell  factor  receptor(421).  Kit
W/Kit
W-v  (W/W
v)  mice  are  a  heterozygous  cross 
between  the  generally  non-viable  Kit
W/Kit
W  mice and the  modestly  mast  cell 
deficient  Kit
W-v/Kit
W-v  mice.  These  W/W
v  mice  are  profoundly  mast  cell 
deficient, with mast cells only detected in the skin, and even there at <1% of the 
level found in normal mice(422). They are also profoundly anaemic, relatively 
neutropenic and sterile(423,424). W/W
v mice were the most utilised strain in the 
investigation of mast cell deficiency until the Kit
W-sh/Kit
W-sh (W-sh) mutation was 
identified, named after the white “sash” coat colouring which was observed on 
heterozygotes(425). W-sh mice have a markedly reduced expression of Kit upon 
mast cells and consequently a dramatic mast cell deficiency with no detectable 
mast cells in any organs including the lung(426,427), with the exception of the 
skin where mast cells have been reported as absent(426) or detected from birth, 
falling  to  around  1%  of  the  level  found  in  wild  type  mice  by  12  weeks  of 
age(427). In addition these mice are fertile and have no evidence of any other 
haematopoietic defect(427,428). For the purposes of this work W-sh mice, on a 
C57Bl/6  background  (B6.Cg-Kit
W-sh/HNihrJaeBsmJ,  stock  number  005051)  were 
ordered directly from The Jackson Laboratory (Bar Harbor, Maine, USA) and a 
colony established with the help of Biological Services, University of Glasgow. 
All  animals  were  housed  in  pathogen-free  conditions  in  facilities  run  by 
Biological  Services,  University  of  Glasgow  in  strict  accordance  with  United 
Kingdom Home Office regulations under the Animals (Scientific Procedures) Act 
1986.  Animals  were  given  access  ad  libitum  to  standard  feed  and  water.  All Chapter 2:  64 
procedures were carried under Project Licence Number 60/3119, Procedure 9, or 
Project Licence Number 60/3791, Procedure 5.  
 
2.3 In vivo procedures 
2.3.1 Antigen dosing procedures 
2.3.1.1  Intranasal dosing 
Mice were anaesthetised by the intraperitoneal injection of 250  µl of avertin 
solution (1:40 dilution of avertin stock in PBS). Using a 200 µl pipette, 30 µl of 
reagent  in  sterile  PBS  was  administered to  the nostrils.  Mice  recovered  from 
anaesthesia in a warmed box with supplemental oxygen. 
2.3.1.2  Intratracheal dosing 
Mice were anaesthetised by the intraperitoneal injection of 250  µl of avertin 
before being placed upon a custom made support which separated the upper and 
lower  incisors.  This  allowed  direct  insertion  of  a  blunt-tipped  25G  needle 
(Becton Dickinson, Franklin Lakes, USA; blunted by the IBLS Workshop, University 
of Glasgow) into the trachea and instillation of 50 µl of reagent in sterile PBS. 
Mice  were  removed  from  the apparatus and  recovered  from anaesthesia  in a 
warmed box with supplemental oxygen. 
2.3.2 Induction of allergic airways inflammation 
Initially a model of experimental asthma was employed that was already in use 
within  the  laboratory(429-431),  and  had  been  adapted  from  a  previously 
published model(432). Female BALB/c mice aged 6-8 weeks were immunised by 
IP injection of 100 µg chicken ovalbumin (OVA, Grade V, Sigma-Aldrich) adsorbed 
to  2mg  aluminium  hydroxide  (alum,  Brenntag  Biosector,  Frederlkssund, 
Denmark) on days 0 and 14. On days 14, 25, 26 and 27 mice were challenged 
with 30 µg OVA by intranasal administration. Mice were culled on day 28 by IP 
injection  of  avertin  500  µl  before  exsanguination.  Samples  were  collected  as 
detailed below. In some experiments airway AHR to methacholine was measured Chapter 2:  65 
by Penh on day 28 prior to culling. As detailed in Chapter 4, modifications were 
made to this model during the course of this work. 
2.3.3 IL-33 administration 
As detailed in Chapter 5, a number of different dosing protocols were used in 
the  study  of  the  effect  of  IL-33  upon  the  lungs.  Female  wild  type  or  ST2
-/- 
BALB/c, or wild type or W-sh C57Bl/6 mice aged 6-8 weeks received 2 µg of 
murine  IL-33  using  the  intranasal  dosing  technique.  In  the  administration  of 
multiple doses the interval was 24 hours between dosing. Mice were culled 24 or 
more hours after the final dose by the method detailed in Section 2.3.2. Samples 
were collected as detailed below. In some experiments AHR was measured by 
Penh prior to culling. 
2.3.4 Measure of airways hyperresponsiveness 
The  gold  standard  for  the  assessment  of  AHR  is  to  directly  measure  airflow 
resistance  and  lung  compliance  in  anaesthetised  mice  via  tracheostomy. 
However this technique is not only technically demanding and time consuming, 
but also requires considerable expertise and investment in equipment. Due to 
local experience the decision was made to use whole body plethysmograph, the 
equipment for which was available. This technique is used to measure Enhanced 
Pause (Penh) as an indicator of airways responsiveness to broncho-provocation 
with  methacholine(29).  Animals  are  placed  in  a  sealed  chamber  with  a 
transducer which measures the pressure changes within it. These changes are 
driven by the respiratory cycle of the mouse within the chamber, partly as a 
direct  result  of  airflow  and  partly  due  to  rapid  warming  and  cooling  of  air 
entering  and  leaving  the  lungs.  Penh  is  a  dimensionless  parameter  which  is 
derived  from  the  relationship  between  inspiratory  and  expiratory  pressure  as 
well as the „pause‟ which occurs at the end of expiration. Penh correlates well 
with the more technically demanding invasive measurements and remains widely 
used in murine models of asthma(29,31-34). 
Penh was measured at doubling doses, from 12.5 to 50 mg/ml of methacholine, 
as  previously  described(29).  Briefly,  individual  mice  were  placed  in  each 
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undisturbed for a 30 minute acclimatisation period. Mice were then challenged 
for  2  minute  periods  with  nebulised  saline  (control)  or  graded  doses  of 
methacholine chloride. Penh was continually measured and an average reading 
for the challenge period calculated using EMMS EDAQ® software. 
2.3.5 Sample collection and preparation 
2.3.5.1  Serum 
Mice  were  injected  with  a  lethal  dose  (500  µg)  of  avertin  and  killed  by 
exsanguinations following the onset of full anaesthesia. The heart was exposed 
and blood withdrawn using a 1 ml syringe and 23G needle. The blood was stored 
in  1.5  ml  centrifuge  tubes  for  2-3  hours  to  allow  clotting,  before  being 
centrifuged at 14,000 rpm at 4°C for 30 mins (Jouan BR4i centrifuge). Serum was 
then decanted and stored at -20°C until analysed. 
2.3.5.2  Bronchoalveolar lavage 
After  termination  by cardiac  puncture,  BAL  was  performed.  The  trachea  was 
exposed and a small incision made at the proximal end to allow cannulation with 
a  1  ml  syringe  and  23G  needle  sheathed  with  polythene  tubing  (0.58mm  ID, 
0.78mm OD; VWR International). The needle was held in place and a seal formed 
using forceps, before instilling 0.8 ml of PBS into the lungs. After 10 seconds the 
fluid was aspirated and the process repeated with a second 0.8 ml aliquot. All 
the aspirated fluid was pooled in a 1.5 ml centrifuge tube and stored on ice until 
further  processing.  Live  cell  counts  were  performed  in  a  Neubauer 
haemocytometer  (Weber  Scientific  International  Ltd,  Teddington,  UK)  using  a 
1:2  dilution  with  0.4%  trypan blue  solution.  1x10
5  cells  were  spun  onto  glass 
slides using a Shandon Cytospin3 (ThermoShandon, Runcorn, UK) at 350rpm for 6 
minutes. Slides were air dried before fixing in methanol at room temperature for 
10 minutes. Fixed slides were stained by the Romanovsky method using Rapi-Diff 
II (BIOS Europe Limited, Lancashire, UK) and coverslips secured in place with 
DPX (BDH Laboratory Supplies, Poole, UK).
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2.3.5.3  Lung and lymph node collection 
Once  BAL  had  been  performed  the  lungs  were  carefully  removed  from  the 
thorax, en bloc with the heart. In some experiments the lymph nodes draining 
the  lungs  were  harvested  to  study  the  response  of  local  T  cells.  For  these 
purposes  mediastinal  lymph  nodes  were  collected  and  placed  in  1.5  ml 
centrifuge tubes containing complete medium, where they were stored on ice 
until further processing. In experiments where lung histology was required lungs 
were inflated with 10% neutral buffered formalin (NBF, Sigma) via the trachea 
using a 1 ml syringe and 23G needle sheathed with polythene tubing, as used for 
BAL. The trachea was then tied off with thread and the lungs immersed in 10% 
NBF for later analysis. 
2.3.5.4  Bone marrow collection 
Mice aged 6-8 weeks were killed by cervical dislocation and the femur and tibia 
aseptically removed from both legs and placed in complete medium on ice until 
further processing. Under sterile conditions the proximal and distal ends were 
removed and the shaft flushed with RPMI 1640 medium using a 0.5 ml syringe 
with a prefitted 29G needle (MONOJECT insulin syringe, Covidien, Ireland). The 
cells  were  then  dispersed  by  passage  through  a  100  μm  nylon  monofilament  
gauze  (Cadisch  Precision  Meshes,  London)  and  washed  twice  in  RPMI  1640 
medium  by  centrifugation  at  1400  rpm  for  5  minutes  at  4°C  (Jouan  CR3i 
centrifuge). Cells were resuspended in complete medium before being counted 
in a haemocytometer. 
2.3.6 In vitro culture 
All cell culture work was carried out under sterile conditions and wash steps 
were performed using sterile RPMI 1640 medium followed by centrifuge at 1400 
rpm for 5 minutes at 4°C (Jouan CR3i centrifuge) unless otherwise stated. Live 
cell counts were performed in a haemocytometer using a between a 1:2 and 1:10 
dilution with 0.4% trypan blue solution. Cultures were incubated at 37°C in a 
humidified incubator supplemented with 5% CO2. Chapter 2:  68 
2.3.7 Cell lines 
The human HMC-1 mast cell line was kindly donated by Dr J.H. Butterfield (Mayo 
Clinic,  USA)  and  maintained  in  tissue  culture  flasks  in  complete  IMDM.  The 
murine P815 mast cell line was obtained from American Type Culture Collection, 
USA and maintained in tissue culture flasks in standard complete medium. Cells 
were split approximately twice per week. 
2.3.8 Bone marrow mast cell culture 
Bone  marrow  cells  were  prepared  at  a  concentration  of  1x10
6  cells/ml  in 
complete  medium  and  cultured  in  tissue  culture  flasks.  Medium  was 
supplemented with stem cell factor (PeproTech, London, UK) at 50 ng/ml and IL-
3 (PeproTech, London, UK) at 1 ng/ml. Twice per week, one third of the culture 
medium was aspirated and centrifuged at 1400 rpm for 5 minutes at 4°C (Jouan 
CR3i centrifuge).  The medium was discarded and the cells resuspened in the 
same volume of complete medium containing stem cell factor (SCF) at 50 ng/ml 
and IL-3 at 1 ng/ml. Once a week cell counts were performed and the volume in 
each flask adjusted to maintain a concentration of between 0.5x10
6 and 1.5x10
6 
cells/ml. 
2.3.9 IL-33 stimulation 
Mast cells were cultured at a concentration of 1x10
6 cells/ml in 24, 48 or 96 well 
culture plates. Recombinant murine IL-33 was added to give the final desired 
concentration, medium alone was used in control cultures. Each condition was 
replicated in duplicate or triplicate. After the desired culture period medium 
was aspirated. In some cases the entire plate was centrifuged at 1400 rpm for 5 
minutes at 4°C (Jouan CR3i centrifuge) before supernatants were aspirated, in 
other cases the medium was aspirated into separate 1.5 ml tubes which were 
then centrifuged prior to supernatants being aspirated. All samples were stored 
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2.3.10  Lymph node culture 
Lymph  nodes  were  prepared  by  crushing  under  100  μm  nylon  monofilament 
gauze (Cadisch) with a 5 ml syringe plunger in RPMI 1640 medium.  Single cell 
suspensions were made by passing through nylon gauze into 25 ml centrifuge 
tubes before being washed twice. Cells were resuspended in complete medium 
and counted. Cells were placed in 24 well culture plates at a final concentration 
of  1x10
6  cells/ml  and  stimulated  with  medium  alone  or  sterile  OVA  at  final 
concentration  of  1  mg/ml.  After  72  hours  of  incubation  supernatants  were 
aspirated frozen for later analysis. 
To asses proliferation, lymph nodes cells were prepared and stimulated as above 
in triplicate for 48 hrs in round-bottomed 96 well tissue culture plates (200 μl 
per  well).  15kBq  of  Tritiated  [
3H]-thymidine  (West  of  Scotland  Radionuclide 
Dispensary, Glasgow, UK) in 10μl sterile wash medium was added for the last 8 
hours of culture. Cells were harvested onto glass fibre filter paper (PerkinElmer, 
Beaconsfield, UK) using a 295-0054 Betaplate 96 well harvester (PerkinElmer). 
[
3H]-thymidine incorporation was measured using a MicroBeta TriLux scintillation 
counter  (PerkinElmer).  All  procedures  were  performed  according  to  local 
radiation safety guidelines. 
 
2.4 Assays and analysis 
2.4.1 Flow cytometry [FACS] 
Prior to analysis mast cell numbers were counted and 1x10
5 cells added to FACS 
tubes (BD Biosciences, Oxford, UK) and kept on ice. Cells were centrifuged at 
1400 rpm for 5 minutes at 4°C (Jouan CR3i centrifuge) and washed in 1 ml FACS 
buffer before being suspended in a final volume of 40 µl FACS buffer. 1 µl of Fc 
block (anti- CD16/CD32, BD Biosciences) was added to each tube and incubated 
for  5  minutes.  Fluorochrome  labelled  anti-ST2,  anti-FcεRIα  and  anti-c-kit 
antibodies were added as detailed in Table 2.2. Full compensation was carried 
out before any FACS analysis and therefore a number of tubes were prepared 
with isotype controls as shown in Table 2.3 using mature mast cells. Antibodies Chapter 2:  70 
were incubated for 30 minutes on ice in the dark, after which cells were washed 
in 1 ml of FACS buffer before being resuspended in 400 µl of FACS buffer. Prior 
to analysis 3 µl of 7-Amino-actinomycin D (7-AAD, Via-Probe, BD Biosciences) was 
added to each tube to enable exclusion of dead cells. 
Samples were analysed using a FACSCalibur flow cytometer (BD Biosciences) and 
data acquired using CellQuest software (BD Biosciences). Live cells were gated 
according to FSC and SSC using the sample “cells”. 7-AAD positive dead cells 
were then excluding by gating using samples “cells” and “via”. Four quadrant 
plots were then made with each combination of FL1 (FITC), FL2 (PE) and FL4 
(APC). Using sample “iso” gates were drawn so that less than 2% of total cells 
were falsely positive on any axis. Using the single stained samples “ST2”, “Fcε” 
and “c-kit” compensation was carried out for emission overlap. The sample “no 
ST2” was run as a final isotype control for detailed analysis of ST2 expression. 
All  data  analysis  was  carried  out  using  the  FlowJo  package  (Tree  Star  Inc., 
Oregon, USA). 
 
Specifcity  Label  Volume  Supplier  Cat No.  Clone  Isotype 
ST2  FITC  2 ul  MDB   101001F  DJ8  Rat IgG1 
isotype  FITC  4 ul  BD  BD553924  R3-34  Rat IgG1 
FcRIα  PE  1 ul  EB  12-5898-81  MAR-1  Hamster IgG 
isotype  PE  1 ul  BD  BD553972  A19-3  Hamster IgG1 
c-kit  APC  1 ul  BD  BD553356  2B8  Rat IgG2b, κ 
isotype  APC  1 ul  BD  BD556924  A95-1  Rat IgG2b 
Table 2.2 – FACS antibodies 
Key -  MDB = MD Biosciences, Zürich, Switzerland. BD = BD Biosciences, Oxford, UK. 
EB = EBioscience, Hatfield, UK.  
 
 
Label  FITC Antibody  PE Antibody  APC Antibody  7AAD 
cells  -  -  -  - 
via  -  -  -  3 l 
iso  isotype  isotype   isotype   - 
ST2  anti-ST2  isotype   isotype   - 
Fc  isotype  anti-FcεRIα   isotype   - 
c-kit  isotype  isotype   anti-c-kit  - 
no ST2  isotype  anti-FcεRIα   anti-c-kit  3 l 
Table 2.3 – Samples used in FACS compensation 
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2.4.2 Cytokine immunoassay 
Enzyme  linked  immunosorbant  assays  (ELISAs)  were  performed  using  paired 
antibodies  or  kits.  Protocols  and  reagents  differed  depending  on  manufacturer. 
Table 2.4 details antibodies used. Buffers used are as detailed in Table 2.1. 
 
Analyte 
 
Supplier 
 
Capture 
(ug/ml) 
Detection 
(ug/ml) 
Sensitivity 
(pg/ml) 
Murine         
IL-4  BD  2  2  20 - 20,000 
IL-5  BD  4  4  10 - 10,000 
IL-6  BD  1  1  10 - 10,000 
IL-13  R&D  Kit  Kit  5 - 5,000 
TNFα  BD  Kit  Kit  4 - 4,000 
IFNγ  BD  1  1  40 – 40,000 
MIP-1α  R&D  Kit  Kit  5 - 5,000 
Eotaxin-1  R&D  0.8  0.4  5 - 500 
Eotaxin-2  R&D  2  0.075  4 - 4,000 
TARC  R&D  2  0.2  5 - 1,000 
RANTES  R&D  2  0.4  5 - 1,000 
OVA-IgE  BD  -  2   -  
OVA-IgG1  BD  -  0.5   -  
OVA-IgG2a  BD  -  0.5   -  
Human         
TNFα  Invitrogen  Kit  Kit  4 - 4,000 
IL-5  R&D  Kit  Kit  3 - 3,000 
MIP-1α  R&D  Kit  Kit  5 - 2,000 
Eotaxin-1  R&D  Kit  Kit  5 - 5,000 
Table 2.4 – ELISA antibodies and concentrations 
 
The protocol that follows is for antibody pairs from BD Biosciences. Unless stated 
otherwise all reagents and samples were added at a final volume of 50 µl/well. 
Immulon  4  HBX  plates  (Thermo  Labsystems,  Franklin,  USA)  were  coated  with 
detection antibody in BD ELISA coating buffer and incubated overnight. Plates 
were  washed  three  times  with  ELISA  wash  buffer  then  incubated  with  200 
µl/well of assay buffer for 1 hour at 37°C. After washing three times samples 
and standards were added. An eleven point doubling dilution standard curve and 
a  blank  were  employed,  both  in  duplicate  and  using  assay  buffer.  After 
incubation  for  2  hours  at  room  temperature  plates  were  washed  five  times 
before biotin-conjugated detection antibody in assay buffer was added to each 
well. After 1 hour at room temperature plates were washed three times and 
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buffer,  was added.  After 30 mintes plates were washed three times and 100 
µl/well of TMB substrate (KPL, Gaithersburg, USA) added. Plates were incubated 
in the dark for up to 30 minutes or until sufficient blue colour had developed. 
Optical density was read on an MRX II microplate reader (Dynex Technologies, 
Worthing, UK) at 630 nm running Revelation (Dynex Technologies) software, and 
sample values calculated from the standard curves generated. 
The protocol for antibodies from R&D (Abingdon, UK) was as above but the R&D 
ELISA assay buffer (Table 2.1) and Streptavidin-HRP conjugate provided by R&D 
and  diluted  to  1:200  were  used.  In  addition  the  detection  antibody  was 
incubated  for  2  hours  rather  than  1.  The  Eotaxin-2  detection  antibody  was 
diluted in the R&D ELISA assay buffer with the addition of 2% heat-inactivated 
normal goat serum. 
The  protocol  for  antibodies  from  Invitrogen  was  as  for  the  BD  ELISA  but  the 
following modifications. Invitrogen ELISA assay buffer was used. The sample and 
detection steps were combined, with 50 µl/well of sample or standard added to 
each well followed immediately by 25  µl/well of detection antibody in assay 
buffer and then a 2 hour incubation. Streptavidin-HRP conjugate (Invitrogen) was 
used at a dilution of 1:200 in assay buffer. 
2.4.3 Ovalbumin-specific immunoassay 
OVA-specific IgE ELISA was carried out using BD ELISA assay buffer and volumes 
of 50 µl/well. Immulon 4 HBX plates (Thermo) were coated with OVA 10 µg/ml in 
OptEIA  buffer and incubated overnight. Plates were washed three times with 
ELISA wash buffer then incubated with 200 µl/well of assay buffer for 1 hour at 
37°C before being washed three times again. In the absence of any standard for 
OVA  specific  immunoglobulins,  serial  dilution  curves  were  obtained  for  each 
sample using assay buffer as a diluent. An initial sample dilution of between 1:10 
and 1:40 was used with serial 1:2 or 1:3 dilutions thereafter. After incubating for 
2 hours at room temperature plates washed five times. Detection antibody and 
Streptavidin-HRP  conjugate  (Enzyme  Concentrate  Avidin-HRP,  BD  Biosciences) 
were both diluted 1:250 together in assay buffer and 50 µl added to each well. 
After 1 hour plates were washed three times and 100 µl/well of TMB substrate 
(KPL) added. Plates were incubated in the dark for up to 30 minutes or until Chapter 2:  73 
sufficient  blue  colour  had  developed.  Optical  density  was  read  on  an  MRX  II 
microplate reader (Dynex Technologies)  at 630 nm running Revelation (Dynex 
Technologies) software. 
OVA-specific IgG1 and IgG2a ELISA were carried out with an identical protocol 
with the following modifications. Initial sample dilution for IgG1 was 1:500 with 
1:3  serial  dilutions  and  for  IgG2a  between  1:20  and  1:50  with  1:2  dilutions. 
Detection  antibody  was  added  alone  as  a  separate  step  with  a  one  hour 
incubation, followed by washing and the addition of Streptavidin-HRP conjugate 
(Sigma) incubated for 30 minutes.  
2.4.4 Multiplexed immunoassay 
Multiplexed  immunoassay  is  a  method  by  which  multiple  cytokines  or  other 
mediators  are  measured  simultaneously  in  a  small  volume  of  fluid.  This  is 
achieved by using latex microbeads that are stably labelled with a characteristic 
mix  of  two  fluorochromes  and  have  an  antibody  to  one  specific  analyte 
covalently attached to the surface.  When incubated in the test solution,  the 
antibody  will  bind  its  target  cytokine  in  proportion  to  its  concentration,  and 
bound cytokine after washing can be detected using a biotin-labelled specific 
antibody in a sandwich-style immunoassay. Each bead can then be identified by 
its intrinsic twin fluorescent characteristics by flow cytometry. A streptavidin-
labelled third fluorochrome is used to quantify the antibody bound to on each 
bead which will be propotional to the concentration of the analyte in the test 
solution.  This  system  can  be  made  to  quantify  multiple  ligands  by  using 
microbeads with different intrinsic fluorescent characteristics that are bound to 
mediator specific antibodies. 
Biosource Multiplex kits LHC0009 (Cytokine Human 25-Plex), LMC0006 (Cytokine 
Mouse 20-Plex) and LMC1031 (RANTES Mouse Singleplex) were used according to 
the manufacturer‟s instructions. All reagents and buffers were sourced from the 
kits. Briefly, the supplied 96 well filter plate was pre-wetted with Wash solution 
before aspiration of well contents using vacuum apparatus. If more than one kit 
was being used, beads were premixed. Otherwise beads were resuspended and 
50  µl  bead  mixture  added  per  well  and  washed  twice  by  the  addition  and 
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added followed by 100 µl/well standard or 50µl Assay Diluent plus 50µl sample. 
Plates were protected from the light by aluminium foil and incubated on shaking 
apparatus at room temperature for 2 hours. The wells were then washed twice 
and 100 µl/well biotinylated detection antibody added and incubated for 1 hour 
as above. Following two more washes, 100 µl/well Steptavidin-RPE was added 
and incubated for 30 minutes as above. The wells were washed three more times 
before resuspending the beads in 100 µl/well Wash solution and acquiring data 
on a Luminex 100TM analyser(Luminex Corp., Texas, USA). Data was analysed 
using Luminex software (Luminex Corp.). 
2.4.5 Mast cell degranulation assay 
Degranulation of BMMCs in response to the calcium ionophore ionomycin (Sigma) 
was  assessed  by  the  measurement  of  β-hexosaminidase  release.  Cells  were 
added to 96 well plates at a concentration of 1x10
6 cells/ml. PBS or ionomycin 
at a final concentration of 1 µg/ml was added and the plates incubated at 37°C 
for 30 minutes. The plates were centrifuged at 1400 rpm for 5 minutes at 4°C 
(Jouan CR3i centrifuge) and the supernatants aspirated. The cell pellets were 
lysed  by  the  addition  of  1%  Triton-X (Sigma)  in  PBS.  25  µl  of  supernatant  or 
lysate  was  then  placed  in  each  well  of  an  Immulon  4  HBX  plate  (Thermo 
Labsystems)  and  50  µl  of  p-nitrophenyl-N-acetyl-β-d-glucosamine  (NAG,Sigma) 
substrate solution 1mM in 0.05M citrate buffer was added. After incubation in 
the dark at 37°C for 1 hour the reaction was quenched by the addition of sodium 
carbonate buffer 150 µl/well. Optical density was read on an MRX II microplate 
reader (Dynex Technologies) at 405 nm running Revelation (Dynex Technologies) 
software. 
2.4.6 Lung lavage analysis 
Differential  cell  counts  were  performed  on  cytospin  preparations  from  BAL 
samples stained and mounted as in Section 2.3.5. Slides were randomised and 
blinded before counting. Using a light microscope at least 400 cells per slide 
were  identified  by  staining  and  morphological  characteristics  at  x1000 
magnification (Figure 2.1). Chapter 2:  75 
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Figure 2.1 – Cytospin preparation of murine bronchoalveolar lavage  
Allergic  airways  inflammation  was  induced  in  BALB/c  mice  as  described  in  2.3.2.  BAL  was 
collected and cytospins prepared and stained with Rapi-Diff II Romanowsky stain as described 
above.  Shown  are  representative  images  of  (A)  a  macrophage,  (B)  eosinophils  and  (C) 
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2.4.7 Lung histology 
The  lungs  and  heart  were  removed  en  bloc  as  detailed  in  Section  2.3.5  and 
placed in 10% NBF for at least 48 hours. They were then mounted in paraffin 
blocks,  and  6  μm  sections  stained  with  haematoxylin  and  eosin  (H&E;  kindly 
performed by Mr. Roderick Ferrier, Department of Pathology, Western Infirmary, 
Glasgow).  Sections  were  examined  by  light  microscopy  and  peribronchial  and 
perivascular inflammation assessed. 
 
2.5 Statistics 
Data  were  obtained  from  in  vitro  experiments  and  samples  from  in  vivo 
experiments. Cell numbers, relative cell percentages, mediator concentrations 
and Penh (a dimensionless measure of AHR) were subject to statistical analysis. 
These are all quantitative variables which are normally distributed with equal 
variance. Therefore mean values were calculated and expressed with standard 
errors of the mean (SEM), and tests of significance performed using  with 95% 
confidence intervals and unpaired Student‟s two-sample T-test, one-way ANOVA 
or  two-way  ANOVA  depending  on  the  data.  A  p  value  of  less  than  0.05  was 
considered significant. Statistical analysis was performed using Excel (Microsoft, 
Redmond, USA) and Minitab (Minitab Inc, State College, USA) software packages. 
Prior  to  undertaking  in  vivo  work  power  calculations  were  performed  where 
possible to inform sample size. For example, in the model of allergic airways 
inflammation, experiments were designed to detect a difference of 20% in mean 
BAL eosinophil percentage with a significance of 0.05 and a power of 0.95. From 
preliminary experiments the standard deviation of the BAL eosinophil percentage 
is 10%. As shown in Figure 2.2 a sample size of 8 mice per group is required. Chapter 2:  77 
 
Power and Sample Size  
 
2-Sample t Test 
 
Testing mean 1 = mean 2 (versus not =) 
Calculating power for mean 1 = mean 2 + difference 
Alpha = 0.05  Assumed standard deviation = 10 
 
 
            Sample  Target 
Difference    Size   Power  Actual Power 
        20       8    0.95      0.960221 
 
The sample size is for each group. 
 
Figure 2.2 – Power calculation for the sample size required in experimental asthma 
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The role of mast cell ST2 and the effect of 
activation by IL-33 
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In this chapter I will investigate the effect of IL-33 on mast cell lines before 
examining the role of ST2 in mast cell development and the effect of IL-33 on 
wild type and ST2 gene knock-out bone marrow mast cells. 
3.1 Introduction 
Initial  studies  of  ST2  focused on  fibroblasts,  where  the  transcripts  were  first 
identified(321). Following the discovery that ST2 is selectively expressed on Th2 
cells but not Th1 cells(359,360,365),  T cells and Th2 inflammation became a 
major  focus  of  ST2  research.  Mast  cells,  however,  received  relatively  little 
attention in studies of ST2. 
Not  only  do  mast  cells  express  ST2  from  a  very  early  stage  of  cell 
development(380) but expression on mature mast cells appears to be ubiquitous 
and at high levels(348,381). Despite this, it has been reported that ST2
-/- mice 
have normal mast cell numbers and that histamine and IL-4 production is not 
impaired in mast cells generated from such mice(381). It seems likely that ST2 is 
a  functional  receptor  on  mast  cells  as  treatment  with  IL-33  induces  NFκB, 
Erk1/2, p38, and JNK phosphorylation(323). 
In an attempt to understand the role of ST2 on mast cells I set out to generate 
bone marrow derived mast cells (BMMCs) from wild type and ST2
-/- mice and to 
study the effect of IL-33 on these cells. My hypothesis is „IL-33 stimulates BMMCs 
to release cytokines and chemokines‟. 
 
3.2 The role of ST2 on human and murine mast cell lines 
Before attempting to establish a bone marrow culture system I sought to obtain 
proof of concept utilising mast cell lines. The HMC-1 human mast cell line is 
immortalised  due  to  a  constitutively  active  form  of  c-kit(433),  the  stem  cell 
factor (SCF) receptor. Although it does not express receptors for IgE(434) it has 
been widely used in studies of mast cells.  The P815 murine mast cell line was 
described over 50 years ago(435) and like the HMC-1 cell line has a constitutively 
active form of c-kit(436) and also lacks the high affinity IgE receptor, FcεRI(437). Chapter 3:  80 
3.2.1 IL-33 induces cytokine production by human HMC-1 cells 
First I attempted to establish if mast cells could be induced to release cytokines 
when  stimulated  with  IL-33.  HMC-1  cells  were  harvested  when  they  reached 
confluence and stimulated with increasing concentrations of recombinant human 
IL-33 (hIL-33). In order to establish a time course, supernatants were harvested 
after 3, 24 and 48 hours of culture. Since activated mast cells are capable of 
releasing  both  pre-formed  and  newly  synthesised  TNFα(438)  and  mast  cell 
derived TNFα appears to be important in asthma(33,163), I chose to measure 
TNFα  release  by  ELISA.  IL-33  induced  a  dose  dependent  rise  in  TNFα 
concentration which was significant at 24 hours but not 48 hours (Figure 3.1). 
TNFα was detected at higher concentrations the longer the incubation period, 
although this effect was also evident in the absence of IL-33, suggesting that 
there is a basal level of TNFα production which is enhanced by IL-33. In summary 
the optimum activation of mast cells with IL-33 was achieved after 24 hours. 
To examine the possibility that the IL-33 induced increase in TNFα concentration 
was due to a pro-proliferative effect, cell counts were performed at each time 
point for each concentration. IL-33 had no effect on cell numbers following 48 
hours  of  culture  (Figure  3.1D)  and  consequently  the  effect  of  IL-33  on  TNFα 
release was preserved even when calculated as pg/10
5 cells (Figure  3.1E). In 
addition there was no effect on cell viability (data not shown). 
Given  that  the  administration  of  IL-33  in  vivo  results  in  the  accumulation  of 
eosinophils(323) I looked for IL-33 induced HMC-1 production of IL-5 and eotaxin, 
which have been shown to play a key role in eosinophil maturation, mobilization 
and  chemotaxis(74).  IL-33  did  not  induce  the  release  of  eotaxin  or  IL-5  at 
detectable levels after 48 hours of culture (Figure 3.2). IL-5 and eotaxin were 
also undetectable after 3 or 24 hours of culture with IL-33 (data not shown). 
To determine the optimum dose of IL-33 and duration of treatment for further 
study a more complete dose response was characterised using between 0.01 and 
100 ng/ml of hIL-33. As TNFα had been almost undetectable following 3 hours of 
culture samples were only collected at 24 and 48 hours. As shown in Figure 3.3 a 
dose  response  curve  was  obtained  which  was  most  robust  at  24  hours,  with 
evidence of a significant response from 10 ng/ml of IL-33. Chapter 3:  81 
Although  there  was  evidence  of  a  dose  responsive  release  of  TNFα  by  IL-33 
stimulated mast cells, levels are low, rising to just above 100 pg/ml following 48 
hours of stimulation with 100 ng/ml of IL-33. This may reflect the fact that HMC-
1 mast cells appear to be relatively poor producers of TNFα(439). Consequently I 
used multiplexed immunoassay as a screening tool to look for the production of 
other  cytokines  or  chemokines  by  HMC-1  cells  stimulated  with  IL-33.  IL-33 
induced the production of the chemokines MIP-1α, MIP-1β and MCP-1 at ng/ml 
levels and TNFα, IL-6 and IL-8 at lower levels (Figure 3.4). IL-1β, IL-2, IL-4, IL-5, 
IL-7, IL-10, IL-12, IL-13, IL-15, IL-17, IFNα IFNγ, eotaxin, RANTES, IP-10, MIG and 
GM-CSF were not induced at appreciable levels (data not shown). 
Although MCP-1 was produced at the highest levels baseline production in the 
absence of IL-33 stimulation was also high, meaning that IL-33 induced just over 
a twofold rise in MCP-1 production. MIP-1α was also produced at high levels, but 
as baseline production was lower the rise represent a 9 fold increase in MIP-1α 
production. In order to characterise the IL-33 induced production of MIP-1α a full 
dose response curve was obtained (Figure 3.5). Although levels of IL-33 induced 
MIP-1α were highest following 48 hours of culture, baseline MIP-1α production 
was  also  higher  and  a  significant  response  to  IL-33  was  only  observed  at 
concentrations of 10 ng/ml and above. Following 24 hours of culture a better 
dose response curve was obtained with significant MIP-1α induction over baseline 
observed with concentrations of IL-33 as low as 1 ng/ml. 
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Figure 3.1 – IL-33 induces TNFα production by HMC-1 cells 
HMC-1 cells were harvested and washed when they reached confluence before being plated into 
24  well  plates  in  duplicate.  hIL-33  was  added  at  0,  6.7  or  20  ng/ml  and  aliquots  of  the 
supernatant were harvested at (A) 3, (B) 24 and (C) 48 hours. TNFα was measured by ELISA. At 
48 hours cell numbers were counted and cell concentration (D) and TNFα production per cell (E) 
calculated. Results are shown as the mean of duplicate culture wells +/- SEM. One-way ANOVA 
p<0.05 for the effect of IL-33 on TNFα at 24 hours, not significant at 3 and 48 hours. Chapter 3:  83 
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Figure 3.2 – IL-33 does not induce IL-5 or eotaxin production by HMC-1 cells 
HMC-1 cells were cultured with hIL-33 as in Figure 3.1 and supernatants were collected after 48 
hours.  IL-5  (A)  and  eotaxin  (B)  were  measured  by  ELISA.  Results  are  shown  as  the  mean  of 
duplicate culture wells +/- SEM. 
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Figure 3.3 – IL-33 induced TNFα production by HMC-1 cells is dose dependent  
HMC-1 cells were harvested when they reached confluence and were washed before being plated 
into a 24 well plate in triplicate. hIL-33 was added at between 0.01 and 100 ng/ml and aliquots 
of the supernatant were harvested at 24 (A) and 48 (B) hours. TNFα was measured by ELISA. 
Results are shown as the mean of triplicate culture wells +/- SEM. * p<0.05, ** p<0.01 compared 
with PBS. Chapter 3:  84 
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Figure 3.4 - IL-33 induces the production of cytokines and chemokines by HMC-1 cells 
HMC-1 cells were cultured with 0 or 100 ng/ml of hIL-33 as in Figure 3.3 and supernatants were 
collected  after  48  hours.  MIP-1α,  MIP-1β,  MCP-1,  TNFα,  IL-6  and  IL-8  were  measured  by 
multiplexed immunoassay. Results are from single samples. 
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Figure 3.5 - IL-33 induced MIP-1α production by HMC-1 cells is dose dependent 
HMC-1  cells  were  cultured  with  between  0.01  and  100  ng/ml  of  hIL-33  as  in  Figure  3.3  and 
aliquots of the supernatant were harvested at 24 and 48 hours. MIP-1α was measured by ELISA. 
Results are shown as the mean of triplicate culture wells +/- SEM. * p<0.05, ** p<0.01 compared 
with PBS. Chapter 3:  85 
3.2.2 IL-33 induces cytokine production by murine P815 cells 
The  data  above  demonstrate  that  IL-33  is  able  to  induce  dose  dependent 
chemokine and cytokine production from a human mast cell line. I hypothesised 
that  this  effect  was  not  species  specific  and  that  a  similar  effect  would  be 
observed in a murine cell line. I set out to test this hypothesis using cells of the 
P815  murine  mast  cell  line,  which  has  been  shown  to  express  ST2  on  the 
surface(348). Before carrying out further in vitro studies I sought not only to 
confirm that P815 cells expressed ST2 on their surface in my hands, but also to 
validate my FACS reagents and technique for the measuring the expression of 
ST2.  P815 cells  were freshly isolated from culture and stained with ST2-FITC 
antibodies before being analysed by FACS. These unstimulated P815 cells grown 
under standard culture conditions were uniformly ST2 positive (Figure 3.6). 
Given that the response to IL-33 was most evident after 24 hours of stimulation 
in  HMC-1  cells  this  time  point  was  also  chosen  in  the  study  of  P815  cells. 
Although there was no evidence of cytokine production at 3 hours in HMC-1 cells, 
this  time  point  was  also  studied  to  examine  the  possibility  of  early  cytokine 
release from P815 cells. Our group have previously found that human IL-33 is 
bioactive on murine T cells in vitro and so in these preliminary experiments hIL-
33 was used. 
P815 cells cultured in the presence of hIL-33 showed a similar pattern of TNFα 
production to HMC-1 cells with evidence of a dose response but with only low 
levels detected (Figure 3.7A). In contrast to HMC-1 cells there was no detectable 
MIP-1α at 24 hours at even the highest concentration of IL-33 (Figure 3.7B). IL-6 
on the other hand was produced at high levels with a significant response to 
concentrations of IL-33 as low as 0.1 ng/ml (Figure 3.7C). Once again I looked 
for  the  production  of  cytokines  associated  with  eosinophilia  but  found  no 
evidence of IL-5, eotaxin-1 or eotaxin-2 production (Figure 3.7D,E,F). At 3 hours 
all tested cytokines and chemokines were undetectable (data not shown). 
These data demonstrate that a murine mast cell line responds to IL-33 in a dose 
dependent  manner  with  the  release  of  pro-inflammatory  cytokines  and 
chemokines. While there are differences between the responses in human and 
murine  mast  cells,  most  notably  the  failure  of  the  murine  mast  cell  line  to Chapter 3:  86 
produce MIP-1α, it is unclear whether these differences represent a true species 
difference or are simply a reflection of the differences between the specific 
transformed cell lines. 
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Figure 3.6 – P815 cells are ST2 positive 
P815 cells were isolated from ongoing cell culture and stained with ST2-FITC (white) or isotype-
FITC antibodies (grey). 
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Figure 3.7 – IL-33 induces the release of TNFα and IL-6 from P815 cells 
P815 cells were harvested and washed before being plated into a 24 well plate in triplicate at a 
concentration of 1x10
6/ml. hIL-33 was added at between 0.01 and 100 ng/ml and aliquots of the 
supernatant harvested at 24. Cytokines and chemokines were measured by ELISA. Results are 
shown as the mean of triplicate culture wells +/- SEM. * p<0.05, ** p<0.01 compared with PBS. Chapter 3:  89 
3.3 Bone marrow derived mast cell culture 
There were a number of reasons to study the effect of IL-33 on murine BMMCs. 
Most importantly, I hoped to generate BMMCs from mice lacking the ST2 receptor 
and thereby demonstrate a specific ligand-receptor dependence of the observed 
effects. Secondly, the differences seen in the responses of P815 and HMC-1 cells 
raised  questions  over  how  representative  each  cell  line  is  of  the  wider 
population of mast cells. In the case of HMC-1 and P815 cell lines not only are 
they  immortalised  due  to  a  constitutively  activated  SCF  receptor  but  the 
absence  of  the  high  affinity  IgE  receptor,  FcεRI  makes  them  unlike  most 
naturally occurring mast cells. 
3.3.1 Bone marrow mast cell maturation 
While it is possible to directly obtain mature mast cells from mice, from the 
peritoneum for example, the relatively small numbers obtained limit the studies 
possible  and  most  investigators  culture  mast  cells  from  bone  marrow 
progenitors. Mast cells can be obtained from unrefined adult bone marrow cells 
by  prolonged  culture  with  mast  cell  growth  factors,  most  commonly  IL-
3(162,348,381) with the addition of SCF in some cases (440-442). On the basis of 
the experience within the laboratory(A.J. Melendez, personal communication) I 
opted to culture murine bone marrow cells with SCF (50 ng/ml) for the first 
three weeks and IL-3 (1 ng/ml) throughout, a protocol which others have also 
used(443). Mast cell maturity was determined by expression of the α chain of the 
high affinity IgE receptor (FcεRIα) and the SCF receptor (c-kit). Figure 3.8 shows 
an example of the typical gating strategy employed. 
By utilising serial FACS analysis it was possible to monitor the development of 
mature mast cells from bone marrow progenitors and so determine the time at 
which the population was fully mature. As shown in Figure 3.9 after 3 weeks of 
culture  the  majority of  cultured  cells  (81%)  express  neither  FcεRIα  nor  c-kit, 
although  12%  are  already  FcεRIα
+c-kit
+.  With  increasing  culture  time  the 
expression of FcεRIα and c-kit rises. By 6 weeks 85% of cells are c-kit positive 
and  74%  FcεRIα
+c-kit
+.  Further  culture  results  in  99%  of  cells  c-kit
+  and  89% 
FcεRIα
+c-kit
+ by 8 weeks. Consequently BMMCs were considered to be mature Chapter 3:  90 
after  8  weeks  of  culture,  although  maturation  was  always  confirmed  by  the 
presence of at least 95% c-kit
+ cells by FACS. Chapter 3:  91 
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Figure 3.8 - Mature mast cells express FcεRIα and c-kit 
BMMCs  were  harvested  after  8  weeks  of  culture  and  stained  with  anti-FcεRIα  and  anti-c-kit 
antibodies. Cells were identified as a population with high FSC and SSC (A). Live cells were then 
gated by excluding 7-AAD positive cells (B). The expression of c-kit and FcεRIα on these cells was 
then analysed (C). 
 
 
 
Figure 3.9 - The expression of FcεRIα and c-kit on mast cells increase with culture time 
BMMCs were harvested after between 3 and 8 weeks of culture and analysed as described in 
Figure 3.8. Chapter 3:  92 
3.3.2 Expression of ST2 on bone marrow mast cells 
Although other investigators have reported the presence of ST2 on the surface of 
BMMCs(348,380,381) I sought to confirm that ST2 was expressed on the BMMCs I 
had obtained using the culture protocol described. Mature, 8 week old, BMMCs 
are 99% ST2 positive with a high fluorescence intensity, suggesting that not only 
do the majority of mature BMMCs express ST2,  but that they express it at a 
relatively high surface density (Figure 3.10). This is particularly striking when 
compared to other ST2 expressing cells such as T cells(359,360).  It has been 
reported that mast cells express ST2 from a very early stage(380) and Figure 
3.10 also shows that a small proportion of cells within the BMMC culture express 
ST2 after as little as 3 weeks of culture. As the culture progresses the proportion 
of ST2
+ cells rises. 
Given the dynamic changes in the expression of FcεRIα, c-kit and ST2 during the 
course of BMMC culture, and the expression of ST2 on a subset of cells from an 
early stage, I sought to study the relationship between the expression of ST2 and 
the  established  mast  cell  markers  FcεRIα  and  c-kit.  When  cells  were  gated 
according  to  their  expression  of  ST2  (Figure  3.11)  there  was  a  very  strong 
correlation with c-kit. After 3 weeks of culture greater than 95% of ST2- cells 
were c-kit
- and over 90% of these were FcεRIα
-c-kit
-. Greater than 95% of ST2
+ 
cells were c-kit
+ and over 85% of these were FcεRIα
+c-kit
+.  
The corollary of this was to study the expression of ST2 by different populations 
of BMMCs depending on their surface expression of FcεRIα and c-kit. Figure 3.12 
shows  the  expression  of  ST2  by  FcεRIα
-c-kit
-,  FcεRIα
+c-kit
-,  FcεRIα
-c-kit
+  and 
FcεRIα
+c-kit
+ populations at different stages of BMMC culture. At no point is ST2 
convincingly expressed by FcεRIα
-c-kit
- or FcεRIα
+c-kit
- cells. FcεRIα
-c-kit
+ cells 
have a bimodal ST2 expression with ST2
- and ST2
+ subpopulations present from 
very early in the culture. FcεRIα
+c-kit
+ cells on the other hand are 100% ST2 
positive at all times. 
These data suggest a relationship between the expression of ST2 and of c-kit. By 
plotting  the  two  surface  markers  against  each  other  it  possible  to  see  the 
relationship more clearly (Figure 3.13). Chapter 3:  93 
 
 
 
Figure 3.10 – The expression of ST2 on mast cells increases with culture time 
BMMCs were harvested after between 3 and 8 weeks of culture and analysed by FACS as detailed 
in Figure 3.8. Cells were also labelled with anti-ST2 (unshaded) or isotype matched antibody as a 
control (shaded). Chapter 3:  94 
 
 
 
Figure 3.11 – The expression of c-kit and FcεRIα differs according to the expression of ST2 
BMMCs were harvested after 3 or 8 weeks of culture and analysed by FACS as detailed in Figure 
3.10. Cells were then gated according to the expression of ST2 and the expression of c-kit and 
FcεRIα by the ST2- and ST2
+ populations analysed. 
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Figure 3.12 - The expression of ST2 differs according to the expression of c-kit and FcεRIα 
BMMCs were harvested after between 3 and 8 weeks of culture and analysed by FACS as detailed 
in Figure 3.10. Cells were then gated according to the expression of c-kit and FcεRIα and the 
expression of ST2 by these populations analysed. Chapter 3:  96 
 
 
       
 
Figure 3.13 – The expression of ST2 correlates with the expression of c-kit 
BMMCs were harvested after 3 or 8 weeks of culture and analysed by FACS as detailed in Figure 
3.10. 
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3.4 ST2 deficient bone marrow mast cells 
The expression of ST2 at high levels on all mast cells from an early stage in 
development raises the possibility that ST2 may play an important role in the 
development or function of mast cells. It is known that BMMCs can be generated 
from mice in the absence of ST2(381,382) and that such ST2
-/- mast cells produce 
normal levels of IL-4 upon stimulation with PMA and ionomycin, and of histamine 
upon  IgE  crosslinking(381).  However  there  are  no  data  regarding  the 
development  and  surface  phenotype  of  such  mast  cells  from  ST2
-/-  mice.  To 
investigate  the  possibility  that  the  absence  of  ST2  would  alter  BMMC 
development, mast cells were cultured from wild type (WT) and ST2
-/- BALB/c 
mice and their expansion and surface expression of FcεRIα and c-kit measured 
over time. 
3.4.1 Growth and maturation of mast cells lacking ST2 
FACS  analysis  of  mature  WT  and  ST2
-/-  BMMCs  demonstrates  that  the  surface 
expression of FcεRIα and c-kit is unaffected by the absence of ST2. WT BMMCs 
are 98% c-kit
+ and 85% FcεRIα
+c-kit
+ and ST2
-/- BMMCs are 99% c-kit
+ and 88% 
FcεRIα
+c-kit
+ (Figure 3.14). Similarly, there was no appreciable difference in the 
expression  of  c-kit  and  FcεRIα  on  less  mature  BMMC  populations  (data  not 
shown). These data also confirm that anti-ST2 antibody binding is specific as 
there is no staining of BMMCs from ST2
-/- mice. 
Figure  3.15A  shows  the  total  number  of  cells  grown  from  bone  marrow  cells 
cultured with IL-3 and SCF culture over successive weeks. There is no difference 
between  the  growth  curves  for  WT  or  ST2
-/-  BMMCs,  demonstrating  that  the 
absence of ST2 has no impact on the number of BMMCs obtained at any of the 
time points studied. Interestingly total cell numbers rise steadily to a peak at 3 
weeks of culture before falling rapidly at week 4. This decline correlates with 
the withdrawal of SCF suggesting that SCF is required to maintain the population 
of BMMCs.  This was  confirmed when BMMCs were cultured with SCF and IL-3 
throughout (Figure 3.15B). Although a peak in cell numbers was still seen, in this 
case at 2 weeks, the fall in numbers was more gradual when SCF was continued. 
Surface expression of FcεRIα, c-kit and ST2 were not affected by the sustained Chapter 3:  98 
use of SCF during culture (data not shown). For subsequent experiments both IL-
3 and SCF were added for the full duration of BMMC culture. Chapter 3:  99 
 
 
 
Figure 3.14 - FcεRIα and c-kit expression is unaffected by the absence of ST2 
The surface expression of c-kit, FcεRIα and ST2 on mature 8 week old WT and ST2
-/- BMMCs was 
analysed by FACS. Results are representative of three separate experiments. 
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Figure 3.15 - ST2 gene knockout does not affect BMMC numbers 
Wild  type  and  ST2
-/-  bone  marrow  cells  were  cultured  with  SCF  for  3  weeks  and  IL-3 
throughout(A) or with both IL-3 and SCF throughout(B). Total cell counts were performed each 
week and this was calculated as a proportion of the number of cells originally seeded. Data in A 
are from 4 separate cultures per group and are shown as the mean +/- SEM. Data from all groups 
is not available at every time point. Data in B are from a single culture per group. Chapter 3:  101 
3.4.2 Function of mast cells lacking ST2 
Having generated WT and ST2
-/- cells with the surface phenotype of mast cells I 
sought  to  confirm  the  finding  that  mast  cell  function  is  unaffected  by  the 
absence of ST2. One of the hallmarks of mast cell activation is degranulation. 
Mast cells can be stimulated to degranulate by the calcium ionophore ionomycin 
and the granule product β-hexosaminidase measured. There was no significant 
difference between the proportional β-hexosaminidase release by activated WT 
and ST2
-/- mast cells (Figure 3.16). There was also no difference in the total β-
hexosaminidase activity within WT and ST2-/- mast cells (data not shown). Chapter 3:  102 
 
0
5
10
15
20
25
30
35
PBS Ionomycin
%
 
t
o
t
a
l
 

-
h
e
x
o
s
a
m
i
n
i
d
a
s
e
WT
ST2-/-
 
Figure 3.16 - ST2 gene knockout does not affect mast cell degranulation 
Mature BMMCs were plated into a 96 well plate at a concentration of 1x10
6 cells/ml before the 
addition of PBS or ionomycin at a final concentration of 1 µg/ml. After a 30 minute incubation 
the  β-hexosaminidase  activity  within  the  supernatant  and  cell  lysate  was  assayed  and  the 
proportion of total activity contained in the lysate calculated. Results are shown as the mean of 
duplicate culture wells +/- SEM and are representative of three separate experiments. 
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3.5 The effect of IL-33 on bone marrow mast cells 
Having  established  that  human  and  murine  mast  cell  lines  produce  pro-
inflammatory cytokines and chemokines in response to stimulation with IL-33, 
and  having  cultured  BMMCs  from  WT  and  ST2
-/-  mice,  which  appear  to  be 
identical in terms of growth, phenotype and function, I set out to examine the 
effect of IL-33 on these cultured mast cells. 
3.5.1 The effect of IL-33 on wild type mast cells 
Preliminary experiments were carried out to establish an effect of IL-33 on WT 
BMMCs  and  to  optimise  the  sampling  times  and  IL-33  concentration.  MIP-1α, 
TNFα and IL-6 were chosen as readouts based on the data from mast cell lines. 
At 10 ng/ml IL-33 induced the release of MIP-1α, TNFα and IL-6 as measured at 
24 hours (Figure 3.17).  Chapter 3:  104 
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Figure 3.17 - IL-33 induces cytokine and chemokine release from BMMCs 
Mature WT BMMCs at a concentration of 1x10
6/ml were cultured in duplicate with mIL-33 at 
between 0.01 and 100 ng/ml and aliquots of the supernatant were harvested at 24 hours. MIP-
1α, TNFα and IL-6 were measured by ELISA. Results are shown as the mean of duplicate culture 
wells +/- SEM. * p<0.05, ** p<0.01 compared with PBS. 
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3.5.2 The need for ST2 in the mast cell response to IL-33 
While  the  data  above  show  that  IL-33  can  induce  cytokine  and  chemokine 
release  from  a  freshly  derived  population  of  murine  mast  cells  they  do  not 
confirm the specificity of action of IL-33. One possible confounding factor would 
be the contamination of the protein preparation with other bioactive molecules, 
for example TLR ligands such as LPS. In addition IL-33 could potentially act via 
another receptor in addition to ST2. In order to address these question mast 
cells from mice lacking ST2 were used as controls. Based on the preliminary data 
WT and ST2
-/- BMMCs were stimulated with IL-33 at concentrations of 10 or 100 
ng/ml  for  24  hours.  The  supernatants  were  analysed  by  a  combination  of 
multiplexed immunoassay and ELISA. There was a significant and dose responsive 
release of the MIP-1α, MCP-1, GM-CSF, VEGF, IL-6 and IL-13(Figure 3.18) from 
WT but not ST2
-/- BMMCs. The following were not detected; IL-1α, IL-1β, IL-2, IL-
4, IL-5, IL-10, IL-12, IL-17, TNFα, IFNγ, eotaxin-1, eotaxin-2, FGF, MIG, IP-10, KC 
(data not shown).  
MIP-1α was produced at high levels, often in the ng/ml range, a finding which 
was highly repeatable across multiple batches of bone marrow mast cells, with 
peak  production  ranging  from  500  to  2000  pg/ml.  While  the  levels  of  IL-6 
produced were much lower this finding was equally robust. Similar results were 
obtained  with  MCP-1,  with  peak  concentrations  varying  between  66  and  310 
pg/ml. IL-13 was not detected in experiments where MIP-1α was produced at 
levels of less than 1000 ng/ml. VEGF and GM-CSF were also not detected in all 
experiments. Chapter 3:  106 
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Figure 3.18 - IL-33 induced cytokine and chemokine production by BMMCs is ST2 dependent 
Mature WT (■) and ST2
-/- (□) BMMCs at a concentration of 1x10
6/ml were cultured in duplicate 
with mIL-33 at between 0.01 and 100 ng/ml and aliquots of the supernatant were harvested at 
24  hours.  Cytokines  and  chemokines  were  measured  by  multiplexed  immunoassay  or  ELISA. 
Results are shown as the mean of duplicate culture wells +/- SEM. One-way ANOVA on WT BMMC 
for the effect of IL-33 on MIP-1α, MCP-1, VEGF and IL-13 p<0.005, GM-CSF and IL-6 p<0.01. Chapter 3:  107 
3.6 Conclusions 
The  work  presented  in  this  chapter  attempts  to  address  the  role  of  the 
expression of ST2 by mast cells.  These experiments demonstrate that normal 
development from bone marrow precursors to fully mature cells as well as mast 
cell function measured by mediator release does not appear to be affected by 
the absence of ST2. In addition, exogenous IL-33, acting via ST2, stimulates mast 
cells to produce pro-inflammatory cytokines and chemokines. 
The possibility that ST2 may be involved in mast cell development is raised as a 
consequence of the detection of cell surface ST2 early in mast cell development, 
which  appears  to  be  unique  among  leucocytes.  An  early  study  reported  that 
almost 8% of unsorted bone marrow cells expressed ST2, with this proportion 
falling to 2% after six days of IL-3 culture before climbing steadily to 99.5% after 
4 weeks(348). With the exception of unsorted bone marrow cells ST2 was only 
expressed on c-kit
+ cells.  
I have described a similar phenomenon during mast cell culture. When ST2 is 
plotted  against  c-kit  there  is  a  strong  correlation,  with  over  90%  of  cells 
expressing either both or neither surface markers. After 3 weeks of culture there 
was  a  small  (<5%)  population  of  cells  which  where  ST2
-  but  expressed  c-kit, 
although at a lower level than on ST2
+ cells. At all time points studied c-kit
- cells 
are ST2
- and c-kit
+FcεRIα
+ cells are ST2
+, whereas the intermediate c-kit
+FcεRIα
- 
cells  contain  ST2
-  and  ST2
+  populations,  with  the  proportion  of  the  latter 
increasing  with  time.  This  suggests  that  during  mast cell  development  ST2  is 
expressed on c-kit
+ single positive cells before they express FcεRIα. The data are 
compatible  with  the  possibility  that  mast  cells  develop  from  c-kit
+ST2
- 
progenitors or that the c-kit
+ population contains subpopulations of c-kit
+ST2
+ 
mast cell progenitors and c-kit
+ST2
- cells which lack the potential to become 
mast cells. Although the previously published report did identify a proportion of 
c-kit
- cells expressing ST2 at the beginning of culture, inspection of the data 
raises  the  possibility  that  this  may  be  a  gating  artefact,  and  the  authors 
themselves refer to these cells as ST2
low(348). 
ST2 has also been used as a marker of mast cell precursors. The Lin
-c-kit
+Sca-1
- 
population of bone marrow cells is known to contain mast cell progenitors(444). Chapter 3:  108 
When  these  cells  were  sorted  by  β7  integrin,  the  majority  of  the  mast  cell 
generating  activity  was  within  the  β7
+  population.  Further  sorting  of  this 
population by ST2 revealed that while the β7
+ST2
- population was multipotent 
and could generate mast cells as well as other haematopoietic cells, the β7
+ST2
+ 
population generated mast cells exclusively, suggesting that ST2 is a marker of 
commitment to the mast cell lineage (380). 
While  these  data  raise  the  possibility  that  ST2  is  involved  in  mast  cell 
development,  data  from  ST2
-/-  mice  has  thus  far  suggested  otherwise.  Two 
independent groups have generated ST2
-/- mice, from which it was possible to 
culture normal mast cells, as assessed by FACS(381,382).  These mast cells were 
also functionally normal with regards to cytokine release following non-specific 
activation,  and  IgE  mediated  histamine  release.  There  was,  however,  no 
comment  on  how  the  growth  and  development  of  these  cells  compared  with 
those from wild type mice. Mast cells were also detected in the gut and skin of 
ST2
-/- mice, although at reduced numbers in the latter(381). While these data 
demonstrate that ST2 is not essential for mast cell development the possibility 
that mast cell development is somehow impaired in the absence of ST2 has not 
been addressed. I have found no evidence of any difference in the number of 
mast cells generated, the time taken to reach maturity or the expression of c-kit 
and FcεRIα in mast cells generated from ST2 deficient mice. Consequently there 
is still no explanation for the expression of ST2 at high levels at an early stage of 
mast cell development, prior to the expression of the IgE receptor. 
It is important to note that these culture systems are likely to be devoid of IL-33 
and also contain an excess of other mast cell growth factors. It is possible that 
under the influence of IL-3 and SCF the role of ST2 is unimportant, but that IL-33 
could play a role in mast cell development and maturation in their absence. In 
keeping with this there is now evidence that IL-33 can enhance the survival of 
both  murine  BMMCs  and  human  cord  blood  derived  mast  cells  (CBMCs)  when 
incubated in the absence of other mast cell growth factors(445,446). 
At the outset of these studies it seemed likely that IL-33 would have an effect on 
mast cells, given their high level of ST2 expression and the finding that IL-33 
induced NFκB and MAP kinase activation in mast cells(323). However the nature 
of  this  effect  was  unknown.  I  have  shown  that  IL-33  induces  the  release  of Chapter 3:  109 
inflammatory  mediators  from  mast  cells.  Specifically  the  pro-inflammatory 
cytokine IL-6, the Th2 cytokine IL-13 and the chemokines MIP-1α and MCP-1, and 
at times the classical growth factors GM-CSF and VEGF. 
Since completing this work these findings have been confirmed by four other 
studies. All found that IL-33 is a potent inducer of cytokine release from murine 
bone marrow mast cells, although the exact cytokine profile varied (Table 3.1). 
This  variation  may  well  be  due  to  differences  in  protocol,  including  BMMC 
culture, sampling time and, perhaps most significantly, mouse strain. The only 
other  data  from  BALB/c  mast  cells  published  by  Kondo  et  al(447)  correlated 
closely with the results I obtained. Human CBMCs have been shown to release IL-
1β, IL-3, IL-5, IL-6, IL-8, IL-13, TNFα, eotaxin-2, MCP-1, MIP-1α, TCA3, RANTES 
and TARC in response to stimulation with IL-33(446,448,449). 
  IL-1β  IL-2  IL-4  IL-5  IL-6  IL-10  IL-12  IL-13  TNFα  IFNγ  MCP-1  MIP-1α 
Pitman  -  -  -  -  +  -  -  +  -  -  +  + 
Kondo (447)      -  -  +      +      +  + 
Ali (450)  +        +      -  +       
Ho (445)      -    +      +         
Moulin (443)  +  +  -  -  +  -  -    +  -  +   
Table 3.1 – Mediators released by IL-33 treated mast cells: comparison with published data 
A comparison of the mediators produced by murine BMMCs stimulated with IL-33 organised by 
investigator. Assay of the supernatant of IL-33 stimulated BMMCs revealed the presence (+) or 
absence (-) of the corresponding protein. In some cases the particular protein was not measured 
(grey boxes). 
 
Investigators have also looked for the possibility that IL-33 could induce mast 
cells degranulation. Several papers have reported that human CBMCs(446,448) or 
murine BMMCs (443,445) show no evidence of degranulation in response to IL-33 
treatment,  even  if  pre-incubated  with  IgE.  However  building  on  the  work 
presented here others within the laboratory have found that murine peritoneal 
mast cells and human CBMCs do degraulate in response to IL-33 provided that 
they are preincubated with IgE for a sufficiently long period(449). 
Other studies attempted to confirm that the effect was IL-33 specific by using 
blocking antibodies against ST2(443) or IL-1RAcP, the other subunit of the IL-33 
receptor(450). However these antibodies were required at µg concentrations, up 
to 10,000 times the concentration of IL-33 used, and inhibition was not always Chapter 3:  110 
complete. I have presented data here from ST2
-/- BMMCs demonstrating that in 
the absence of ST2 there is a complete abrogation of IL-33 induced cytokine and 
chemokine production, confirming that IL-33 acts on mast cells in a completely 
ST2 dependent manner.  
The  mast cell  product  of  IL-33  stimulation  most  consistently  detected is  IL-6 
(Table 3.1). Having originally been identified as a B-cell differentiation factor IL-
6  is  traditionally  considered  to  be  primarily  involved in  the  proliferation and 
differentiation of both B- and T-lymphocytes(451). However IL-6 has also been 
shown to promote mast cell survival(452), drive helper T cells towards a Th2 
phenotype(453)  and  to  be  an  important  co-factor  in  IL-4  induced  IgE 
synthesis(454). In addition IL-6 has been implicated in the transition from acute 
to  chronic  inflammation  and  the  associated  resolution  of  neutrophilic 
inflammation and initiation of macrophage recruitment(455), partly acting via 
the induction of MCP-1 release(456). As a consequence IL-6 is thought to play an 
important  role  in  auto-immune  diseases  such  as  rheumatoid  arthritis  and 
inflammatory bowel disease(457). 
While  less  frequently  measured,  the  chemokines  MIP-1α  and  MCP-1  are  both 
consistently  produced  by  IL-33  stimulated  mast  cells  (Table  3.1).  MCP-1  is  a 
potent monocyte chemoattractant(458,459) and MIP-1α was originally identified 
as  a  neutrophil  chemoattractant  released  by  LPS  treated  macrophages(460), 
although both can be produced by a number of cell types and are capable of 
recruiting other inflammatory cells(461-464). In addition they play a role in the 
Th1-Th2 balance. MCP-1 drives T cells towards a Th2 phenotype(465-467) and 
MCP-1
-/- mice have a marked defect in Th2 responses(468), while MIP-1α induces 
Th1 differentiation(466,467). 
With this in mind it is not difficult to see how IL-33 induced release of IL-6, MIP-
1α and MCP-1 by mast cells could play an important role in the initiation of 
inflammation. Given the data suggesting a role of ST2 in allergic inflammation 
and  the  strong  eosinophilic  response  IL-33  promotes  in  vivo  it  is  seems 
reasonable to consider the role that IL-33 induced release of IL-6, MIP-1α and 
MCP-1 by mast cells might play in asthma.  
Not only have elevated levels of IL-6 and the IL-6 receptor been detected in 
asthma(469-472), but IL-6 can induce subepithelial fibrosis(473) and lymphocyte Chapter 3:  111 
infiltration(474) in the airway. Mast cells can also be an important source of IL-6 
in allergic inflammation with mast cells accounting for over 90% of IL-6 positive 
cells  in  biopsies  of  allergic  rhinitis(475).  MCP-1  and  MIP-1α  are  elevated  in 
clinical asthma(258,476,477), and also play a role in experimental asthma. MCP-
1  is  associated  with  lymphocyte  and  macrophage  accumulation,  mast  cell 
degranulation  and  AHR(179,478,479)  and  MIP-1α  with  eosinophil 
recruitment(41,478,480). The other mediator commonly released by mast cells 
upon IL-33 stimulation is IL-13 (Table 3.1) which has a well established role in 
asthma as previously discussed. 
Having demonstrated a role for ST2 on mast cells, in the next two chapters I 
sought  to  examine  the  role  of  ST2  in  airways  inflammation  by  studying  the 
impact of ST2 gene knock-out in a model of asthma (Chapter 4), and the effect 
of ST2 activation by IL-33 in the airways (Chapter 5).  
 
 
 
 
 
 
Chapter 4   
 
The role of ST2 in  
murine models of asthma Chapter 4:  113 
In this chapter I will establish, modify and validate a murine model of asthma 
before  using  this  to  study  the  requirement  for  ST2  in  allergic  airways 
inflammation. 
4.1 Introduction 
There is much to suggest that ST2 may play an important role in asthma. ST2 
expression is most widely recognised on Th2 cells and mast cells, and in the 
previous chapter mast cells were shown to release pro-inflammatory mediators 
upon  stimulation  via  ST2.  Both  Th2  cells  and  mast  cells  are  though  of  as 
important elements of human and murine asthma. Activation of ST2 in vivo, by 
the systemic administration of IL-33, results in local eosinophilia and elevated 
levels of IgE, IL-5 and IL-13(323), phenomena which are characteristic of asthma. 
There  is  also  evidence  that  the  absence  of  ST2  can  result  in  dramatically 
impaired Th2 responses in vivo(382). ST2 is detected at increased levels in both 
experimental(360,372,395) and clinical asthma(398) giving further support to the 
notion that ST2 may be important in allergic airways inflammation. 
However, at the outset of this work the literature regarding the role of ST2 in 
murine  models  of  asthma  was  far  from  clear.  Studies  utilising  neutralising 
antibodies against ST2 that modified disease in a number of different models all 
supported a role for ST2 in experimental asthma(298,372,396). Conversely ST2 
gene-deleted  mice  demonstrated  no  difference  in  airway  inflammation(381). 
This last study used an OVA and alum driven 35 day model of asthma with mice 
on a C57Bl/6 background. The main experimental endpoints including airways 
eosinophilia and raised total IgE titres occurred equally in wild type and ST2
-/- 
mice, although AHR was not measured. BALB/c mice are generally considered 
more prone to Th2 inflammation than C57Bl/6 mice. As discussed in Chapter 1 
there can be significant differences in experimental outcome depending on the 
strain of mouse used, for example IL-5 gene deletion generally results in the loss 
of AHR in C57Bl/6 but not BALB/c mice(94,100). In addition the study of ST2
-/- 
mice by Hoshino et al(381) utilised an intensive challenge protocol with mice 
receiving  15  OVA  challenges  in  total,  which  resulted  in  high  BAL  eosinophil 
counts of greater than 50 x10
5 cells/ml. Chapter 4:  114 
In these examples there is incomplete evidence to conclude that ST2 has a role 
in airway inflammation. The effects of ST2 gene-deletion might be obscured by 
redundant  mechanisms  and  it  is  conceivable  that  any  contribution  that  ST2 
might  make  to  airways  inflammation  was  masked  by  strong  stimuli  involving 
multiple challenges and powerful adjuvants. 
In an attempt further examine the role of ST2 in experimental asthma I sought 
to  study  the  effect  of  ST2  gene  knock-out  on  AHR  as  well  as  eosinophilic 
inflammation in an antigen based model using mice from a BALB/c background. 
 
4.2 Developing a murine model of asthma 
The most well studied murine models of asthma employ systemic sensitisation 
with OVA, combined with alum as a Th2 adjuvant, followed by airways challenge 
with OVA alone. There are many published variations of this model, with changes 
in the dose, timing and number of administrations of OVA during sensitisation 
and  challenge,  and  differing  methods  of  delivery  to  the  airways.  There  was 
considerable previous experience within our laboratory using a 28 day model of 
asthma(429-431), adapted from a previously published model(432). Therefore I 
set  out  to  reproduce  this  model  before  making  any  modifications  to  the 
protocol. 
4.2.1 Induction of allergic airways inflammation in a 28 day model  
Mice immunised and challenged with OVA using the 28 day protocol developed 
significant airways eosinophilia (Figure  4.1).  While there was a corresponding 
decrease in the proportion of macrophages there was nonetheless a significant 
rise in the absolute number of BAL macrophages. Neutrophils and lymphocytes 
were found at very low frequency. OVA-specific immunoglobulins, including high 
titres of IgE, were significantly elevated in the serum (Figure 4.2). In order to 
confirm the induction of a robust Th2 response the draining lymph nodes were 
studied. Single cell suspensions from the lymph nodes were restimulated with 
OVA in vitro (Figure 4.3). Cell proliferation was induced which was almost four-
fold  greater  from  mice  treated  with  OVA  than  those  treated  with  PBS.  OVA Chapter 4:  115 
treated mice also produced high concentrations of the Th2 cytokines IL-4 and IL-
5, in addition to the Th1 cytokine IFNγ. PBS treated mice produced higher levels 
of IFNγ with no IL-4 or IL-5. Cells from either group treated with medium alone 
did not proliferate or produce cytokines (data not shown). These results are all 
in keeping with the expected findings in this model of asthma. Chapter 4:  116 
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Figure 4.1 – A 28 day model of asthma induces pulmonary eosinophilia 
BALB/c  mice  were  immunised  with  OVA  (100  µg)  in  1%  alum  on  days  0  and  14  and  were 
challenged with intranasal OVA (30 µg) on days 14, 25, 26 and 27 (■). Control mice received PBS 
alone (□). BAL was collected on day 28. Total and differential cell counts were performed. Data 
are shown as the mean +/- SEM. n=9. * p<0.05, ** p<0.01 compared with PBS. Chapter 4:  117 
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Figure 4.2 – A 28 day model of asthma induces antigen specific immunoglobulins 
Mice  were  immunised  and  challenged  with  OVA  (●)  or  PBS  (○)  as  is  Figure  4.1.  Serum  was 
collected the day after the final challenge. OVA specific IgE, IgG1 and IgG2a were measured in 
the serum at the indicated dilutions. Results are shown as the mean of each group of mice +/- 
SEM. n=9 mice. * p<0.05, ** p<0.01 compared with PBS. Chapter 4:  118 
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Figure 4.3 - A 28 day model of asthma induces antigen specific Th2 lymphocytes 
Mice were immunised and challenged with OVA (■) or PBS (□) as is Figure 4.1 and lymph nodes 
harvested the day after the final challenge. Single cell suspensions were stimulated with OVA (1 
mg/ml). (A) After 72 hours proliferation was measured by 
3H thymidine uptake. (B) After 96 
hours supernatants were collected and IL-4, IL-5 and IFNγ measured by ELISA. Results are shown 
as pooled samples from groups of 9 mice. 
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4.2.2 Intranasal versus intratracheal dosing 
The most common methods of delivering antigen to the murine airway are either 
by placing conscious animals in a chamber containing nebulised antigen or by 
directly instilling the antigen into the airways of anaesthetised mice. There is no 
evidence that either method is superior to the other, therefore I chose direct 
instillation due to our established local experience with intranasal delivery. 
One concern with intranasal delivery is that not all of the instilled solution is 
guaranteed to reach the lungs, with the possibility that some is retained in the 
nasopharynx,  or  aspirated  into  the  stomach.  Although  less  common  than 
intranasal administration, some investigators have reported using intratracheal 
delivery  (282).  By  direct  cannulation  of  the  trachea  it  should  be  possible  to 
deliver the entire solution into the lungs. 
Both  delivery  methods  were  compared  using  the  28  day  model  of  asthma. 
Although  total  BAL  eosinophil  numbers  appeared  lower  in  the  intratracheal 
group,  there  was  no  significant  difference  in  BAL  eosinophil  percentage  or 
absolute number (Figure 4.4), with no associated reduction in intra- or inter-
experiment  variability.  Given  that  intratracheal  administration  was  more 
technichally  demanding,  more  time  consuming  and  more  likely  to  lead  to 
trauma, the decision was made to use intranasal administration in all subsequent 
experiments. Chapter 4:  120 
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Figure 4.4 – Intratracheal OVA administration is not superior to intranasal administration 
BALB/c mice were immunised with OVA and alum on days 0 and 14 and were challenged with 
OVA on days 14, 25, 26 and 27 via the intranasal (■) or intratracheal (□) route. BAL was collected 
the  day  after  the  final  challenge  and  eosinophil  percentage  (A)  and  absolute  numbers  (B) 
counted. Data are shown as the mean +/- SEM. n=6. Chapter 4:  121 
4.2.3 Validation of BAL differential cell counts 
One  of  the  key  endpoints  in  asthma  models  is  the  measurement  of  BAL 
eosinophilia. While FACS analysis can be used to analyse the cellular composition 
of  BAL  the  gold  standard  remains  microscope  counting  of  stained  cytospin 
preparations.  Although  internal  bias  is  prevented  by  rigorous  blinding  any 
cytological system may be at risk of subjective error. In order to confirm inter-
observer  consistency  I  undertook  a  blind  comparison  of  results  with  another 
experienced  investigator  in  the  laboratory.  Asthma  was  induced  and  BAL 
cytospins prepared. Each individual then performed differential counts on all the 
samples from the experimental group. Samples were unblinded independently 
and results compared. 
As shown in Figure 4.5 there was good inter-observer correlation. Chapter 4:  122 
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Figure 4.5 – BAL differential cell counts are reproducible 
Mice  were  immunised  and  challenged  with  OVA  and  BAL  cells  collected  as  is  Figure  4.1. 
Differential cell counts were performed by Investigator 1 (■) and investigator 2 (□). Data are 
shown as the mean +/- SEM. n=4 Chapter 4:  123 
4.2.4 Pooled versus individual LN culture 
While the primary endpoints in the murine asthma models are generally lung 
eosinophil infiltration, IgE antibody and AHR; additional important information 
can come from the measurement of other variables. When antigen is delivered 
to the lung it can act directly on local cells, but is also taken up by dendritic 
cells which then migrate to the draining lymph nodes to become professional 
antigen presenting cells where they activate antigen specific lymphocytes(292). 
By antigen stimulation of the cells within the lymph nodes that drain the lung it 
is  possible  obtain  information  on  the  profile  of  the cytokines  these  cells  are 
producing. 
Historically this had been carried out by pooling all the draining lymph nodes 
from the mice in each group and restimulating a fixed number with OVA. There 
are frequently variations in the extent of BAL eosinophilia within any treatment 
group, which can include quite extreme outliers. I was concerned that the cells 
from  such  over-  or  under-responsive  mice  could  skew  the  data  from  pooled 
lymph  node  samples.  In  addition  when  lymph  nodes  are  pooled  there  is  no 
information on the variance within any given group making statistical analysis 
difficult. Consequently I set out to determine whether it would be feasible to 
culture the draining lymph nodes from individual mice separately, and to study 
the data obtained in this way. 
Although the total numbers of cells retrieved from the draining lymph nodes of a 
single animal is small, I established that with optimisation of culture conditions 
it  was  almost  always  possible  to  carry  out  individual  lymph  node  cultures. 
Interestingly, despite similar cell counts in both groups (Figure 4.6A), the mean 
levels of proliferation (Figure 4.6B) and cytokine production (Figure 4.6C) were 
lower in the individual lymph node cultures than in pooled lymph nodes. This 
raises the possibility that when lymph nodes are  pooled the response can be 
dominated by a small proportion of highly reactive cells from one or two mice. 
Individual  lymph  node  culture  provides  addition  data,  allows  for  statistical 
analysis  and  may  prevent  skewing  of  the  data  by  a  small  subset  of  mice. 
Consequently  all  subsequent  lymph  node  culture  was  performed  by  isolating 
individual lymph nodes from each animal.  Chapter 4:  124 
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Figure 4.6 – Individual lymph node culture provides additional information 
BALB/c mice were immunised with OVA and alum before being challenged with intranasal OVA as 
in Figure 4.4. (A) Total eosinophils within the BAL were counted. Data are shown as the mean +/- 
SEM. Draining lymph nodes were either pooled from all mice (■,●) or separated by individual 
mice (□,○). A total of 2x10
6 lymph node cells were cultured with complete medium alone (■ and 
□) or with OVA at 1 mg/ml (● and ○). (B) Proliferation was measured by thymidine uptake. (C) 
Supernatant IL-4 and IL-5 were assayed by ELISA. The result from each culture well is plotted, in 
the case of individual node cultures the mean is represented by a bar. n=6. 
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4.2.5 Establishing  a  method  to  measure  airways 
hyperresponsiveness 
One of the hallmarks of clinical asthma is AHR and this is generally reproduced in 
murine models of asthma. In both the clinical setting and animal models this is 
measured by establishing the degree of airflow resistance in subjects before and 
after  inhalation  of  a  bronchoconstricting  agent  such  as  histamine  or 
methacholine. In humans, airflow resistance is measured by quantifying air flow 
during forced expiratory manoeuvres. Such techniques are effort-dependent and 
require  co-operation  and  are  therefore  not  possible  in  animals.  The  gold 
standard  method  of  measuring  AHR  in  animals  requires  anaesthesia  and 
intubation.  As  discussed  in  Chapter  2,  it  is  also  possible  to  measure  AHR  in 
conscious, unrestrained animals using whole body plethysmography, where mice 
are placed in a chamber within which the pressure differences  occurring are 
recorded and from these changes the parameter of enhanced Pause (Penh) is 
derived(29). 
Before utilising this method to answer experimental questions it was important 
that I validated the technique. As a positive control I used BALB/c mice in which 
allergic airways inflammation was induced using a 28 model of asthma which is 
well  recognised  to  induce  AHR(21).  As  a  negative  control  naïve  mice  were 
challenged with intranasal PBS alone. As expected there is a significant rise in 
Penh,  the  measure  of  AHR,  with  increasing  broncho-provocation  with 
methacholine in both the control and the treated group (Figure 4.7). Chapter 4:  126 
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Figure 4.7 - Airways hyperresponsiveness can be measured by Penh 
BALB/c mice were immunised with OVA and alum before being challenged with intranasal OVA as 
in Figure 4.4. Unimmunised control mice were challenged with PBS alone. The day after the final 
airways challenge Penh was measured with increasing doses of nebulised methacholine. Results 
are shown as the mean of each group of mice +/- SEM. n=4. Two-way ANOVA p<0.01 PBS vs OVA. 
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4.3 Establishing a twelve day model of asthma 
When S. mansoni eggs are used to drive pulmonary eosinophilic inflammation 
ST2  is  only  essential  in  mice  that  have  not  already  been  immunised(382), 
highlighting the fact that differences in sensitisation can affect the contribution 
of  ST2.  Speculating  that  the  use  of  multiple  systemic  immunisations  and  an 
extended period of repeated challenges may obscure any requirement for ST2, a 
12 day model which had been described was attractive(49). This model utilised a 
single  immunisation,  followed  by  three  airways  challenges.  Furthermore  the 
move from a 28 day to a 12 day model not only allows for increased productivity 
in a shorter time frame, but also has economic implications. While the 12 day 
protocol  had  been  shown  to  induce  AHR,  airways  inflammation  and 
immunoglobulin generation were not assessed. Therefore I set out to validate 
and optimise a novel 12 day model of asthma, base on that published by Stock et 
al(49). 
4.3.1 Features  of  asthma  can  be  induced  using  a  twelve  day 
model 
The published protocol was for an immunisation using OVA (100 µg) with alum 
adjuvant followed by daily intranasal challenges of OVA (50 µg) on days 9 to 11 
in BALB/c mice (Figure 4.8). Initially I set out to repeat the protocol exactly as 
described  and  to  look  for  the  presence  of  eosinophilic  inflammation  in  the 
airways. 
This  protocol  induced  a  robust  inflammatory  response  in  the  airways  as 
represented  by  total  eosinophilia  (Figure  4.9).  The  level  of  eosinophilia  is 
towards the upper limit of what we would expect to see for the 28 day model 
and this was even more marked in subsequent repeats (data not shown). Chapter 4:  128 
 
 
 
Figure 4.8 - The twelve day model of asthma 
Mice  are  immunised  with  OVA  and  alum  by  the  intraperitoneal  route  on  day  1  before  being 
challenged with intranasal OVA once on each of days 9, 10 and 11. On day 12 AHR is measured 
and/or mice are culled. Chapter 4:  129 
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Figure 4.9 – BAL eosinophilia is induced by a twelve day asthma protocol 
BALB/c mice were immunised with OVA (100 µg) and alum on day 1 and were challenged with 
OVA (50 µg) on days 9, 10 and 11 (■). Control mice received PBS alone (□).BAL was collected the 
day  after  the  final  challenge  and  (A)  total  cell  count,  (B)  differential  percentages  and  (C) 
absolute cell numbers counted. Data are shown as the mean +/- SEM. n=5. * p<0.05, ** p<0.01 
compared with PBS.   
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4.3.2 Dose  response  to  ovalbumin  challenge  in  the  twelve  day 
model  
Having established that a significant BAL eosinophilia can be generated using a 
12 day model of asthma it was important to optimise this model. Following the 
observation  that  this  model  generated  a  more  extensive  eosinophilia  than 
normally  seen  with  the  28  day  model,  I  anticipated  that  the  effect  of 
therapeutic intervention might be less readily detected with an inflammatory 
response  of  this  magnitude.  Therefore  I  adjusted  the  dose  of  OVA  used  at 
challenge  in  the  12  day  model  and  performed  a  dose  titration  in  order  to 
establish a protocol which might be more susceptible to reasonable intervention. 
Given that a dose of 50 µg per mouse generated a marked eosinophilia I chose 
this as a starting point and studied this dose and below. 
Reducing the dose of OVA given at challenge resulted in a dose related decrease 
in BAL eosinophil numbers (Figure 4.10). While there was also a reduction in the 
percentage of eosinophils with lower doses of OVA challenge, even at 2.5  µg 
eosinophils still comprised 39% of BAL cells. Given that a dose of 10 µg appears 
to represent the mid-point of the dose response curve it likely that this protocol 
will  be  susceptible  to  interventions  which  either  exacerbate  or  attenuate 
eosinophilic inflammation. Consequently a dose of 10 µg was used in subsequent 
experiments. Chapter 4:  131 
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Figure 4.10 - BAL cell content related to OVA challenge dose 
BALB/c mice were immunised with OVA (100 µg) and alum on day 1 and were challenged with 
OVA (0 to 50 µg) on days 9, 10 and 11. BAL was collected on day 12 and (A) total and (B,C) 
differential cell counts performed. Data are shown as the mean +/- SEM. n=6 mice. 
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4.3.3 Validation of a twelve day model 
Thus  far  I  have  focused  on  BAL  eosinophils  as  the  primary  end  point  when 
assessing the 12 day model of asthma, but there are other features one would 
expect to find in such a model. Before using this protocol I set out to confirm 
that these features of clinical asthma were reproduced. Most importantly BAL 
eosinophilia  should  be  accompanied  by  eosinophilic  inflammation  in  the  lung 
tissue, OVA specific IgE in the serum and the generation of AHR. 
There is good evidence to suggest that eosinophilic inflammation and AHR can be 
dissociated,  for  example  some  models  generate  eosinophilia  but  not  AHR  in 
C57Bl/6 mice(50) whereas IL-5 gene deletion results in loss of eosinophilia with 
preserved  AHR  in  BALB/c  mice(100,103).  Therefore  one  cannot  assume  that 
because the 12 day protocol generates a robust BAL eosinophilia that AHR will 
also be generated. Therefore I confirmed that the 12 day protocol selected did 
indeed induce significant AHR as measured by Penh (Figure 4.11). 
It is unresolved whether BAL eosinophilia is always associated with lung tissue 
eosinophil infiltration, therefore it is important to confirm if these features are 
present  in  the  12  day  model.  When  the  28  day  and  12  day  models  were 
compared directly there was no significant difference in BAL eosinophilia (Figure 
4.12) with a similar degree of inflammation also seen on histology (Figure 4.13). 
In models of atopic asthma antigen-specific IgE should also be generated. In both 
the 28 day and 12 day models OVA specific IgE was detected in the serum at 
comparable levels at a titre of 1/20 (Figure 4.12C), although at a titre of 1/180 
IgE was significantly lower in the 12 day model. OVA specific IgG1 and IgG2a 
were  also  generated  and  serum  concentrations  were  once  again  significantly 
lower in the 12 day model than the 28 day model (Figure 4.14). 
The  generation  of  antigen-specific  antibodies  provided  evidence  of  effective 
immunisation.  I  choose  to  further  examine  T-lymphocyte  immunisation  by 
observing cells in culture from the draining lymph nodes in this model, to see 
whether they served as a readout of the antigen recall response. 
Cells from the draining lymph nodes of mice immunised and challenged with the 
12 day protocol were restimulated with OVA. These cells showed evidence of Chapter 4:  133 
activation as measured by proliferation (Figure 4.15A). It was also possible to 
measure  the  cytokines  produced  by  these  cells  upon  antigen  restimulation 
(Figure 4.15B). As expected the recall response demonstrated Th2 polarisation 
with  production  of  high  concentrations  of  the  Th2  cytokines  IL-4  and  IL-5  in 
much greater relative concentrations than that of the Th1 cytokine IFNγ. 
These data demonstrate that the selected 12 day protocol produces all the acute 
features  of  clinical  asthma  expected  of  a  murine  model,  namely  AHR, 
eosinophilic inflammation, IgE production and a Th2 cytokine response. Chapter 4:  134 
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Figure 4.11 – The twelve day model of asthma induces airways hyperresponsiveness  
BALB/c mice were immunised with OVA (100 µg) and alum on day 1 and were challenged with 
OVA (10 µg) on days 9, 10 and 11. Unimmunised control mice were challenged with PBS alone. 
The day after the final airways challenge Penh was measured. Results are shown as the mean of 
each group of mice +/- SEM. n=4 mice. * p<0.05, ** p<0.01 compared with PBS. Two-way ANOVA 
p<0.001 PBS vs OVA. Chapter 4:  135 
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Figure 4.12 - The twelve day model of asthma induces lung eosinophilia  
BALB/c mice were immunised and challenged using the 28 day protocol (OVA 100 µg IP days 1 
and 14, OVA 10 µg IN days 25, 26 and 27) or the 12 day protocol (OVA 100 µg IP on day 1, 10 µg 
days 9, 10 and 11). Control mice received PBS challenge alone. The day after the final challenge 
BAL was collected. Differential counts were performed on BAL samples. Results are shown as the 
mean of each group of mice +/- SEM. n=4 mice. Chapter 4:  136 
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Figure 4.13 - The twelve day model of asthma induces lung eosinophilia  
BALB/c mice were immunised and challenged as in Figure 4.12. The day after the final challenge 
lungs were collected and fixed in formalin. Sections were prepared and stained with H&E. Panels 
shown are representative sections. Chapter 4:  137 
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Figure 4.14 - The twelve day model of asthma induces antigen specific immunoglobulins 
Mice were immunised and challenged as is Figure 4.12. Serum was collected the day after the 
final challenge. OVA specific IgE was measured in the serum at dilutions of 1/20 and 1/80. OVA 
specific IgG1 and IgG2a were measured at dilutions of 1/500 and 1/20 respectively. Results are 
shown  as  the  mean  of  each  group  of  mice  +/-  SEM.  n=4  mice.  *  p<0.05  compared  with  12d 
protocol. Chapter 4:  138 
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Figure 4.15 - The twelve day model of asthma induces antigen specific Th2 lymphocytes 
Mice were immunised and challenged as is in Figure 4.8 and lymph nodes harvested the day after 
the final challenge. Single cell suspensions were stimulated with PBS or OVA (1 mg/ml). (A) After 
72 hours proliferation was measured by 
3H thymidine uptake. (B) After 96 hours supernatants 
were collected and IL-4, IL-5 and IFNγ measured by ELISA. Results are shown as pooled samples 
from groups of 4 mice. Chapter 4:  139 
4.4 Cytokines and chemokines in the twelve day model 
Before studying any potential role for ST2 in the 12 day model of asthma I sought 
to characterise the model further. Having shown that IL-33, acting via ST2, could 
be a potent inducer of chemokine production I was interested in the relationship 
between cytokines, chemokines and the inflammatory response in the airways. 
There  have  been  a  number  of  studies  examining  the  expression  of  and 
requirement  for  chemokines  in  asthma.  As  discussed  in  Chapter  1  there  is 
evidence  that  chemokines,  such  as  the  eotaxins,  as  well  as  cytokines, 
particularly  IL-5,  play  an  important  role  in  eosinophil  recruitment  to  the 
airways.  However  there  is  less  information  on  the  temporal  expression  of 
chemokines following antigen challenge in allergic airways inflammation. While 
some data are available in many cases they are at the RNA level only(179,481) or 
use unconventional models or limited time points(41,179). Therefore I set out to 
measure cytokine and chemokine levels in the BAL and serum at multiple time 
points throughout airways challenge. 
4.4.1 Kinetics  of  airways  inflammation  following  multiple 
challenges 
Having chosen to investigate the challenge phase of the 12 day model I designed 
an  experiment  where  groups  of  mice  were  sacrificed  at  different  intervals 
throughout  the  challenge  period.  This  would  make  it  possible  to  study  the 
relationship  between  cytokines,  chemokines  and  eosinophil  accumulation.  My 
hypothesis  was  that  each  intranasal  challenge  would  stimulate  cytokine  and 
chemokine release and that eosinophil numbers would rise with each challenge, 
perhaps falling again between challenges. As shown in Figure 4.16 all mice were 
immunised according to the standard 12 day protocol. The first group were then 
culled immediately prior to the first intranasal challenge (0h), the next group 3 
hours after the first challenge (3h), the next immediately prior to the second 
challenge (24h), the next 3 hours after the second challenge (27h) and so on. A 
final group was culled at what would be the standard cull day in the 12 day 
model (72h). 
Throughout the challenge period the total number of cells recovered from the 
airways increased and was highest at 72 hours after the first challenge (Figure Chapter 4:  140 
4.17A);  a  time  point  analogous  to  the  standard  final  day  cull  in  the  12  day 
model.  This  rise  in  total  cell  numbers  was  mirrored  by  an  increase  in  the 
percentage of eosinophils within the BAL to a peak of 72% at 72 hours (Figure 
4.17B). While the absolute number of macrophages increased slowly throughout 
the challenge period this is eclipsed by the rise in eosinophils by 72 hours (Figure 
4.17C). 
When the local cytokine and chemokine levels within the BAL were assayed, the 
Th2 cytokine levels all peaked at 24h after the initial challenge and decreased to 
almost  undetectable  levels  at  72  hours  (Figure  4.18).  IL-4,  IL-5  and  IL-13 
increased to concentrations of 1810 pg/ml, 101 pg/ml and 459 pg/ml at 24 hours 
respectively  before  falling  to  59  pg/ml,  7  pg/ml  and  19  pg/ml.  The  pro-
inflammatory cytokine IL-6 followed a similar pattern with a peak concentration 
of 74 pg/ml at 24 hours (data not shown). Concentrations of IL-1, IL-2, IL-10, IL-
12, IL-17, IFNγ and TNFα were below 50 pg/ml. 
Given that eosinophilic inflammation within the airways progresses despite a fall 
in local Th2 cytokine levels I hypothesised that local chemokine production could 
be responsible for ongoing eosinophil recruitment and activation. Although MIP-
1α reached a peak of 217 pg/ml at the later time point of 48h, levels had fallen 
to only 76 pg/ml by  72h (Figure  4.18). Eotaxin-2 and TARC  however did rise 
progressively  throughout  the  challenge  period  (Figure  4.18).  The  changes  in 
eotaxin-2 concentrations correlated particularly well with eosinophil numbers as 
shown in Figure 4.19. Concentrations of GM-CSF, KC, IP-10, MCP-1, MIG, eotaxin-
1 and TCA3 in the BAL were below 50 pg/ml. 
Although  local  cytokine  and  chemokine  concentrations  are  likely  to  play  an 
important role in the recruitment of cells to the site of inflammation, cytokines 
and chemokines  released  systemically  can  drive  selective  haematopoiesis  and 
the mobilisation of cells from the bone marrow. Serum cytokine levels followed 
a similar pattern to that seen in the BAL with IL-5 and IL-13 peaking at 227 
pg/ml and 256 pg/ml at 24 to 27 hours before falling to 0 pg/ml and 40 pg/ml at 
72 hours (Figure 4.20A). IL-10 followed a similar pattern, peaking at 116 pg/ml 
at 24h (data not shown). Concentrations of IL-1, IL-2, IL-4, IL-6, IL-12, IL-17, 
IFNγ and TNFα in the serum were below 50 pg/ml.  Chapter 4:  141 
The chemokines eotaxin-1 and KC did show a trend towards rising 3h after each 
challenge before falling again at 24h,  whereas the converse was true of MIG 
(Figure 4.20B). Concentrations of GM-CSF, IP-10, MCP-1, MIP-1α, eotaxin-2, TCA3 
and TARC in the serum were below 50 pg/ml.  
Antigen  specific  IgE  is  generated  in  response  to  immunisation  with  OVA  and 
there was no evidence that titres were affected by intranasal antigen challenge 
at dilutions of between 1/10 (Figure 4.21) and 1/1280. 
To  obtain  information  on  the  local  specific  immune  response  cells  from  the 
lymph nodes draining the lungs were cultured with OVA and the cytokines and 
chemokines produced assayed (Figure 4.22). The cytokines produced by lymph 
node cells at the highest concentrations were IL-5 and IL-13, which increased 24 
hours after the first challenge and remained elevated thereafter. The other Th2 
cytokine  IL-4  was  produced  in  increasing  amounts  from  lymph  nodes  as  the 
challenge  period  progressed.  The  pro-inflammatory  cytokines  IL-17  and  IFNγ 
were also detected at high concentrations, but there was no obvious relationship 
with the timing of intranasal challenges. A similar pattern, although at lower 
concentrations,  was  seen  for  IL-6  and  MCP-1.  The  chemokines  eotaxin-2  and 
TARC were released at relatively low concentrations, but lymph node cells from 
later  in  the  challenge  period  produced  these  chemokines  at  higher 
concentrations  than  those  from the beginning  of  the challenge period.  IL-10, 
TNFα, GM-CSF, KC, MIP-1α, TCA3 and eotaxin-1 were produced at concentrations 
of  between  100  to  300  pg/ml  prior  to antigen challenge  and did  not change 
significantly throughout the time course (data not shown). IL-1, IL-2, IL-12, IP-10 
and MIG were not detected in draining lymph node supernatants. 
These data demonstrate that in the 12 day model eosinophil numbers in the 
airways  rise  steadily  during  the  challenge  period,  despite  the  fact  that  Th2 
cytokine concentrations, both locally in the BAL and systemically in the serum, 
peak prior to the second challenge before falling to very low concentrations by 
day  12.  Chemokines  may  be  responsible  for  the  accumulation  of  eosinophils 
within  the  airways  given  that  BAL  eotaxin-2  concentrations  correlate  with 
eosinophil  numbers  and  intranasal  antigen  challenges  appear  to  result  in 
transient increases in eotaxin-1 and KC within the serum. Chapter 4:  142 
 
 
 
Figure 4.16 – A time course study of the twelve day asthma model 
BALB/c mice were immunised with OVA (100 µg) and alum on day 1 and were challenged with 
OVA (10 µg) on days 9, 10 and 11. BAL, serum and draining lymph nodes were collected from 
groups of mice immediately prior to each challenge (0, 24 and 48 hours) or at 3 hours after each 
challenge (3, 27, 51 hours). Samples were collected from a final group at the standard day 12 
end point for the model (72 hours). 
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Figure 4.17 - Eosinophil numbers increase with time during challenge 
Mice were immunised and challenged as in Figure 4.16. (A) Total BAL counts were performed. 
(B,C) Differential counts were performed and macrophage (○) and eosinophil (●) proportions 
calculated. Arrows indicated intranasal challenges (0h, 24h and 48h). Results are shown as the 
mean of each group of mice +/- SEM. n=8 mice. Chapter 4:  144 
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Figure 4.18 – BAL cytokine and chemokine concentrations change throughout the challenge 
period 
Mice were immunised and challenged as in Figure 4.16. BAL was collected from groups at each 
time point and cytokines and chemokines measured by ELISA or multiplexed immunoassay. Eo2 = 
eotaxin-2. Results are shown as the mean of each group of mice +/- SEM. n=8 mice. 
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Figure 4.19 - Airways eosinophilia correlates with local eotaxin-2 concentrations 
Mean total eosinophil numbers (Figure 4.17C) were plotted against BAL eotaxin-2 concentration 
(Figure 4.18D) for mice treated as in Figure 4.16. Chapter 4:  146 
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Figure 4.20 – Serum cytokine and chemokine concentrations change throughout the 
challenge period 
Mice were immunised and challenged as in Figure 4.16. Serum was collected from groups at each 
time  point  and  cytokines  and  chemokines  measured  by  ELISA  or  multiplexed  immunoassay. 
Results are shown as the mean of each group of mice +/- SEM. n=8 mice Chapter 4:  147 
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Figure 4.21 - Serum IgE titres are unaffected by intranasal antigen challenge 
Mice were immunised and challenged as in Figure 4.16. Serum was collected from groups at each 
time point and OVA-specific IgE measured by ELISA at a dilution of 1/10. Results are shown as 
the mean of each group of mice +/- SEM. n=8 mice Chapter 4:  148 
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Figure 4.22 – Th2 cytokines and eotaxins are produced by draining lymph node cells 
Mice were immunised and challenged as in Figure 4.16. Draining lymph nodes were collected 
from groups at each time point and single cell suspensions from individual mice restimulated 
with OVA 1 mg/ml. Supernatants were collected after 96 hours and cytokines and chemokines 
measured by ELISA or multiplexed immunoassay. Eo1 = eotaxin-1, Eo2 = eotaxin-2. Results are 
shown as the mean of each group of mice +/- SEM. n=8 mice Chapter 4:  149 
4.4.2 Kinetics  of  airways  inflammation  following  a  single 
challenge 
During the three day challenge period of the 12 day model, BAL Th2 cytokine 
concentrations  decreased  early  while  chemokine  concentrations  continued  to 
rise.  My  hypothesis  was  that  the  stimulus  for  the  increasing  chemokine 
concentrations was the repeated antigen challenges. To test this hypothesis I 
chose  to  study  the  changes  occurring  after  a  single  antigen  challenge.  I 
predicted that, as in the three challenge protocol, Th2 cytokines would increase 
transiently and then fall rapidly after a single challenge, but that chemokine 
concentrations would also fall in the absence of further challenges, and that this 
would result in a fall in eosinophil numbers. 
Mice  were  immunised  with  OVA  and  alum  as  previously.  In  order  to  make 
comparisons I choose to study the same time period as that used with three 
challenges, from days 9 to 12 (0 to 72 hours). Therefore the challenge given on 
day  9  would  be  identical  in  both  experiments,  but  in  the  single  challenge 
protocol there would not be the usual second and third challenge on days 10 and 
11. Groups of mice were culled at 24 hour intervals following the challenge and 
BAL and serum collected (Figure 4.23). 
Following a single intranasal OVA challenge the percentage of eosinophils in the 
BAL increased steadily throughout the following 72 hour period and reached a 
maximum of 27% at 72 hours post challenge (Figure 4.24A). This was associated 
with a rise in total eosinophil numbers over time to a maximum of 0.5 x 10
5 
cells/ml at 72 hours (Figure 4.24B).  
In the BAL IL-4 peaked 24 hours after challenge before falling rapidly (Figure 
4.24C).  A  similar  pattern  was  seen  with  serum  IL-5  (Figure  4.24D).  BAL  IL-5, 
serum  IL-4  and  BAL  and  serum  IL-13  were  undetectable.  BAL  eotaxin-2 
concentrations increased more slowly to a peak at between 48 and 72 hours. 
These data demonstrated that, as in the three challenge model, BAL and serum 
Th2  cytokine  concentrations  peak  at  24  hours  after  challenge  before  rapidly 
falling again. Surprisingly BAL eosinophils continued to rise in the absence of Chapter 4:  150 
further challenges with the highest number recorded at the final 72 hours time 
point. This was associated with a continued rise in eotaxin-2 concentration. 
On day 12 of the single challenge protocol eosinophils are still in the minority at 
27% of total BAL cells, and absolute numbers are low at 0.5 x 10
5 cells/ml. This 
is in contrast to an eosinophilia of 59% or 4.6 x 10
5 cells/ml on day 12 in the 
three challenge model. Taking this into account I chose to continue to work with 
the three challenge 12 day model in which I had demonstrated the generation of 
AHR and histological changes earlier. Chapter 4:  151 
 
 
 
Figure 4.23 – A time course study of the twelve day asthma model 
BALB/c mice were immunised with OVA (100 µg) and alum on day 1 and were challenged with 
OVA (10 µg) on day 9. BAL, serum and draining lymph nodes were collected from groups of mice 
immediately prior to the challenge (0h) and then every 24 hours thereafter up to 72 hours. Chapter 4:  152 
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Figure 4.24 – A single airways challenge induces eosinophilia and Th2 cytokines 
Mice were immunised and challenged as in Figure 4.23. BAL and serum samples were collected 
immediately  prior  to  challenge  (0h)  or  at  the  noted  interval  after  challenge.  (A,B)  BAL 
differential counts were performed. (C,D,E) Cytokine and chemokine concentrations in BAL and 
serum were determined by ELISA. Results are shown as the mean of each group of mice +/- SEM. 
n=5 mice. Chapter 4:  153 
4.5 The role of ST2 in murine asthma models 
As  discussed  earlier  the  importance  of  ST2  in  experimental  asthma  remains 
unclear.  Neutralising  antibodies  against  ST2  have  attenuated  eosinophilic 
inflammation(298,372,396). Whereas, at the outset of this work, the only study 
of asthma in ST2
-/- mice found no difference in inflammation when a 35 day OVA 
based model of asthma utilising 15 airways challenges was used in C57Bl/6 mice. 
Given the conflicting data utilising antibodies, the intensive challenge protocol 
used  in  the  ST2
-/-  study  and  the  possibility  that  the  strain  could  contribute 
significantly to the outcome; as in IL-5
-/- studies where AHR is lost in C57Bl/6 but 
not BALB/c mice(94,100), I chose to study the effect on ST2 gene deletion on a 
BALB/c background in the 12 day model of asthma. 
4.5.1 The effect of ST2 gene knock-out in the twelve day model 
Using  the  12  day  asthma  model  validated  above,  we  observed  that  in  ST2 
deficient mice airways inflammation was significantly reduced compared with 
similarly challenged wild type (WT) mice. There was a reduction in the total 
number  of  inflammatory  cells  within  the  airways  (Figure  4.25A).  This  was 
predominantly  due to  a  reduction  in  the percentage  and  absolute number of 
eosinophils (Figure 4.25B,C), although there was also a reduction in macrophage 
numbers(Figure 4.25C). 
Cytokines and chemokines were generally only detected at low concentrations in 
the BAL in both groups and although there appeared to be a trend towards a 
reduction in BAL IL-4, eotaxin-2 and TARC in ST2
-/- mice the changes were not 
statistically significant (Figure 4.26A). Concentrations of IL-1, IL-2, IL-5, IL-10, 
IL-12,  IL-13,  IL-17,  IFNγ,  TNFα,  GM-CSF,  FGF,  IP-10,  MCP-1,  KC,  TCA3  and 
eotaxin-1 in the BAL were below 50 pg/ml. 
With the exception of eotaxin-1, cytokines and chemokines were detected at 
low  concentrations  in  the  serum  (Figure  4.26B).  There  was  a  significant 
reduction in serum IL-13 in ST2
-/- mice, although the concentration in WT mice 
was only 40 pg/ml.  Concentrations of IL-1, IL-2, IL-4, IL-5, IL-6, IL-12, IL-17, 
IFNγ, TNFα, GM-CSF, IP-10, MCP-1, MIP-1α, TARC and TCA3 in the serum were 
below 50 pg/ml. Chapter 4:  154 
When draining lymph node cells were restimulated with OVA IL-5 and IL-13 were 
produced  at  ng/ml  concentrations  with  other  cytokines  and  chemokines 
produced at lower concentrations (Figure 4.27). The only statistically significant 
difference between WT and ST2
-/- mice was a reduction in the concentration of 
TNFα in ST2
-/- mice. 
These data demonstrate that the absence of ST2 significantly attenuates allergic 
airways inflammation, but do not offer any insights into the mechanism behind 
this. Chapter 4:  155 
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Figure 4.25 - ST2 gene knockout attenuates airways inflammation 
BALB/c WT and ST2
-/- mice were immunised with OVA and alum prior to being challenged with 
OVA  utilising  the  12  day  protocol  (Figure  4.8).  The  day  after  the  final  challenge  BAL  was 
performed.  (A)  Total  cell  numbers  were  counted.  (B,C)  Differential  counts  were  performed. 
Results are shown as the mean of each group of mice +/- SEM. n=7 mice. * p<0.05, ** p<0.01. 
Results are representative of three separate experiments.  
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Figure 4.26 –ST2 gene knockout does not affect BAL and serum cytokine and chemokines 
BAL was obtained from immunised and challenged WT and ST2
-/- mice as in Figure 4.25. Cytokine 
and chemokine concentrations were measured by ELISA and multiplexed immunoassay in (A) BAL 
and (B) serum. Eo1 = eotaxin-1, Eo2 = eotaxin-2. Results are shown as the mean of each group of 
mice +/- SEM. n=7 mice. * p<0.05. Chapter 4:  157 
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Figure 4.27 - ST2 gene knockout does not affect draining lymph node responses 
WT and ST2
-/- mice were immunised and challenged as in Figure 4.25. Draining lymph nodes were 
collected on day 12 and single cell suspensions from individual mice restimulated with OVA 1 
mg/ml. Supernatants were collected after 96 hours and cytokines and chemokines measured by 
ELISA or multiplexed immunoassay.  Eo2 = eotaxin-2. Results are shown as the mean of  each 
group of mice +/- SEM. n=7 mice. * p<0.05. 
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4.5.2 Establishing an alum-free model of asthma 
Having  demonstrated  that  ST2  is  important  in  a  12  day  model  of  asthma  in 
BALB/c  mice  I  sought  to  explore  the  mechanism  for  this.  In  addition  to  the 
previously cited paper(381), during the course of this work further data came to 
light published by Mangan et al(383). Both these studies are summarised in Table 
4.1. Using a 30 day OVA and alum based model in BALB/c mice Mangan et al 
found that,  while  histological  inflammation  and  AHR  were  unaffected  by  ST2 
gene deletion, BAL eosinophils were elevated. The fact that I found a reduction 
in  airways  eosinophilia  and  Hoshino  et  al  did  not  could  be  attributed  to 
differences in mouse strain as well as model. However the fact that Mangan et al 
and I reached opposite conclusions using the same strain of ST2
-/- BALB/c mice 
suggests that the model used may be crucial. I have used a 12 day model in 
which mice were immunised with OVA 100 µg in alum before being challenged on 
days 9 to 11 with 10 µg of intranasal OVA. Mangan at al immunised with 2 µg of 
OVA in alum on days 1 and 14 before challenging with nebulised OVA on days 28 
to 30. 
Investigator  Mice  Sensitisation  Challenges  Length  EØ 
Hoshino(381)  C57Bl/6  OVA + Alum 
d0 + d12  15  32 days  NC 
Mangan(383)  BALB/c  OVA + Alum 
d1 + d14  3  31 days   
Pitman  BALB/c  OVA + Alum 
d1  3  12 days   
Table 4.1 – The effect of ST2 gene deletion in experimental asthma 
Key –   Sensitisation: antigen and adjuvant administered on indicated days. Challenges: number 
of  airways  challenges  given.  Length:  Total  duration  of  model.  EØ:  effect  on  lung 
eosinophil numbers. 
 
It is possible that the requirement for ST2 in experimental asthma is upon mast 
cells. The data I presented in Chapter 3 suggests that ST2 can be an important 
receptor on mast cells. As discussed previously conventional models of asthma 
featuring immunisation with OVA and alum are mast cell independent(157,162). 
The 12 day model used here has not been extensively studied, the difference 
between it and more conventional models, and the importance of mast cells in 
this model are unknown. One of the only models utilising alum in which mast cell 
deficiency  resulted  in  reduced  eosinophilia  was  very  similar.  Mice  were Chapter 4:  159 
immunised with OVA and alum on days 1 and 5 before being challenged with OVA 
twice on day 12(159). 
I hypothesised that ST2 was required in models of asthma which were mast cell 
dependent.  The  omission  of  alum  has  been  shown  to  induce  mast  cell 
dependency in models which otherwise do not require mast cells. Therefore I 
chose to study the role of ST2 in one of these published models. 
I tested two alum-free models based on published protocols. The first paper to 
highlight the role of mast cells in alum-free models used seven sensitisations of 
OVA (10 µg) alone over 14 days followed by three intranasal challenges of OVA 
(200 µg) on days 40, 43 and 46(162). A more recent paper demonstrated that the 
omission of alum from a shorter more conventional model resulted in mast cell 
dependence.  Mice  were  sensitised  with  OVA  (20  µg)  alone  on  days  0  and  14 
before being challenged with nebulised OVA on days 28, 29 and 30(163). 
Both protocols were adapted slightly in line with our own laboratory experience, 
specifically they were both shortened from 47 and 31 days to 28 days, and in the 
later model intranasal delivery was used in place of nebulised delivery. Figure 
4.28 details the two models, Protocol A and Protocol B. I set out to confirm that 
with  these  minor  changes  these  models  generated  airways  and  tissue 
inflammation, AHR and antigen specific IgE. 
Although  BAL  total  cell  counts  were  increased  in  both  models  this  was  only 
statistically  significant  in  Protocol  A  (Figure  4.29A).  The  proportion  of 
eosinophils within the BAL was significantly elevated in both protocols but was 
again more marked in Protocol A (Figure 4.29B). This translated to a rise in total 
BAL eosinophils which was greater and more statistically significant in Protocol A 
than Protocol B (Figure 4.29C). IL-4, IL-5 and IL-13 were not detected in the 
BAL. 
Significant AHR was generated in both models (Figure 4.30). Antigen specific IgE 
was also generated using both protocols, although levels were only significantly 
higher than PBS with Protocol B (Figure 4.31). 
The  reason  for  the  generally  more  pronounced  inflammatory  response,  but 
reduced IgE titres in Protocol A is unclear. The only difference between the two Chapter 4:  160 
protocols was in the immunisation, with Protocol A using a total of 40 µg of OVA 
administered  at  two  immunisations  and  Protocol  B  using  a  total  70  µg 
administered at seven immunisations. 
Protocol A was selected for further study. Not only was BAL eosinophilia more 
marked, but the reduced number of immunisations was preferable in terms of 
animal  welfare.  Histological  sections  confirmed  that  Protocol  A  also  induced 
tissue eosinophilia (Figure 4.32). 
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Figure 4.28 – Two alum-free models of asthma 
(Protocol  A)  Mice  were  immunised  with  OVA  (20  µg)  alone  on  days  0  and  14  before  being 
challenged with intranasal OVA (200 µg) on days 25, 26 and 27. AHR was measured on day 28 and 
mice culled on day 29. (Protocol B) Mice were immunised with OVA (10 µg) alone on days 0, 2, 4, 
6, 8, 10 and 12 before being challenged with intranasal OVA (200 µg) on days 25, 26 and 27. AHR 
was measured on day 28 and mice culled on day 29. Chapter 4:  162 
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Figure 4.29 – BAL eosinophilia is generated in the absence of alum 
Mice were immunised, challenged and culled according to Protocol A (IP x 2) or Protocol B (IP x 
7) as detailed in Figure 4.28. Control mice (PBS) were sensitised with OVA (20 µg) on days 0 and 
14 before being challenged with PBS alone on days 25, 26 and 27. (A) Total cell counts were 
performed upon BAL. (B,C) BAL differential counts were performed. Results are shown as the 
mean of each group of mice +/- SEM. n=6 mice. * p<0.05, ** p<0.01. Chapter 4:  163 
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Figure 4.30 – Airways hyperresponsiveness is generated in the absence of alum 
Mice were immunised and challenged as in Figure 4.29 with Penh being measured on day 28. 
Results  are  shown  as  the  mean  of  each  group  of  mice  +/-  SEM.  n=6  mice.  Two-way  ANOVA 
p<0.001 IP x 2 compared with PBS, p<0.001 IP x 7 compared with PBS. 
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Figure 4.31 – Antigen specific IgE is generated in the absence of alum 
Mice were immunised, challenged and culled as in Figure 4.29. OVA specific IgE was measured in 
serum by ELISA at dilutions from 1/20 to 1/540. Results are shown as the mean of each group of 
mice +/- SEM. n=6 mice.  Two-way ANOVA p<0.05  IP x 2 compared with  PBS, p<0.001 IP x 7 
compared with PBS. Chapter 4:  164 
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Figure 4.32 - Histological inflammation is induced in the absence of alum 
Mice were immunised, challenged and culled as in Figure 4.29. Lungs were fixed in formalin and 
stained with H&E. Panels shown are representative sections. Chapter 4:  165 
4.5.3 The role of ST2 in an alum-free model of asthma 
In order to determine whether or not there was an alum dependent requirement 
for  ST2  in  murine  asthma  I  induced  asthma  in  WT  and  ST2
-/-  mice  with  and 
without  alum.  Mice  were  immunised  and  challenged  with  OVA  alone  (Figure 
4.28A) or using an identical protocol with the addition of 1% alum to both the 
day 0 and day 14 immunisation. 
When  immunised  and  challenged  with  OVA  alone  (OVA  group)  BAL  total  cell 
counts, eosinophil percentage and total eosinophil numbers were all significantly 
reduced  in  ST2
-/-  mice  as  compared  with  WT  mice.  Conversely,  in  the  group 
immunised  with  OVA  and  alum  (OVA-Alum  group)  BAL  total  cell  counts  and 
eosinophilia were no different between WT and ST2
-/- mice (Figure 4.33). There 
was also evidence of attenuated eosinophilic inflammation on histology (Figure 
4.34). 
Despite ST2 gene deletion attenuating airway inflammation, the increased AHR 
in both asthma models was maintained. As expected AHR was generated in both 
the OVA alone model and the OVA-Alum model in WT mice. In both models AHR 
was unaffected by ST2 gene deletion (Figure 4.35). 
BAL cytokines and chemokines provided no clear explanation for the significant 
reduction in eosinophils in ST2
-/- mice immunised with OVA alone. IL-1, IL-2, IL-
4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFNγ, TNFα, GM-CSF, KC, FGF, IP-10, MIG, 
MCP-1, MIP-1α and RANTES were undetectable or present at concentrations of 
less than 50 pg/ml, and did not differ significantly between protocols or strains. 
Eotaxin 1 and 2 were detected at slightly higher concentrations, and there was a 
non-significant trend for lower concentrations of eotaxin-2 in ST2
-/- mice in both 
the OVA and the OVA-Alum protocols (Figure 4.36). 
As  with  the  BAL,  cytokine  and  chemokine  concentrations  in  the  serum  were 
generally low, those detected at the highest concentrations are shown in Figure 
4.37. The mean concentration of IL-10 in WT mice immunised with PBS alone 
was high, although there was marked variance within this group. Concentrations 
of IL-10 were also relatively high in OVA-Alum mice immunised with OVA and 
Alum, but were undetectable in the serum of OVA mice. IL-12 was detected in 
the serum of all mice and was significantly reduced in ST2
-/- mice relative to WT Chapter 4:  166 
mice in the OVA protocol. KC was present only in the serum of OVA or OVA-Alum 
WT mice, but despite the absence of KC in ST2
-/- mice the difference was not 
significant due to the high variance. MIG was present in the serum of all OVA and 
OVA-Alum mice with the exception of ST2
-/- mice immunised with OVA alone, but 
this  difference  was  also  not  significant.  Eotaxin-1  was  detected  at  high 
concentrations and eotaxin-2 at lower concentrations. Both were detected at 
similar concentrations in the serum of all mice. Concentrations of IL-1, IL-2, IL-
4, IL-5, IL-6, IL-13, IL-17, IFNγ, TNFα, GM-CSF, FGF, IP-10, MCP-1, MIP-1α and 
RANTES in the serum were below 50 pg/ml. 
Antigen specific IgE is a critical component of any model of atopic asthma. While 
OVA specific IgE was unaffected by ST2 gene deletion in the OVA-Alum model, 
there  was  a  significant  reduction  in  IgE  production  in  the  OVA  alone  model 
(Figure 4.38A). The other Th2 associated antibody, IgG1 was unaffected by ST2 
gene deletion in either model (Figure 4.38B). OVA specific IgG2a was also not 
significantly different between WT and ST2
-/- mice (Figure 4.38C). 
Given that isotype switching is likely to occur in the local draining lymph nodes 
under the influence of IL-4 or IL-13(120) I went on to examine the production of 
Th2 cytokines by draining lymph node cells when restimulated with OVA. When 
draining  lymph  node  cells  from  mice  immunised  with  OVA  and  alum  were 
restimulated  with  OVA  there  was  no  difference  in  IL-4,  IL-5  and  IL-13 
concentrations between WT and ST2
-/- mice (Figure 4.39). In contrast when mice 
were immunised with OVA alone there was a significant reduction in IL-5 and IL-
13 in lymph node cultures from ST2
-/- mice, and a trend towards reduced IL-4 (p= 
0.06). There was no significant cytokine production when lymph node cells were 
cultured with medium alone (data not shown). 
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Figure 4.33 - BAL eosinophils are reduced in ST2
-/- mice in the absence of alum 
WT (■) and ST2
-/- (□) mice were immunised with OVA (10µg) and 1% alum (OVA Alum), OVA (10 
µg) alone (OVA) or PBS (PBS) on days 0 and 14. All mice were challenge with intranasal OVA (200 
µg) on days 25, 26 and 27. Mice were culled on day 29. (A) Total cell counts were performed 
upon BAL. (B,C) BAL differential counts were performed. Results are shown as the mean of each 
group of mice +/- SEM. n=8 mice. ** p<0.01 compared with WT. Chapter 4:  168 
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Figure 4.34 – Tissue eosinophilia is reduced in ST2
-/- mice in the absence of alum 
WT and ST2
-/- mice were immunised and challenged and culled as in Figure 4.33. Lungs were 
fixed in formalin and stained with H&E. Panels shown are representative sections. Chapter 4:  169 
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Figure 4.35 - Airways hyperresponsiveness is preserved in ST2
-/- mice 
WT (■) and ST2
-/- (□) mice were immunised and challenged as in Figure 4.33. Penh was measured 
on day 28. Results are shown as the mean of each group of mice +/- SEM. n=8 mice. 
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Figure 4.36 – BAL cytokines and chemokines are not significantly altered in ST2
-/- mice 
WT (■) and ST2
-/- (□) mice were immunised and challenged as in Figure 4.33. BAL was collected 
and cytokine and chemokine concentrations measured by ELISA and multiplexed immunoassay. 
Results are shown as the mean of each group of mice +/- SEM. n=8 mice. Chapter 4:  171 
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Figure 4.37 – Serum cytokines and chemokines are not significantly altered in ST2
-/- mice 
WT  (■)  and  ST2
-/-  (□)  mice  were  immunised  and  challenged  as  in  Figure  4.33.  Serum  was 
collected  and  cytokine  and  chemokine  concentrations  measured  by  ELISA  and  multiplexed 
immunoassay. Results are shown as the mean of each group of mice +/- SEM. n=8 mice. ** p<0.01 
compared with WT Chapter 4:  172 
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Figure 4.38 – Antigen specific IgE is reduced in ST2
-/- mice in the absence of alum 
WT (■) and ST2
-/- (□) mice were immunised and challenged as in Figure 4.33 Serum was collected 
and OVA specific immunoglobulins measured by ELISA. Results are shown as the mean of each 
group of mice +/- SEM. n=8 mice. ** p<0.01 compared with WT  Chapter 4:  173 
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Figure 4.39 – Lymph node Th2 cytokines are reduced in ST2
-/- mice in the absence of alum 
WT  (■)  and  ST2
-/-  (□)  mice  were  immunised  and  challenged  as  in  Figure  4.33.  Single  cell 
suspensions from draining lymph nodes were stimulated with OVA 1 mg/ml. Supernatants were 
collected after 96 hours and cytokines and chemokines measured by ELISA. Results are shown as 
the mean of each group of mice +/- SEM. n=8 mice. * p<0.05, ** p<0.01 compared with WT. Chapter 4:  174 
4.6 Conclusions 
The experiments in this chapter initially served to develop a murine model of 
allergic airways inflammation for later use in the study of the role of ST2 in 
experimental  asthma.  There  were  several  stages  in  the  development  and 
validation of this model. A crucial step in the induction of airways inflammation 
is the introduction of antigen to the lungs. Ideally the dose delivered should be 
repeatable and equally distributed throughout the bronchial tree. One solution is 
to allow conscious animals to inhale a nebulised solution of antigen. While, with 
careful engineering(482), the concentration of particles within the chamber can 
be uniform, the dose delivered will be affected by the ventilatory pattern of 
each  animal.  Distribution  throughout  the  airways  may  also  be  uneven  with 
particle  deposition  in  the  upper  airways(483)  and  significant  variation  in  the 
dose delivered to different parts of the lung(484). An alternative method is to 
use  intranasal  administration,  which  can  ensure  that  the  same  total  dose  is 
delivered on each occasion. However there is concern as to how the delivered 
antigen is distributed, with evidence that a significant proportion of delivered 
agent  is  localised  to  the  upper  GI  tract  and  upper  respiratory  tract(485).  By 
instilling  antigen  directly  into the  lungs  via  cannulation  of the trachea  these 
problems  may  be  overcome.  I  found  that  there  was  no  difference  in  the 
magnitude  of  the  inflammatory  response  or  intra-group  variance  between 
intranasal and intratracheal dosing. In addition when Evan‟s blue was instilled 
via the intratracheal route under terminal anaesthesia a significant quantity of 
dye was found within the upper respiratory tract and stomach (data not shown). 
It is likely that all routes of administration result in delivery of antigen to the 
upper  respiratory  tract,  but  given  that  this  alone  can  result  in  pulmonary 
inflammation and AHR(486) the model is unlikely to be adversely affected. While 
in theory ingestion of antigen may result in oral tolerance(487), in practice all of 
the described delivery methods result in a robust recall immune response. 
Information on the nature of the T cell response upon antigen challenge can be 
obtained by culturing cells from the draining lymph nodes. I have found that the 
culture of lymph nodes from each mouse individually, as opposed to pooled from 
all mice, is practical and not prohibitively time consuming. This technique also 
allows  for  variance  to  be  calculated  and  statistical  comparisons  to  be  made Chapter 4:  175 
between groups. The data also suggest that there may be a problem of high 
responders skewing the response in pooled cultures. 
I  also  set  out  to  establish  a  method  to  measure  AHR.  While  invasive 
measurement of airways resistance and compliance remains the gold standard it 
was  out  with  the  scope  of  this  project  to  establish  this  technique  within 
laboratory.  Considerable  technical  skill  is  required  to  perform  cut-down  and 
tracheal  intubation  in  live  anaesthetised  mice  and  such  expertise  was  not 
available locally. A significant investment in equipment is also required. Within 
the group there was already the equipment and experience to measure Penh. 
The principles of this investigation have been discussed in Chapter 2. There are 
however concerns regarding the use of the dimensionless parameter Penh. These 
are in part due to the fact that although Penh measurements generally correlate 
well with direct measures of airways resistance, it is not clear exactly what Penh 
is  a  measure  of(488,489).  Although  Penh  is  acknowledged  to  be  affected  by 
changes in airways resistance there is concern over the contribution  of other 
factors such as nasal resistance, ambient temperature and humidity within the 
chamber  and  tidal  volume(488,490).  I  found  that,  provided  sufficiently  large 
groups were used, all three models of asthma utilised in this chapter generated 
reproducible  methacholine-induced  changes  in  Penh  which  were  significantly 
greater  than  in  control  mice.  Furthermore  Penh  continues  to  be  utilised  by 
leading investigators in the field of experimental asthma(31-34). 
Having optimised and validated a short model of asthma I was able to study the 
kinetics  of  the  immune  response  to  antigen  challenge.  This  led  to  two  key 
observations.  Firstly,  it  would  appear  that  antigen  challenge  induces  an 
inflammatory  response  within  the  airways  which  continues  to  develop  in  the 
absence of ongoing antigen dosing. One might predict that during the challenge 
period  eosinophil  numbers  rise  following  each  successive  challenge,  but  the 
changes following a single antigen challenge were more unexpected. While it is 
recognised that by 7 to 14 days after challenge eosinophil numbers have fallen 
significantly(491-493), there is little data on earlier time points.  In a 31 day 
model of asthma in which mice were sensitised twice with OVA and alum before 
being  challenged  with  OVA  on  three  consecutive  days,  eosinophil  numbers 
peaked 48 hours after the final challenge, and began to fall by 72 hours(493). It 
was therefore surprising that in mice which had been sensitised once, a single Chapter 4:  176 
antigen  challenge  resulted  in  an  inflammatory  response  which  continued  to 
develop for up to 72 hours. 
In light of this ongoing inflammation it was also unexpected that Th2 cytokines 
were produced only transiently. It is well established that IL-4, IL-5 and IL-13 are 
detected  within  the  BAL  and  serum  in  murine  models  of  asthma,  usually 
measured  24  hours  after  the  final  challenge,  and  often  at  relatively  low 
concentrations. BAL IL-4 was detected at high (ng/ml) concentrations 24 hours 
after a single antigen challenge, with IL-5 and IL-13 at lower concentrations. In 
the  serum  IL-5  and  IL-13  were  also  elevated  24  hours  after  challenge. 
Surprisingly  even  when  further  challenges  were  given  Th2  cytokine 
concentrations  decreased  and  were  at  much  lower  or  undetectable 
concentrations  24  hours  after  the  third  challenge.  While  there  is  some  data 
available  for  the  kinetics  of  BAL  Th2  cytokine  concentrations  after  the  final 
challenge(493)  I  could  find  no  data  regarding  changes  during  the  challenge 
period. 
While Th2 cytokine concentrations in the BAL and serum decreased after the 
first  challenge,  eosinophil  numbers  in  the  airways  continued  to  rise.  The 
sustained  chemokine  release  seen  may  account  for  this,  with  eotaxin-2 
concentrations rising regardless of whether or not further challenges were given. 
In fact BAL eotaxin-2 concentrations correlated closely with eosinophil numbers. 
In  asthmatic  patients  eotaxin-1  and  eotaxin-2  expression  rises  after  a  single 
antigen challenge(494,495) and eotaxin-2 also correlates closely with eosinophil 
numbers in bronchial biopsies(495). The close relationship between eosinophilic 
inflammation and eotaxin-2 is in keeping with the key role of the CCR3-eotaxin 
pathway in eosinophil recruitment during experimental asthma(268-270). 
These data suggest that initial exposure to allergen results in a Th2 cytokine 
response,  which  then  appears  to  be  down-regulated  despite  ongoing  allergen 
exposure. This is followed by local eotaxin-2 production which drives eosinophil 
recruitment. Even though Th2 cytokine expression is fairly transient, IL-4, IL-5 
and IL-13 are required for eosinophilic inflammation in experimental asthma, as 
discussed in Chapter 1. It may be that inflammation is initiated by Th2 cytokine 
release but then perpetuated by ongoing eotaxin-2 production. IL-5 can induce 
eosinophils  to  mobilise  from  the  bone  marrow  and  express  CCR3(496,497) Chapter 4:  177 
whereas IL-4 can induce eotaxin-2 production by macrophages(498), which are 
the most abundant cells within the airways. 
The other key finding was regarding the requirement for ST2 in allergic airways 
inflammation.  In  the  12  day  model  of  asthma  airways  inflammation  was 
significantly reduced in ST2 deficient mice. This is in contrast to published data 
from different asthma models. While the study by Hoshino et al found no effect 
of ST2 gene deletion on airways inflammation, they utilised a protocol in which 
C57Bl/6  mice  were  used  rather  than  BALB/c  mice,  and  15  challenges  were 
administered(381).  However  the  study  by  Mangan  et  al,  which  also  found  no 
requirement  for  ST2  in  the  generation  of eosinophilic inflammation,  not  only 
used BALB/c mice, but also a more conventional 30 day model in which mice 
were challenged three times(383). 
The reason for the dramatic difference between the 12 day and 30 day models is 
unclear. Subtle differences in models, such as the route of sensitisation, can 
have  significant  impact  on  the  pathways  required.  For  example  when 
sensitisation is carried out by the epicutaneous rather than the intraperitoneal 
route, the requirement for IL-4 is bypassed(213). As there have been few studies 
using the short model little is know about how it differs functionally from other 
models. However a very similar model, in which mice were sensitised with OVA 
and alum on days 1 and 5 before being challenged twice on day 12, was unusual 
in  showing  a  requirement  for  mast  cells  in  the  generation  of  eosinophilic 
inflammation(159).  
In light of these data and the role of ST2 on mast cells demonstrated in Chapter 
3, I went on to show that ST2 was required in an alum-free, mast cell dependent 
model of asthma. Eosinophilic inflammation was dramatically reduced in ST2
-/- 
mice in the alum-free model while AHR was preserved. This was associated with 
a marked reduction in antigen specific IgE and reduced Th2 cytokine production 
by antigen stimulated lymph node cells. However when alum was used as an 
adjuvant  during  sensitisation  ST2  gene  deletion  had  no  effect  on  airways 
inflammation or AHR. 
While the results from the 28 day alum model are in keeping with the published 
literature(381,383),  the  results  from  the  alum-free  model  are  novel.  My 
hypothesis  prior  to  performing  the  experiment  was  that  mast  cell  ST2  is Chapter 4:  178 
necessary for allergic airways inflammation provided that the models of asthma 
used has a requirement for mast cells. Given that the use of alum confers mast 
cell  independence  and  the  omission  of  alum  mast  cell  dependence(162),  the 
data  would  support  this  hypothesis,  ST2  was  only  required  in  the  mast  cell 
dependent  model  of  asthma.  This  is  of  course  not  the  only  possible 
interpretation of the data. While the alum-free model of asthma is a mast cell 
dependent  model,  this  may  not  be  the  sole  effect  of  omitting  alum.  To 
appreciate  other  possible  explanations  it  is  important  to  consider  the 
mechanisms by which alum functions as an adjuvant. 
In  1926  Glenny  et  al  discovered  that  precipitating  antigen  onto  insoluble 
aluminium potassium sulphate improved antibody responses(45). It was initially 
thought that alum worked simply by effecting a slow release of antigen over 
time. This theory persisted for many years but more recent data suggests that 
alum works by other methods. 
Following intraperitoneal administration of OVA alone antigen appears to travel 
passively to the draining lymph nodes where it is taken up and presented by 
resident DCs(499). When OVA is administered with alum it induces an influx of 
peritoneal monocytes that take up the OVA before maturing to become DCs and 
migrating to lymph nodes where they activate T cells. This process is dependent 
on urate production, and results in more effective activation of CD4 T cells than 
with  OVA  alone.  One  of  the  reasons  why  alum  is  able  to  recruit  DCs  in  this 
manner appears to be by activation of the inflammasome. 
The innate immune system has a collection of receptors to recognise conserved 
molecules associated with pathogens or pathogen-associated molecular patterns 
(PAMPs). The best characterised of the PAMP receptors are the predominantly 
surface expressed TLRs, but there also the intracellular nucleotide binding and 
oligmerization domain (NOD)-like receptors (NLRs). They function in association 
with other proteins including pro-caspases, to form a complex referred to as the 
inflammasome(500). The NLRP3 containing inflammasome is associated with pro-
caspase-1  which is  converted to  active caspase-1  upon  triggering  and  in  turn 
cleaves IL-1β and IL-18 to their active forms(501). 
It  has  recently  been  demonstrated  that  alum  synergises  with  LPS  in  vitro  to 
induce  IL-1β  and  IL-18  release  from  macrophages  via  the  NLRP3 Chapter 4:  179 
inflammasome(502-505).  While  IL-18  is  expressed  constitutively,  LPS  may  be 
required in vitro to induce pro-IL-1β which is then cleaved by alum-mediated 
activation  of  the  inflammasome(506,507).  The  NLRP3  inflammasome  is  also 
required  for  the  adjuvant  effect  of  alum  administered  with  OVA  in  vivo, 
including  antigen  uptake  and  maturation  of  peritoneal  DCs,  IgG1  and  IgE 
production and eosinophilic inflammation in experimental asthma(502,503,505). 
Despite  these  findings  it  is  in  alum-free  models  of  asthma  that  IL-1  is 
indispensable(508,509). 
These  data  demonstrate  that  the  use  of  alum  results  in  alternative  antigen 
transport and processing, activation of the NLRP3 inflammasome and generation 
IL-1β and IL-18.  In an alum-free model of asthma there is a requirement for 
TNFα producing mast cells(33,162,163), IgE(125) and IL-1. I have demonstrated 
that in alum-free models there is also a requirement for ST2. 
The  question  remains  as  to  whether  or  not  ST2  is  required  at  the  time  of 
sensitisation, perhaps as part of the pathway which is activated in the absence 
of alum, or whether in the absence of alum a pathway is utilised which then 
requires ST2, perhaps on mast cells, at the time of antigen challenge. 
In the following chapter I set out establish whether the activation of ST2 in the 
lungs with IL-33 induces the features of experimental asthma. 
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In this chapter I will study the effect of activating ST2 in the airways by the 
administration of IL-33. 
5.1 Introduction 
In Chapter 3 I demonstrated that IL-33 activated mast cells via the receptor ST2 
to release pro-inflammatory cytokines and chemokines in vitro. In particular IL-
6, IL-13, MIP-1α and MCP-1; all of which have the potential to play a pathological 
role in clinical and experimental asthma.  
In  Chapter  4,  I  found  that  ST2  contributes  to  airways  inflammation  and  IgE 
generation, but not AHR, in an alum-free model of asthma. A key difference 
between models of asthma which utilise alum and those that do not is that the 
use  of  alum  appears  to  eliminate  the  requirement  for  mast  cells  in  the 
development of airways inflammation and AHR(162).  
Taken together these data support the possibility that activating ST2 on mast 
cells plays an important role in experimental asthma. 
Schmitz  et  al(323)  found  that  the  systemic  activation  of  ST2  by  the 
administration of IL-33 induced blood eosinophilia, the generation of serum IgE 
and IgA, Th2 cytokine production and some perivascular and epithelial changes 
in the lungs. 
I hypothesised that the activation of ST2 on mast cells within the airways by IL-
33 would induce the features of experimental asthma. 
5.2 The effect of IL-33 on airways inflammation 
In  the  first  instance  I  set  out  to  establish  whether  or  not  the  intranasal 
administration of IL-33 would induce inflammation within the lungs. Schmitz et 
al  administered  0.4  or  4  µg  of  recombinant  human  IL-33  intraperitoneally  to 
C57BL/6  mice  daily  for  seven  days  and  culled  the  animals  the  following 
day(323). I based the protocol for intranasal administration upon these methods. 
Others within the lab had found in studies of murine T cells in vitro that human 
recombinant IL-33 has approximately half the bioactivity of recombinant murine 
IL-33 (M. Kurowska-Stolarska, personal communication). Consequently I selected Chapter 5:  182 
a dose of 2 µg of murine IL-33 for initial studies. C57BL/6 mice were chosen 
given  the  proven  efficacy  of  systemic  IL-33  administration  in  this  strain.  In 
addition this would allow for future investigation of the contribution of mast 
cells to any effect observed, as mast cell deficient mice are available on the 
C57Bl/6 background. 
5.2.1 The effect of intranasal IL-33 
Recombinant murine IL-33 (2 µg) was administered via the intranasal route to 
C57Bl/6 mice each day for seven days. The day after the final dose mice were 
culled and BAL fluid and lungs collected. 
IL-33 administration resulted in a dramatic rise in cell numbers within the BAL, 
with a mean total cell count of 54 x10
5 cells/ml (Figure 5.1A). This compares 
with  counts  in  the  region  of  2  –  5  x10
5  cells/ml  in  the  models  of  asthma 
presented previously. There was an associated dramatic rise in the proportion of 
eosinophils in the BAL from 0% to 79% (Figure 5.1B). Consequently there was a 
marked rise in absolute eosinophil numbers from 0 to 43 x10
5 cells/ml (Figure 
5.1C). While the proportion of macrophages fell from 93% to 16% there was still 
a significant rise in absolute numbers from 1 to 8 x10
5 cells/ml. The proportion 
of neutrophils was low in both groups at 6% in the PBS group and 5% in the IL-33 
group, this did however translate to a rise in absolute neutrophil numbers from 
0.2 to 2.5 x10
5 cells/ml in the IL-33 group. 
Histological  examination  of  the  lungs  revealed  extensive  eosinophilic 
inflammation  throughout  (Figure  5.2).  The  degree  of  inflammation  was  much 
more pronounced than that seen with the murine models of asthma in Chapter 4. 
Concentrations of the Th2 cytokines IL-4 and IL-13 were slightly elevated in the 
BAL  at  34  pg/ml  and  29  pg/ml  respectively  (Figure  5.3).  The  eosinophil 
chemoattractants eotaxin 1 and 2 were induced at relatively high concentrations 
by IL-33, 116 pg/ml and 397 pg/ml respectively. 
These  data  confirm  that  the  intranasal  administration  of  IL-33  induces 
inflammatory changes in the lungs similar to those seen in experimental asthma, 
the most striking of which is a profound eosinophilia. Chapter 5:  183 
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Figure 5.1 – Intranasal IL-33 induces BAL eosinophilia 
C57BL/6 mice received PBS or 2 µg of recombinant murine IL-33 via the intranasal route on days 
1 to 7 before being culled on day 8 at which point BAL was collected. (A) Total cell counts were 
performed upon BAL. (B,C) BAL differential counts were performed. Results are shown as the 
mean of each group of mice +/- SEM. n=7 mice. ** p<0.01 compared with PBS Chapter 5:  184 
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Figure 5.2 – Intranasal IL-33 induces inflammation within the lung 
PBS or IL-33 was administered to mice as in Figure 5.1. Lungs were fixed in formalin and stained 
with H&E. Panels shown are representative sections. 
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Figure 5.3 – Intranasal IL-33 induces BAL cytokines and chemokines 
PBS or IL-33 was administered to mice as in Figure 5.1. BAL was collected and cytokines assayed 
by ELISA. Results are shown as the mean of each group of mice +/- SEM. n=7 mice. * p<0.05, ** 
p<0.01 compared with PBS Chapter 5:  185 
5.2.2 Kinetics during serial IL-33 administration 
To  better  understand  the  changes  that  lead  to  the  development  of  airways 
inflammation  in  mice  administered  repeated  doses  of  IL-33,  particularly  the 
cytokines  and  chemokines  which  may  be  responsible  for  the  recruitment  of 
eosinophils, I undertook a study of the dynamic response to IL-33. I designed a 
protocol to study the kinetics of cytokines, chemokines and cell numbers within 
the  lungs  over  the  course  of  the  eight  day  treatment  period.  As  detailed  in 
Figure 5.4, mice received up to 7 daily doses of intranasal IL-33 and groups of 
mice were culled at 24 hour intervals throughout this period. 
Total  cell  counts  began  to  rise  on  day  three,  24  hours  after  the  third  dose. 
Numbers continued to rise with time and repeated dosing to a maximum of 50 
x10
5 after the seventh dose (Figure 5.5A). Differential cell changes are shown in 
Figure 5.5B. Macrophage numbers rose gradually over the time course from 1.4 
x10
5  in  untreated  mice  to  9.5  x10
5  after  seven  doses.  Neutrophils  were  first 
detected  on  day  3  and  rose  thereafter  to  8.4  x10
5  after  seven  doses.  As 
predicted the most striking change was in eosinophils, which first appeared in 
the BAL at low numbers (0.5 x10
5) 24 hours after the third dose. Numbers rose 
sharply  thereafter  reaching  31.5  x10
5  on  day  seven,  at  which  point  they 
comprised 59% of the BAL cell population. 
Locally  within  the  BAL  IL-13  was  the  cytokine  detected  at  the  highest 
concentration (Figure 5.6). It was first detectable on day four, peaked at 770 
pg/ml on day five and fell thereafter. IL-5 followed a similar pattern but at a 
much lower concentration, peaking at 175 pg/ml. The other Th2 cytokine IL-4 
was never detected at a concentration greater than 82 pg/ml. Eotaxin-1 and 
eotaxin-2 were first detected on day three, earlier than IL-5 and IL-13. Eotaxin-1 
remained at a similar concentration over time while eotaxin-2 then fell slightly. 
IL-12 and IP-10 also rose modestly to peak on day four and three respectively. 
Concentrations of IL-1, IL-2, IL-6, IL-10, IL-17, IFNγ, TNFα, GM-CSF, KC, FGF, 
MCP-1, MIP-1α, RANTES and MIG were below 50 pg/ml.  
Within the serum the most marked change was a rise in IL-13 over time to a peak 
concentration of 614 pg/ml on day seven (Figure 5.7). The other Th2 cytokines 
IL-4 and IL-5 were detected at much lower concentrations, with IL-4 never rising Chapter 5:  186 
above 50 pg/ml and IL-5 peaking at 157 pg/ml after 3 doses. IP-10 and FGF were 
the only chemokines which changed significantly over time,  rising and falling 
respectively from day zero to day seven. Concentrations of IFNγ, IL-6, GM-CSF, 
IL-17, MCP-1, MIP-1α, RANTES and MIG within the BAL were below 50 pg/ml. IL-
1, IL-2, IL-12 and TNFα were detected but did not change significantly over the 
time course. 
These data demonstrate that with repeated consecutive administrations of IL-33 
to the airways an eosinophilia is generated after four days which rises thereafter 
and is associated with elevated Th2 cytokine and eotaxin concentrations. Chapter 5:  187 
 
 
 
Figure 5.4 – Protocol for studying the kinetics of the response to IL-33 
2 µg of recombinant murine IL-33 was administered via the intranasal route once daily on days 1 
to 7. Groups of mice were culled 24 hours after each dose. For example Group 0 was culled prior 
to the first administration, Group 1 culled 24 hours after the first dose and Group 7 culled 24 
hours after the seventh and final dose. 
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Figure 5.5 - Eosinophils rise with successive IL-33 doses 
IL-33 was administered to mice as in Figure 5.4. (A) Total cell counts were performed upon BAL. 
(B) BAL differential counts were performed. Results are shown as the mean of each group of 
mice +/- SEM. n=4-5 mice. One-way ANOVA for the effect of IL-33 dose on macrophages p<0.001, 
eosinophils p<0.001, neutrophils p<0.001. Chapter 5:  189 
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Figure 5.6 - Change in BAL cytokines and chemokines with repeated IL-33 dosing 
IL-33 was administered to mice as in Figure 5.4. BAL was collected and cytokines and chemokines 
assayed by multiplexed immunoassay or ELISA. Results are shown as the mean of each group of 
mice  +/-  SEM.  n=4-5  mice.  One-way  ANOVA  for  the  effect  of  IL-33  dose  on  IL-13  p=0.005, 
Eotaxin-1 p<0.001, Eotaxin-2 p<0.001. Chapter 5:  190 
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Figure 5.7 - Change in serum cytokines and chemokines with repeated IL-33 dosing 
IL-33  was  administered  to  mice  as  in  Figure  5.4.  Serum  was  collected  and  cytokines  and 
chemokines assayed by multiplexed immunoassay or ELISA. Results  are shown as the mean of 
each group of mice +/- SEM. n=4-5 mice. One-way ANOVA for the effect of IL-33 dose on IL-4 
n.s., IL-5 p<0.05, IL-13 p<0.001, FGF n.s., IP-10 p<0.05. 
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5.2.3 Kinetics following IL-33 administration 
Having shown that in the context of repeated IL-33 administration BAL eosinophil 
counts  rise  continuously  I  was  interested  to  establish  whether  or  not  an 
inflammatory  process  had  been  initiated  which  would  be  perpetuated  in  the 
absence of ongoing ST2 stimulation. We had previously found that a single dose 
of IL-33 is insufficient to generate an appreciable airways eosinophilia at any 
point up to seven days after administration (P. Kewin et al unpublished), and so 
would need a protocol with multiple doses. 
Additionally, as I was interested in studying the contribution of mast cells to the 
response to IL-33 I wanted to establish an endpoint at which the response was 
not so great as to mask any contribution by individual cells and pathways. With 
seven  doses  of  IL-33  inducing  a  profound  eosinophilia  I  chose  a  point  in  the 
middle of the IL-33 dose response curve shown in Figure 5.5. Having shown that 
24  hours  after  4  doses  of  IL-33  a  moderate  eosinophilia  of  1.6x10
5/ml  is 
generated I chose to study the changes within the BAL and serum for up to eight 
days after 4 consecutive IL-33 administrations (Figure 5.8). 
Following  four  intranasal  doses  of  IL-33  total  cell  numbers  continued  to  rise 
steadily,  reaching  a  peak  four  days  after  dosing,  before  falling  again  (Figure 
5.9). Eosinophil numbers followed an identical pattern peaking at 24x10
5/ml four 
days after dosing, at which point they comprised 68% of BAL cells. Macrophages 
similarly  rose  to  a  peak  at  the  earlier  time  point  of  three  days  post  dosing, 
although the relative change was less dramatic with a maximum of 12x10
5/ml 
and  a  minimum  of  5.3x10
5/ml.  Neutrophils  were  also  induced,  peaking  at 
4.2x10
5/ml on day two. While numbers had fallen significantly by day eight, with 
virtually  no  detectable  neutrophils,  there  were  still  a  significant  number  of 
macrophages and eosinophils present at this late time point. Macrophages are 
the default cell found on BAL, where generally they make up 100% of the total 
cell  count.  While  numbers  are  higher  than  those  seen  in  naïve  mice,  at 
5.3x10
5/ml this is perhaps less striking than the persistence of eosinophils seen 
over a week after IL-33 administration. At day eight the eosinophil count was 
still 6x10
5/ml, making up 50% of all BAL cells, levels which are often not even 
achieved in standard asthma models immediately after antigen challenge. Chapter 5:  192 
Perhaps unsurprisingly Th2 cytokine levels within the BAL fell with the cessation 
of IL-33 dosing (Figure 5.10). IL-13 was present at high concentrations the day 
after  final  dosing,  but  fell  rapidly  thereafter.  IL-4  and  IL-5  began  at  more 
modest levels and also fell rapidly. Eotaxin-1 and eotaxin-2 followed a similar 
pattern, although with a more gradual decline, not beginning until day three in 
the case of eotaxin-2. IFNγ and IL-10 followed a different pattern, rising from 
zero  to  peak  briefly  two  days  after  the  last  IL-33  administration.  IL-12  was 
initially  detected  at  low  levels  then  also  fell  rapidly  (data  not  shown). 
Concentrations  of  IL-1,  IL-2,  IL-6,  TNFα,  GM-CSF,  KC,  FGF,  MCP-1,  MIP-1α, 
RANTES, IP-10 and MIG were below 50 pg/ml. 
Serum cytokine concentrations were all very low. IL-4 and IL-5 concentrations 
remained below 100 pg/ml, where IL-13 fell gradually from 160 pg/ml at day one 
to below the limit of detection at day eight (Figure 5.11). Concentrations of IL-
1, IL-2, IL-6, IL-10, IL-12, IL-17, IFNγ, TNFα, eotaxin-1, eotaxin-2, GM-CSF, KC, 
FGF, MCP-1, MIP-1α, RANTES, IP-10 and MIG were below 50 pg/ml. 
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Figure 5.8 – Protocol for studying the kinetics following four doses of IL-33 
2 µg of recombinant murine IL-33 was administered via the intranasal route once daily on days 1 
to 4. Groups of mice were culled 1, 2, 3, 4, 5 and 8 days after the final dose. 
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Figure 5.9 – Change in BAL cell numbers with repeated IL-33 dosing 
IL-33  was  administered  to  mice  as  in  Figure  5.8.Total  and  differential  cell  counts  were 
performed upon BAL. Results are shown as the mean of each group of mice +/- SEM. n=5 mice. Chapter 5:  194 
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Figure 5.10 - Change in BAL cytokines and chemokines with repeated IL-33 dosing 
IL-33 was administered to mice as in Figure 5.8. BAL was collected and cytokines and chemokines 
assayed by multiplexed immunoassay or ELISA. Results are shown as the mean of each group of 
mice +/- SEM. n=5 mice. 
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Figure 5.11 - Change in serum cytokines and chemokines with repeated IL-33 dosing 
IL-33  was  administered  to  mice  as  in  Figure  5.8.  Serum  was  collected  and  cytokines  and 
chemokines assayed by multiplexed immunoassay or ELISA. Results are shown as the mean of 
each group of mice +/- SEM. n=5 mice. 
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5.2.4 A three dose protocol for the study of IL-33 in C57Bl/6 mice 
Using the data from the previous dose response and time course experiments we 
designed  a  model  to  utilise  for  subsequent  experiments.  In  Figure  5.9  the 
midpoint of the eosinophil response occurred three days after the last intranasal 
IL-33  dose.  Given  that  eosinophil  numbers  continue  to  rise  after  dosing  is 
completed we reduced the number of doses from four to three. This also had 
advantages in terms of reducing both the demands upon the limited supply of IL-
33  and  the  number  of  procedures  mice  were  subjected  to,  improving  animal 
welfare. The final protocol of three doses followed by a cull three days later is 
shown in Figure 5.12. 
Figure 5.13 demonstrated that this protocol did induce a moderate eosinophilia 
of 10x10
5/ml or 60%  (Figure  5.13). The magnitude of this is not dramatically 
greater than that seen in the asthma models in Chapter 4, but is significantly 
less than that seen with seven doses of IL-33 (Figure 5.1). Lung eosinophilia was 
also  evident  on  histology  (Figure  5.14).  This  protocol  was  then  used  for 
subsequent studies. Chapter 5:  197 
 
 
 
Figure 5.12 – Final protocol for intranasal IL-33 administration 
2 µg of recombinant murine IL-33 was administered via the intranasal route once daily on days 1 
to 3. Mice were culled on day 6. 
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Figure 5.13 – BAL eosinophilia is induced by the modified IL-33 administration protocol 
C57BL/6 mice received recombinant murine IL-33 as in Figure 5.12. (A) Total cell counts were 
performed upon BAL. (B,C) BAL differential counts were performed. Results are shown as the 
mean of each group of mice +/- SEM. n=5 mice. Chapter 5:  198 
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Figure 5.14 –Lung Inflammation is induced by the modified IL-33 administration protocol 
PBS or IL-33 was administered to mice as in Figure 5.12. Lungs were fixed in formalin and stained 
with H&E. Panels shown are representative sections. Chapter 5:  199 
5.2.5 The effect of IL-33 in BALB/c mice 
As discussed in Chapter 1 there can often be significant differences between 
different strains of mice. I initially chose to study the effect of IL-33 on the 
airways of C57Bl/6 mice for two reasons. This was the strain proven to respond 
to  intraperitoneal  IL-33,  and  mast  cell  deficient  mice  are  available  on  this 
background. 
Before proceeding further it was important to determine the specificity of the 
observed effects of IL-33 for ST2. In Chapter 3 I demonstrated that the effect of 
IL-33 on mast cells in vitro was completely ST2 dependent. To confirm that the 
in vivo effects are mediated via ST2 I planned to utilise ST2
-/- mice. The ST2
-/- 
mice I had access to were on the BALB/c background. Therefore I needed to test 
the effect of IL-33 on mice from this background. 
The administration of IL-33 into the lungs of BALB/c mice resulted in a rise in 
total cell numbers within the BAL (Figure 5.15A), as well as eosinophil numbers 
(Figure 5.15B). The other cell types detected in the BAL were predominantly 
macrophages, with a very small proportion of neutrophils (Figure 5.15C). Chapter 5:  200 
 
A              B 
Total Count
0
1
2
3
4
5
6
PBS IL-33
c
e
l
l
s
 
(
X
1
0
5
)
*
Eosinophils
0.0
0.5
1.0
1.5
2.0
2.5
PBS IL-33
c
e
l
l
s
 
(
X
1
0
5
)
**
 
 
C 
Differential Count
0
10
20
30
40
50
60
70
macrophages eosinophils neutrophils lymphocytes
p
e
r
c
e
n
t
a
g
e
 
 
Figure 5.15 – IL-33 induces airways eosinophilia in BALB/c mice 
IL-33  (■)  or  PBS  (□)  was  administered  to  mice  as  in  Figure  5.12.  (A)  Total  cell  counts  were 
performed upon BAL. (B,C) BAL differential counts were performed. Results are shown as the 
mean of each group of mice +/- SEM. n=5 mice. * p<0.05, ** p<0.01 compared with PBS  Chapter 5:  201 
5.2.6 The role of ST2 in IL-33 induced inflammation 
In order to confirm the specificity of IL-33 for ST2 in vivo I employed ST2
-/- mice 
on a BALB/c background. 
IL-33 was administered to wild type (WT) and ST2
-/- mice. As expected a robust 
eosinophilia was generated in the BAL of WT mice (Figure 5.17). In ST2
-/- mice 
the total cell count was similar to that in PBS treated mice, and there was a 
complete  absence  of  eosinophils.  The  same  was  true  of  lung  histology,  with 
eosinophilic inflammation induced in WT but not ST2
-/- mice (Figure 5.17). 
This  confirms  that  IL-33  is  acting  exclusively  through  the  ST2  receptor  to 
mediate the inflammatory effects seen in the lungs  in vivo. It also serves to 
verify that the phenomena observed are not due to contamination by other bio-
active material of the IL-33, which is produced within our laboratory. Chapter 5:  202 
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Figure 5.16 – IL-33 induced BAL eosinophilia is ST2 specific 
IL-33 or PBS was administered to wild type (WT) or ST2
-/- mice as in  Figure  5.12. Total and 
differential cell counts were performed upon BAL. Results are shown as the mean of each group 
of mice +/- SEM. n=5 mice. * p<0.05, ** p<0.01 compared with PBS. Chapter 5:  203 
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Figure 5.17 – IL-33 induced lung inflammation is ST2 specific 
IL-33 or PBS was administered to wild type (WT) or ST2
-/- mice as in Figure 5.12. Lungs were 
fixed in formalin and stained with H&E. Panels shown are representative sections.  Chapter 5:  204 
5.3 The effect of IL-33 on airways hyperresponsiveness 
The  data  here  demonstrate  that  IL-33  can  induce  eosinophilic  airways 
inflammation similar in nature to that seen in models of asthma, although of a 
greater magnitude than is generally seen in such models. One of the other key 
features  of  experimental  asthma  is  the  development  of  AHR.  As  discussed  in 
Chapter 1 eosinophilia and AHR do not always accompany each other and are 
regulated by different mechanisms. I therefore wanted to establish if IL-33 could 
induce airways eosinophilia alone, or both eosinophilia and AHR. 
5.3.1 Airways hyperresponsiveness following three doses of IL-33 
Given that I planned to assess the contribution of mast cells play to the effects 
of  IL-33  in  vivo  I  began  by  testing  the  attenuated  three  dose  protocol  I  had 
developed for use in C57Bl/6 mice (Figure 5.12). 
As shown in Figure 5.18A there was a complete failure of IL-33 to generate AHR. 
While it is certainly possible to induce AHR in C57Bl/6 mice with a number of 
asthma protocols, it is well know that they have a tendency to display reduced 
spontaneous(50,53)  and  induced  AHR(21,50,54).  Consequently  I  went  on  to 
examine the effect of IL-33 on AHR in BALB/c mice. 
While  IL-33  did  appear  to  enhance  AHR  in  BALB/c  mice  this  result  was  not 
statistically significant (Figure 5.18B). ST2
-/- mice were also used to confirm the 
specificity of any observed effect. The dose response curve to methacholine for 
ST2
-/-  mice  mirrored  that  seen  with  PBS  in  wild  type  mice,  supporting  the 
hypothesis that the effects of IL-33 are once again ST2 dependent. 
The failure to demonstrate statistical significance in the wild type BALB/c mice 
treated with IL-33 may be in part due to the small group size used. It is also 
possible that the magnitude of the response is attenuated by the fact that the 
protocol  involves  a  delay  of  three  days  from  the  last  intranasal  IL-33 
administration. While I have demonstrated that eosinophilia persists for many 
days after treatment this may not be true of AHR.  Chapter 5:  205 
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Figure 5.18 – IL-33 induces a trend towards AHR in BALB/c but not C57Bl/6 mice 
(A)  IL-33  or  PBS  was  administered  to  wild  type  C57Bl/6  mice  as  in  Figure  5.12.  AHR  was 
measured by Penh on day 6 (B) Wildtype or ST2
-/- BALB/c mice were similarly treated. Results 
are shown as the mean of each group of mice +/- SEM. n=4-5 mice. 
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5.3.2 Airways  hyperresponsiveness  following  seven  doses  of    
IL-33 
Given the failure to generate statistically significant AHR in either strain of mice 
using  the  attenuated  protocol  I  investigated  whether  seven  consecutive 
administrations of IL-33, which induces a profound BAL eosinophilia (see Figure 
5.1A), would be capable of inducing AHR, measured the day after the final dose. 
I  chose to study both C57Bl/6 mice,  due to the background of the mast cell 
deficient strain, and BALB/c mice, due to the encouraging results in the three 
dose  protocol.  Based  on  the  data  from  the  three  day  protocol  a  power 
calculation  with  a  power  of  0.95  for  a  result  with  a  significance  of  0.05 
recommended a group size of 11 and group sizes were increased accordingly. 
Once again AHR in C57Bl/6 mice was unchanged between the PBS group and the 
treatment group despite the increased IL-33 dose, reduced time from dosing to 
AHR measurement, and increased group size (Figure 5.19A). 
In  BALB/c  mice  AHR  was  induced  by  treatment  with  IL-33,  and  this  became 
statistically significant at all does of methacholine (Figure 5.19B). Also shown in 
the graph is the response curve for mice in which experimental asthma had been 
induced using the 12 day protocol (Figure 4.8) which I had previously found to 
generate  AHR  as  effectively  as  the  more  traditional  28  day  protocol  (Figure 
4.11). This serves to demonstrate that the degree of AHR generated by IL-33 is 
very similar to that seen in allergic airways disease. Chapter 5:  207 
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Figure 5.19 – IL-33 induces significant AHR in BALB/c but not C57Bl/6 mice 
(A) IL-33 or PBS was administered to wild type C57Bl/6 mice as in Figure 5.1. AHR was measured 
by Penh on day 6 (B) Wild type BALB/c mice were similarly treated. Asthma was also induced in 
wild type BALB/c mice as in Figure 4.8. Results are shown as the mean of each group of mice +/- 
SEM. n=8-12 mice. Two-way ANOVA p<0.001 BALB/c PBS vs IL-33. 
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5.3.3 Study of the seven day protocol in BALB/c and C57Bl/6 mice 
Although eosinophilia and AHR are not always associated, as discussed in Chapter 
1, it seemed possible that the magnitude of the response to IL-33 in BALB/c 
mice, which are predisposed towards Th2 responses(510,511), might be greater 
in terms of both eosinophilic inflammation and AHR. Given that the difference in 
AHR between the two strains was most marked following seven doses of IL-33 I 
performed  a  direct  comparison  between  BALB/c  and  C57Bl/6  mice  using  this 
protocol. 
Figure 5.20 shows that the magnitude and nature of the inflammatory response 
generated in the BAL is identical in BALB/c and C57Bl/6 mice. Therefore there is 
a marked dissociation between AHR and eosinophilia.  Chapter 5:  209 
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Figure 5.20 – IL-33 induced inflammation is equal in BALB/c and C57Bl/6 mice 
IL-33 (■) or PBS (□) was administered to BALB/c and C57Bl/6 mice mice as in Figure 5.1. Total 
and differential cell counts were performed upon BAL. Results are shown as the mean of each 
group of mice +/- SEM. n=8 mice. 
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5.4 The role of mast cells in the response to IL-33 
It is unclear why IL-33 failed to generate AHR in C57Bl/6 mice, despite a robust 
eosinophil response identical to that seen in the BALB/c mice, in which AHR is 
generated. While the failure may be due to the intrinsically reduced AHR seen in 
C57Bl/6 mice rather than a specific difference in the response to IL-33, it is 
generally possible to induce AHR in these mice with the appropriate protocols. 
Therefore I hypothesised that there may be a difference in the response to IL-33 
at  a  cellular  level.  Given  the  response  of  BALB/c  mast  cells  to  IL-33 
demonstrated in Chapter 3 I asked whether this response was affected by mouse 
strain. There is already evidence of functional differences in mast cells between 
these strains, including a deficiency in mast cell protease 7 in C57Bl/6 mice(56) 
and differences in mediator release upon FcεR cross-linking(512).  
5.4.1 Strain differences in bone marrow mast cell development 
Bone marrow mast cells were cultured in parallel from wild type C57Bl/6 and 
BALB/c  mice  for  7  weeks  with  SCF  and  IL-3  as  detailed  previously.  Before 
studying  the  effect  of  IL-33  I  looked  for  phenotypical  differences  between 
BALB/c and C57Bl/6 BMMCs. Due to the prolonged culture time I was unable to 
make robust comparisons of growth rates, but there was a suggestion that the 
C57Bl/6 population grew more slowly (data not shown). 
C57Bl/6 mast cells appeared to mature more rapidly than BALB/c mast cells. At 
5 weeks, 93% of C57Bl/6 cells were double positive for both c-kit and FcεRIα, 
compared with 83% of BALB/c cells at the same time point (Figure 5.21). The 
level of c-kit expression was similar at 98% and 99% respectively. ST2 expression 
was also similar for both strains. By 8 weeks of culture BMMCs from both strains 
were at least 95% c-kit
+ and 90% FcεRIα
+. 
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Figure 5.21 – C57Bl/6 BMMCs mature more rapidly than those from BALB/c mice 
The surface expression of c-kit, FcεRIα and ST2 on 5 week old BALB/c and C57Bl/6 BMMCs was 
analysed by FACS. 
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5.4.2 Strain differences in the effect of IL-33 on mast cells 
To  assess  whether  mature  BMMCs  from  these  two  strains  of  mice  responded 
similarly  to  IL-33  C57Bl/6  and  BALB/c BMMCs  were  simultaneously  stimulated 
and the following cytokines and chemokines measured. MIP-1α was measured as I 
had consistently detected it at the highest concentrations from IL-33 stimulated 
BALB/c BMMCs. IL-13 was selected as it was also released by BALB/c BMMCs, was 
detected at the highest concentrations in the BAL of IL-33 treated mice, and 
plays a key role in the generation of AHR in asthma, as discussed in Chapter 1. 
Despite  the  previous  lack  of  induction  from  BALB/c  BMMCs  eotaxin-1  and 
eotaxin-2 were also measured as they are potently induced by intranasal IL-33, 
and are important chemokines in eosinophil migration. 
IL-13 was induced at low levels from BALB/c BMMCs stimulated with IL-33, but at 
higher  levels  from  C57Bl/6  BMMCs,  particularly  when  IL-33  was  used  at  a 
concentration of 100 ng/ml (Figure  5.22).  MIP-1 was more potently induced 
from  both  strains  of  mast  cells,  but  was  again  released  at  markedly  higher 
concentrations from C57Bl/6 than BALB/c BMMCs. Eotaxin-1 and eotaxin-2 were 
undetectable in supernatants of IL-33 stimulated BMMCs of either strain (data 
not shown). Given the failure to demonstrate a difference in the cytokines or 
chemokines produced which might account for the enhanced AHR in BALB/c mice 
a small number of samples were screened by multiplexed immunoassay. IL-6 and 
GM-CSF were detected at high  concentrations,  but as with IL-13 and MIP-1, 
were  higher  from  C57Bl/6  than  BALB/c  BMMCs.  None  of  the  cytokines  or 
chemokines assayed were released at higher concentrations from BALB/c than 
C57Bl/6 BMMCs (data not shown). 
These data do not support a strain difference in mast cell chemokine or cytokine 
release as the explanation for the enhanced AHR in BALB/c mice. Chapter 5:  213 
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Figure 5.22 – C57Bl/6 BMMCs are more responsive to IL-33 than those from BALB/c mice 
Mature WT BMMCs from C57Bl/6 and BALB/c mice at a concentration of 1x10
6/ml were cultured 
in duplicate with mIL-33 at between 10 and 100 ng/ml and aliquots of the supernatant were 
harvested at 24 hours. MIP-1α and IL-13 were measured by ELISA. Results are shown as the mean 
of duplicate culture wells +/- SEM. Two-way ANOVA for the effect of strain on IL-13 p<0.001, on 
MIP-1α p<0.001. 
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5.4.3 The role of mast cells in the response to intranasal IL-33 
I have demonstrated that IL-33 has potent activity within the lung, generating a 
marked  eosinophilia  in  addition  to  AHR  in  BALB/c  mice,  two  key  features  of 
asthma. While I could find no evidence of a mast cell basis for the difference in 
AHR between strains of mouse, mast cells are still a strong candidate as the first 
line  cells  responding  to  IL-33  administered  to  the  lungs.  They  are  the  most 
strongly ST2 positive of all cells studied thus far. I have shown they produce pro-
inflammatory cytokines and chemokines in response to IL-33, including the Th2 
cytokine linked to AHR, IL-13. They are essential for AHR and eosinophilia in 
adjuvant  free  models  of  asthma(162)  where  I  have  found  that  ST2  is  also 
essential. 
This led me to the hypothesis that in asthma IL-33 is released locally and acts on 
mast  cells  which  in  turn  release  mediators  to  induce  AHR  and  eosinophil 
recruitment. 
Having demonstrated that IL-33 can induce the features of experimental asthma 
when delivered to the lungs the question remained as to whether these effects 
are  mediated  by  ST2  on  mast  cells.  In  order  to  answer  this  question  I 
administered IL-33 to the lungs of mast cell deficient, W-Sh mice. As discussed in 
Chapter  2  these  mice  are  profoundly  mast  cell  deficient  with  no  mast  cells 
detectable  in  the  lungs(426,427).  Having  developed  an  attenuated  dosing 
schedule to improve the chances of detecting any contribution by mast cells to 
the inflammatory response to IL-33, I used this three dose protocol in C57Bl/6 
wild type and W-Sh mice. 
When IL-33 was administered intranasally mast cell deficiency had no impact on 
the total cell count or the extent of eosinophilia generated in the BAL (Figure 
5.23). The accumulation of other cell types was similarly unaffected. 
Since I had only been able generate AHR in BALB/c mice, a background on which 
there  are  no  mast  cell  deficient  strains,  it  was  not  possible  to  assess  the 
importance of masts cells in IL-33 induced AHR. Chapter 5:  215 
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Figure 5.23 – IL-33 induced inflammation is unaffected by mast cell deficiency. 
IL-33 was administered to C57Bl/6 mice wild type (■) or W-sh (□) mice as in Figure 5.12. Total 
and differential cell counts were performed upon BAL. Results are shown as the mean of each 
group of mice +/- SEM. n=5 mice. Chapter 5:  216 
5.5 Conclusion 
The  data in  this  chapter  demonstrate  that  IL-33  has  a  profound  effect  when 
administered  directly  into  the  airways,  inducing  the  key  features  of 
experimental asthma. Based on the initial dosing regime utilised by Schmitz et al 
for  intraperitoneal  administration(323)  I  demonstrated  that  following  seven 
doses of intranasal IL-33 a marked eosinophilia is generated within the BAL and 
lung parenchyma. 
In  order  to  better  understand  the  events  which  led  to  pulmonary  eosinophil 
accumulation time course experiments were carried out. When repeated doses 
of IL-33 were administered eosinophils were not detected in the BAL until three 
days after the initial dose, but increased steadily to a very high cell count after 
seven  days.  In  models  of  asthma,  eosinophils  accumulate  within  24  hours  of 
initial  challenge,  as  demonstrated  in  Chapter  4.  Although  it  is  possible  that 
antigen sensitisation in these models somehow primes or mobilises eosinophils, 
in  studies  administering  recombinant  cytokines  such  as  IL-5  and  eotaxin-1  to 
naïve  animals,  eosinophils  also  begin  to  appear  in  the  BAL  within  24 
hours(513,514). The three day delay I observed in accumulation within the lungs 
suggests that the effect of IL-33 on eosinophils is indirect. In the time course 
experiments eotaxin-1 and eotaxin-2 are also undetectable until after the third 
dose.  The  correlation  between  eotaxin  detection  and  initial  eosinophil 
accumulation  suggests  that  this  release  of  eotaxin-1  and  eotaxin-2  may  be 
responsible for recruiting the eosinophils to the lungs.  The eotaxins certainly 
have  the  potential  to  recruit  eosinophils,  and  play  an  important  part  in  the 
eosinophilia  that  is  seen  is  experimental  asthma(179,260,266-268,514).  Given 
that eosinophils themselves can produce eotaxin(515) one other possibility would 
be that the eosinophils are recruited by another mechanism and then they are 
responsible for the release of the eotaxins detected. The Th2 cytokines IL-5 and 
IL-13  were  not  present  within  the  BAL  until  24  hours  after  eosinophils  and 
eotaxins  were  detected  suggesting  that  Th2  cytokine  production  is  not  the 
initiating factor responsible for eosinophil recruitment. It is possible that the 
converse is true and that eosinophil recruitment is required for Th2 cytokine 
production,  and there is evidence from eosinophil deficient mice that this is the 
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When  four  doses  of  IL-33  were  given  there  were  still  a  high  number  of 
eosinophils within the BAL eight days after the final administration. In models of 
asthma eosinophil numbers are generally very low by seven days after cessation 
of antigen challenge(492,493). While one must be cautious in interpreting the 
limited  time  course  data  available  they  raise  the  possibility  that  an  initial 
release  of  IL-33  may  be  sufficient  to  initiate  an  inflammatory  process  which 
becomes  self-sustaining.  To  test  the  hypothesis  that  a  limited  number  of 
administrations  of  IL-33  induces  persistent  inflammation,  and  perhaps  airway 
remodelling, it would be necessary to obtain BAL and histological samples at 
time points many days after initial IL-33 treatment.  
After  initially  studying  C57Bl/6  mice  I  went  on  to  demonstrate  that  airways 
eosinophilia  was  also  generated  in  BALB/c  mice,  and  that  the  extent  of 
inflammation was unaffected in by strain, despite the preponderance for Th2 
responses generally seen in BALB/c mice(510,511). By using BALB/c mice it was 
also  possible  to  confirm  that  IL-33  had  no  effect  in  ST2
-/-  mice.  This 
demonstrated for the first time that the effects of IL-33 in vivo are mediated via 
ST2 alone. It also served to confirm that all the phenomena observed were due 
to a specific effect of IL-33 rather than any possible contaminant. 
Using BALB/c mice I have demonstrated that the administration of IL-33 to the 
lungs induces AHR. When studied initially in a protocol where 3 doses of IL-33 
where followed by a delay of 3 days AHR appeared to be induced, but the effect 
did not reach statistical significance. This failure to reach significance may be 
due to the delay between the final administration and measurement of AHR, 
although in models of asthma in BALB/c mice AHR can persist for up to seven 
days after antigen challenge(492). Alternatively this failure may have been due 
to the small group size, with only four to five mice in each group. When AHR was 
studied in BALB/c mice 24 hours after a seventh dose of IL-33, using eight to 
twelve  mice  per  group,  there  was  a  statistically  significant  increase  with 
methacholine doses as low as 12.5 mg/ml. The magnitude of AHR generated was 
similar to that seen in a model of asthma. 
In C57Bl/6 mice there was no evidence of IL-33 induced AHR regardless of the 
protocol used. Given that the extent of eosinophilia induced is the same in both 
strains it seems unlikely to be due to a fundamental inability of C57Bl/6 mice to Chapter 5:  218 
respond to IL-33. The dissociation of eosinophilia and AHR is not unprecedented 
as  AHR  occurs  alone  in  some  IL-5  knock-out  asthma  studies  and  eosinophilia 
alone in some IL-13 knock-out studies(100,225,228). 
I could find no evidence that the strain difference in the response to IL-33 was 
due  to  different  responses  of  mast  cells  to  IL-33.  However  as  mentioned 
previously there are reported functional differences in mast cells between these 
strains (56,512). Having been unable to induce BALB/c mast cell degranulation 
with IL-33 I did not study this in C57Bl/6 mice, although building on the data in 
Chapter 3 others within our research group have gone on to demonstrate that IL-
33 can induce the degranulation of IgE primed mast cells in vitro(449). 
Another possible reason for the failure to generate AHR in C57Bl/6 mice might 
relate  to  the  use  of  Penh.  It  has  been  demonstrated  that  the  correlation 
between Penh and other invasive measures of AHR is not as strong in C57Bl/6 
mice  as  it  is  in  BALB/c  mice(516,517).  There is  now  one  published  report  in 
which IL-33 appeared to generate AHR in C57Bl/6 mice as measured by Penh, 
however the was no measure of variance reported and no attempt at statistical 
analysis(447).  There  has  since  been  data  presented  at  the  recent  American 
Thoracic  Society  conference  in  2009  showing  that  IL-33  can  induce  AHR  in 
C57Bl/6 mice(518). IL-33 was used at a higher dose than I used (5 µg) and AHR 
was measured invasively. 
My hypothesis was that the activation of mast cells via ST2 would be responsible 
for the effects if IL-33 in the lungs in vivo. Using mast cell deficient W-sh mice I 
have demonstrated that there is no requirement for mast cells in IL-33 induced 
pulmonary eosinophilia. Due to the failure to generate AHR in C57Bl/6 mice I 
was  unable  to  utilise  W-sh  mice  to  assess  the  contribution  of  mast  cells. 
However in the recent abstract mentioned above not only did IL-33 treatment 
result in increased concentrations of mast cell protease within the BAL, but AHR 
was induced in wild type but not mast cell deficient mice(518). 
In summary I have demonstrated that IL-33 acts in an ST2-dependent manner to 
induce two of the key features of asthma; pulmonary eosinophilia and AHR. This 
provides further evidence that the ST2-IL-33 axis may play an important role in 
clinical asthma.   
 
 
 
 
 
 
Chapter 6   
 
General Discussion Chapter 6:  220 
While the contribution of Th2 inflammation in asthma is accepted, the function 
of different cells and cytokines at different stages of disease development and 
resolution  remains  unclear.  Key questions  include the  role of mast  cells,  the 
relationship  between  structural  cells  and  inflammatory  cells  and  the  factors 
involved in the initiation of asthma. In the context of the emerging role of ST2 in 
allergic  inflammation  and  the  discovery  of  IL-33,  the  ligand  for  ST2  and  an 
inducer of Th2 inflammation, at the outset of this thesis I set out the hypothesis 
that „the activation of ST2 on mast cells by IL-33 plays an important role in 
allergic airways inflammation‟. 
My aims were to test this hypothesis by meeting three objectives; to assess the 
effect of IL-33 on mast cells  in vitro, to study the requirement for ST2 in a 
murine model of asthma, and to examine the effect of IL-33 administration to 
the airways. A summary of my findings and their interpretation is below. 
6.1 Summary of results 
I addressed the first of these aims in Chapter 3, where I demonstrated that ST2 
was expressed at high levels from a very early stage of mast cell development in 
vitro and correlated closely with expression of the early mast cell marker c-kit. 
Despite this, the absence of ST2 did not alter the growth or maturation of mast 
cells from the bone marrow of ST2 gene-deleted mice in vitro, implying that IL-
33  does  not  play  an  essential  role  in  mast  cell  development.  Mast  cells 
stimulated  with  IL-33  released  a  number  of  pro-inflammatory  mediators, 
specifically the pro-inflammatory cytokine IL-6, the Th2 cytokine IL-13 and the 
chemokines  MIP-1α  and  MCP-1,  and  at  times  the  growth  factors  GM-CSF  and 
VEGF. I was also able to utilise ST2
-/- mast cells to confirm the ST2 specificity of 
this effect. 
Having demonstrated the pro-inflammatory effect of IL-33 in vitro I went on to 
study the role if ST2 in experimental asthma in Chapter 4. I began by optimising 
and validating a short model of asthma in mice and used this to demonstrate for 
the first time that ST2 gene deficiency could attenuate allergic inflammation. To 
try and understand the discrepancy between this finding and those published 
using other models of asthma(381,383) I went on to compare the requirement 
for ST2 between a mast cell dependent and a mast cell independent model of Chapter 6:  221 
asthma.  As  others  had  reported(381,383),  I  demonstrated  that  ST2  gene 
deficiency did not attenuate AHR or inflammation in a mast cell independent 
model of asthma in which mice were immunised with OVA and alum. However 
when mice were immunised with OVA alone, a protocol which has been shown to 
confer mast cell dependence(162,163), ST2 deficiency had no impact on AHR but 
resulted  in  a  significant  reduction  in  eosinophilic  inflammation.  This  was 
associated with a specific reduction in IgE and reduced Th2 cytokine production 
by draining lymph node cells. 
In Chapter 5, I went on to study the effect of ST2 activation in the airways by 
the direct administration of IL-33. Intranasal IL-33 induced a dramatic and long 
lasting airways eosinophilia as well as generating AHR, two of the key features of 
murine models of asthma. Using ST2
-/- mice it was possible to demonstrate that 
these effects were specific for ST2. Based on the effect of IL-33 on mast cells 
demonstrated in Chapter 3 and the requirement for ST2 in a mast cell dependent 
model of asthma reported in Chapter 4 I  formulated the hypothesis that the 
effect of IL-33 administration to the airways was mediated by the activation of 
ST2  on  mast  cells.  However  when  I  tested  this  hypothesis  using  mast  cell 
deficient mice, there was no impact on eosinophil recruitment, demonstrating 
that  this  component  of  inflammation  was  induced  by  IL-33  in  a  mast  cell 
independent manner. Due to the fact that AHR was only generated in BALB/c 
mice  it  was  not  possible  to  assess  the  contribution  of  mast  cells  to  this 
phenomenon. 
In order to interpret these findings in the context of asthma it is necessary to 
consider the potential source of biologically active IL-33 and the effects it is 
likely to have at a cellular level. 
6.2 The cellular source of IL-33 
While Schmitz et al published data on the expression of IL-33 RNA in a number of 
cells and tissues in their initial report(323), any data on the detection of IL-33 
protein  was  limited  until  very  recently.  This  is  due  in  part  to  the  lack  of 
available reagents but primarily to the apparent scarcity of extracellular IL-33 
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The first studies to detect IL-33 protein did so by immunohistochemistry, with 
the  earliest  report  identifying  nuclear  localisation  within  epithelial  cells  of 
tonsillar  HEVs(417),  specialized  blood  vessels  which  mediate  lymphocyte 
recruitment into lymphoid organs. The investigators referred to the protein as 
nuclear  factor  from  HEV  (NF-HEV)  as  this  report  predated  the  formal 
characterisation of the protein as IL-33 by two years. This finding has since been 
confirmed  by  others(418,519)  and  IL-33  has  been  identified  by 
immunohistochemistry  in  other  vascular  endothelial  cells(520-523)  as  well  as 
fibroblasts(407,521,523) and epithelial cells(521).  
Despite these findings doubt remained as to whether IL-33 was ever released 
from cells. IL-33 contains a DNA-binding domain and both naturally occurring and 
transfected IL-33 localises to the nucleus (417,418,519,521). Also, even though a 
commercial IL-33 ELISA eventually became available we and others struggled to 
detect  IL-33  in  a  number  of  in  vivo  and  in  vitro  settings.  It  was  originally 
proposed that as IL-33 was an IL-1 family member it would be processed for 
secretion in a similar manner to IL-1β(323), which is activated by the cleavage of 
pro-IL-β by caspase-1(524). However, as discussed in Chapter 1, while Schmitz et 
al showed that IL-33 could be cleaved by caspase-1 in vitro it does not have a 
classical caspase-1 cleavage site. 
Four papers published within the last few months have greatly enhanced our 
understanding of IL-33 processing. While three of these studies confirmed that 
IL-33 could be cleaved by caspase-1, cleavage was shown to be inefficient as 
compared  with  the  cleavage  of  IL-1β,  and  very  limited  when  physiological 
concentrations of caspase-1 were used(525-527).  Furthermore in a stringently 
controlled setting where all other proteases were eliminated caspase-1 failed to 
cleave IL-33(526), suggesting that any cleavage by caspase-1 may be due to the 
ability of caspase-1 to activate other proteases(528). However IL-33 did appear 
to  be  cleaved  more effectively  by  caspase-7  and  to  a  lesser  extent caspase-
3(525,527). A separate study using inhibitors suggested that LPS induced IL-33 
cleavage was mediated by calpain rather than caspase-1(529). The other novel 
finding was that the cleavage site for these caspases was within the IL-1 like 
domain, therefore neither of the cleavage products corresponded to so called 
“mature IL-33” and both were biologically inactive(525,527). This cleavage of IL-
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to  avoid  the  release  of  potentially  bio-active  IL-33  during  programmed  cell 
death. 
These  data  do  not  support the theory  that  active  IL-33  is  released  upon the 
cleavage  of  “pro-IL-33”  to  “mature  IL-33”  by  caspase-1  and  therefore  led 
investigators to study the properties of full length “pro-IL-33”. It has now been 
convincingly demonstrated that full length IL-33 is biologically active in vitro 
(525-527). These recent findings have led to a revision of the theory regarding 
IL-33 processing and release. 
Two other molecules with similarities to IL-33 are High Mobility Group Box 1 
(HMGB1)  and  IL-1α. HMGB1  is  generally  found  within  the nucleus  and affects 
transcriptional regulation. HMGB1 can also act via pattern recognition receptors 
such  as  RAGE(530)  and  TLRs(531)  to  mediate  a  number  of  pro-inflammatory 
effects  on  macrophages,  neutrophils,  T  cells  and  endothelial  cells  including 
cytokine  secretion  and  upregulation  of  surface  receptors(532).  Like  IL-33, 
HMGB1 is inactivated during apoptosis(533). While HMGB1 can be secreted by 
non-classical pathways similarly to IL-1β(534,535), it is well recognised for being 
released by necrotic cells(536). 
IL-1α is synthesised as a precursor, pro-IL-1α which is targeted to the nucleus by 
nuclear localisation sequence within the pro-domain(537), although the function 
of nuclear IL-1α remains unknown. While there is also uncertainty regarding the 
active  secretion  of  IL-1α(538,539),  it  is  clear  that  IL-1α  is  released  by  cell 
necrosis(540,541). IL-1α and IL-1β both act via the IL-1 receptor with identical 
biological effects and are collectively referred to as IL-1. IL-1 is a classical pro-
inflammatory cytokine with wide ranging effects including the induction of nitric 
oxide  and  eicosanoid  synthesis,  triggering  of  the  acute  phase  response,  the 
release  of  a  wide  number  of  other  cytokines  and  chemokines  and  the 
upregulation of adhesion molecules(542,543). 
The  concept  that  the  specific  immune  response  can  be  activated  by  the 
presence of „danger signals‟ was formalised with the discovery of receptors for 
exogenous  pathogen-associated  molecular  patterns  (PAMPs),  such  as  the  TLRs 
and  NOD-like  receptors  (NLRs).  More  recently  it  has  been  suggested  the 
endogenous „danger signals‟ released in response to tissue injury and necrosis be 
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of damage-associated molecular patterns, or DAMPs(544,545). Both HMGB1 and 
IL-1α have been classed as alarmins due to the fact that they are released by 
necrotic  but  not  apoptotic  cells  and  act  to  recruit  and  activate  immune 
cells(544,545). 
It now appears that IL-33 is also a member of this family. In addition to the 
other characteristics shared with HMGB1 and IL-1α, several investigators have 
been  able  to  detect  IL-33  protein  release  from  damaged  or  necrosed 
cells(525,527,529).  Similarly  to  HMGB1,  there  is  also  data  to  show  that 
proinflammatory signals such as TLR agonists or cytokine cocktails can induce 
the  release  of  full  length  IL-33(503,526,546,547),  although  the  possible 
contribution  of  cell  necrosis  was  not  assessed  in  these  experiments.    The 
potential role of IL-33 as an alarmin released upon tissue damage may explain 
why the main sites of IL-33 protein detection have been within structural cells 
such as endothelial cells, fibroblasts and epithelial cells. This may also account 
for the recent detection of IL-33 protein in the damaged tissues from diseases 
such as rheumatoid arthritis(523,548) and dermatitis(449). 
6.3 Cellular targets of IL-33 
At the outset of this research a number of cells were known to express ST2 on 
their surface but there was almost no data on the functional effect of IL-33 upon 
cells in vitro. Schmitz et al had demonstrated that IL-33 enhanced IL-5 and IL-13 
production by  Th2  cells  and  activated  signalling  pathways  in  mast  cells(323). 
Since then IL-33 has been shown to have effects on a wide range of different 
cells. 
In Chapter 3 I demonstrated that IL-33 could activate mast cells to release pro-
inflammatory cytokines from murine mast cells. This has since been published by 
us(449) and confirmed by other investigators in both human and murine mast 
cells(443,445,447,450). Basophils are closely related to mast cells and are also 
targets of IL-33. Upon IL-33 stimulation basophils produce a number of cytokines 
and chemokines, particularly IL-4, IL-6 and IL-13, although this is generally at 
low levels unless pretreated or co-cultured with IL-3, which is required to induce 
ST2  expression(447,549-551).  IL-33  also  enhances  basophil  adhesion,  integrin 
expression, chemotaxis, degranulation and survival(549,551). Chapter 6:  225 
While  others  have  confirmed  the  finding  that  IL-33  enhances  IL-5  and  IL-13 
production by Th2 cells(550,552), our group have published data showing that IL-
33 can polarise naïve T cells to produce IL-5 and IL-13,  and that this occurs 
independently  of  IL-4,  which  is  usually  required  for  Th2  polarisation(553).  In 
addition data from our laboratory has shown that IL-33 can be chemotactic for 
Th2 cells(419). IL-33 has a less restricted effect on NK and iNKT cells, enhancing 
the release of Th2 cytokines, including IL-4, as well as Th1 cytokines(552,554). 
Both the original data published by Schmitz et al(323) and the data presented 
here show that IL-33 is a potent inducer of eosinophilia in vivo. Eosinophils do 
not  appear  to  express  surface  ST2,  although  it  can  be  induced  by  GM-
CSF(550,555,556).  However  IL-33  is  active  on  eosinophils,  inducing  IL-8  and 
superoxide  production,  upregulating  adhesion  molecules,  enhancing  adhesion 
and  prolonging  survival(550,555,556).  It  does  not  appear  to  induce 
chemotaxis(556) and there was conflicting data regarding the ability of IL-33 to 
induce degranulation(555,556). The only granulocyte upon which IL-33 does not 
appear to have any effect is the neutrophil(550,555). 
There is also data now to demonstrate that IL-33 has effects upon cells of the 
monocytes lineage. It enhances the production of TNFα by LPS and LTA treated 
macrophages, probably by increasing receptor, co-receptor and adapter protein 
expression(557). Dendritic cells also have no detectable ST2 upon their surface 
but  respond  to  IL-33  by  upregulating  surface  HMC-II  and  costimulatory 
CD86(558). IL-33 can induce the release of IL-6 from pure DCs, and of IL-5 and 
IL-13 when co-cultured with CD4 T cells(558), possibly due to the ability of DC 
derived  IL-6  to  induce  Th2  polarisation(453).  The  lack  of  detectable  ST2 
expression on cells responding to IL-33 is likely to represent a limitation of flow 
cytometry in detecting low level expression on a small subset of cells, as there 
have been no reports of IL-33 acting in an ST2 independent manner. 
In light of all this new information on the effects of IL-33 at a cellular level, and 
the data presented in this thesis, we can postulate how IL-33 may be involved in 
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6.4 The role of IL-33 in airways inflammation 
In Chapter 5 I demonstrated that in an alum free model of asthma eosinophilia 
but not AHR was markedly reduced in the absence of ST2. This may be due to a 
requirement for ST2 at sensitisation, at challenge, or both. 
6.4.1 IL-33 at sensitisation 
In support of a role for IL-33 at sensitisation was the finding that antigen specific 
IgE was dramatically reduced in ST2
-/- mice in the alum free model, suggesting a 
primary failure of allergic sensitisation.  As discussed in Chapter 4 the use of 
alum  fundamentally  changes  the  way  antigen  is  taken  up,  transported  and 
presented(499). The action of alum is also dependent on the activation of the 
NLRP3 inflammasome(502-505). It is therefore possible that in the absence of 
alum a pathway is required which is dependent on IL-33 and ST2 for effective 
antigen presentation and T cell activation. 
In the absence of alum, antigen is taken up and presented by resident DCs in the 
local draining lymph nodes and there may be a requirement for ST2 at this point. 
IL-33 can activate DCs to upregulate costimulatory molecules(558) and drive CD4 
cell  Th2  polarisation  as  well  as  enhancing  Th2  recruitment  and  activation 
(323,419,553). 
Given the high level of ST2 expression on mast cells and the requirement for 
mast cells in this model, IL-33 induced activation of mast cells may be required 
at  sensitisation.  There  is  accumulating  evidence  that  mast  cells  can  play  an 
important role during antigen presentation. They play a significant role in lymph 
node hypertrophy during infection(559) and mast cell activation can enhanced 
DC  recruitment  and  migration  to  draining  lymph  nodes  resulting  in  the 
generation of antibodies against otherwise innocuous antigens(560). Both these 
effects were dependent on mast cell derived TNFα. Mast cells are a crucial early 
source of TNFα, being the only cells capable of releasing pre-stored TNFα(438) 
and mast cell derived TNFα is essential in alum free models of asthma(33,163). 
One could hypothesise that there are two separate pathways for the generation 
of  a  Th2  memory  response  to  antigen,  as  represented  in  Figure  6.1.  These Chapter 6:  227 
represent activation of the adaptive immune response due to the effect of two 
different types of DAMP acting initially on the innate immune system. Pathway A 
represents  the  effect  of  antigen  presented  with  a  PAMP,  in  this  case  the 
activation of the inflammasome by alum acting as an NLR agonist. In pathway B 
Th2 development is driven by the effect of activation by the „alarmin‟ IL-33. 
This may act directly on DCs and Th2 cells or indirectly via the release of TNFα 
and other mediators from mast cells. Although I found that IL-33 induced TNFα 
release  from  mast  cells  in  vitro  was  variable,  it  has  been  reported  by 
others(443,450).  
Interestingly activation of the NLRP3 inflammasome by LPS and alum resulted in 
the release of IL-33 protein from monocytic cell lines(503). The mechanism for 
this is unclear given that the majority of IL-33 detected was full length “pro-IL-
33”. This may represent some form of crosstalk between the two pathways. 
 
 
 
Figure 6.1 – Two pathways of pathogen-associated molecular pattern (PAMP) activation 
Pathway A – Alum acts as an NLR agonist to activate the NLRP3 inflammasome which in turn 
leads to the activation of T cells by dendritic cells (DC). 
Pathway  B  –  Tissue  damage  during  the  intraperitoneal  administration  of  OVA  results  in  the 
release of IL-33 which can activate DCs, Th2 cells or mast cells (MCs) directly. IL-3 induced TNFα 
from mast cells can also activate DCs. Chapter 6:  228 
In support of the role of „alarmins‟ in models utilising OVA alone is the finding 
that when mice were injected with intraperitoneal OVA alone on the right side 
of the abdomen T cell proliferation occurred in the draining lymph node at that 
side only, but when mice also received a sterile needle puncture on the other 
side  then  T  cell  proliferation  also  occurred  in  the  draining  lymph  at  that 
side(499). While the antigen could be readily available it may be that the local 
needle puncture is required to induce the co-stimulatory „alarmin‟ signal. Work 
from our laboratory has demonstrated that the injection of intraperitoneal IL-33 
at the time of sensitisation enhances the inflammatory response in an OVA/alum 
model of asthma(553). 
6.4.2 IL-33 at challenge 
Alternatively ST2 and IL-33 may be required at the time of antigen challenge. 
The  fact  that  AHR  is  preserved  even  though  eosinophilic  inflammation  is 
dramatically  reduced  suggests  that  a  memory  response  to  OVA  has  been 
generated. Studies using anti-ST2 antibodies suggest a requirement for ST2 at 
challenge. When asthma is induced by adoptive transfer of antigen specific T 
cells the administration of anti-ST2 at the time of antigen challenge results in a 
substantial reduction in BAL and lung eosinophilia and AHR(360,372). The data 
presented in Chapter  5  also  demonstrates  that  the  activation of  IL-33  in the 
airways by ST2 can induce the features of experimental asthma. The question 
remains as to which cells are respond to IL-33 in the airways to elicit airways 
inflammation and AHR.  
Given that I and others have demonstrated that IL-33 can activate mast cell to 
generate pro-inflammatory cytokines and chemokines in vitro I speculated that 
IL-33 was acting via mast cells to induce eosinophilia and AHR in vivo. However I 
have  demonstrated  that  airways  eosinophilia  is  unaffected  in  W-sh  mice. 
Although these mice may not be completely mast cell deficient there are no 
reports of mast cells being detected within the lungs and only one report of mast 
cells within the skin at 1% of normal levels(426,427). Unfortunately I was only 
able to generate significant AHR in BALB/c mice and not in C57Bl/6 mice, the 
background on which the W-sh mutation is present. This meant that it was not 
possible for me to asses any contribution of mast cells to IL-33 induced AHR. 
However others have been able to induce AHR, as measured invasively, with IL-Chapter 6:  229 
33 in C57Bl/6 mice and found that this was IL-13 dependent and was lost in the 
absence of mast cells(518). 
Th2  cells  release  IL-5  and  IL-13  in  response  to  IL-33,  and  work  from  our 
laboratory has demonstrated that such IL-33 polarised cells can be used induce 
airways inflammation in an adoptive transfer model of asthma(553). However 
studies  from  our  group  and  others  have  demonstrated  that  T  cells  are  not 
required for the induction of eosinophilic inflammation and AHR by intranasal IL-
33(G. Murphy et al unpublished)(447,518). 
It is possible that IL-33 acts directly on eosinophils themselves. Although there 
are  normally  no  eosinophils  present  in  the  lungs,  as  demonstrated  by  the 
absence  of  eosinophils  in  control  mice  in  experiments  presented  here  and 
published by others, it is possible that IL-33 acts to recruit eosinophils directly 
from the pulmonary circulation.  However, as discussed above, IL-33 does not 
appear  to  be  chemotactic  for  eosinophils(556).  The  delay  in  eosinophil 
recruitment demonstrated in Chapter 5,  with eosinophils first detected three 
days after IL-33 dosing begins, suggests a less direct effect. The appearance of 
the eosinophil chemokines eotaxin-1 and eotaxin-2 at the same time suggests 
that  these  chemokines  drive  eosinophil  recruitment.  We  have  been  able  to 
demonstrate that blocking eotaxin-1 or eotaxin-2 results in a marked reduction 
in IL-33 induced airways eosinophilia(561). 
Macrophages are the most abundant inflammatory cell within the lung and have 
been  shown  to  respond  to  respond  to  IL-33(557).  On  the  basis  of  the  data 
presented in Chapter 5, work within the laboratory has been carried to look at 
the possible role of macrophages in this response(562). IL-33 is able to synergise 
with  IL-4  or  IL-13  in  vitro  to  induce  macrophages  to  differentiate  to  the 
alternatively  activated  macrophage  (AAM)  phenotype  and  produce  eotaxin-2. 
Furthermore  intranasal  IL-33  administration  induces  AAM  development  and 
macrophage depletion attenuates eosinophilic inflammation. 
As discussed earlier it appears that, like the other „alarmins‟ IL-1α and HMGB1, 
IL-33 is released upon cell breakdown in response to injury. In addition to the 
data regarding the expression of IL-33 in vascular endothelial cells, IL-33 protein 
has  also  been  detected  in  epithelial  cells(521)  and  we  have  reported  the 
detection of IL-33 protein within the lung parenchyma(553). Chapter 6:  230 
Figure 6.2 is a schematic representation of how tissue injury within the lung 
could result in the release of IL-33 which induces eosinophilic inflammation and 
AHR by two distinct pathways. IL-33 triggers eotaxin release from alternatively 
activated macrophages which results in the recruitment of eosinophils, and mast 
cells are activated by IL-33 to induce AHR. 
 
 
 
Figure 6.2 – The release of IL-33 as an ‘alarmin’ inducing the features of asthma 
Local tissue injury in the lung results in the release of IL-33 which acts on macrophages (MO) to 
recruit eosinophils (EO) via eotaxin and on mast cells (MC) to induce airways hyperresponsiveness 
(AHR) via IL-13. 
 
6.5 IL-33 in clinical asthma 
The data presented in this thesis have been derived entirely from in vitro studies 
and in vivo animal models. The effect of IL-33 on mast cells described in Chapter 
3 has since been repeated within our group using human cord blood derived mast 
cells(449). However it is important to consider the role of the IL-33 – ST2 axis in 
the context of the intact organism in vivo. Given that it would not be practical 
or ethical to study the effect of blocking ST2 or administering IL-33 in humans, I 
have chosen to utilise mice. In Chapter 4 I demonstrated that the requirement 
for ST2 was dependent on the model of asthma used. One might criticise the 
validity of a model where such modifications can have such a dramatic impact 
on the outcome. However one of the limitations of gene-deletion studies is the 
degree of redundancy which occurs in many biological systems. It is interesting 
to note that in all studies using anti-ST2 antibodies in intact animals treatment Chapter 6:  231 
attenuated experimental asthma(298,360,372,396,492) with similar results in a 
recent study using anti-IL-33 antibody(563). It may be that the modification to 
the model is required to overcome such redundancy, perhaps by emphasising the 
contribution of mast cells. One could argue that the omission of adjuvant makes 
the model more akin to clinical asthma. 
In  Chapter  5  I  demonstrated  that  IL-33  is  a  potent  inducer  of  eosinophilic 
inflammation and AHR, and this data in combination with the work of others 
suggests that this occurs via two separate pathways. This raises the possibility 
that IL-33 has a pivotal place in the cytokine hierarchy. If IL-33 is an alarmin 
which is released by structural cells in response to tissue damage then it could 
be a key upstream mediator of inflammation and bronchospasm in asthma. IL-33 
release could be induced by bioactive allergens such as those from house dust 
mite. Such allergens have been shown to induce cytokine release from epithelial 
cells(564) and there is a preliminary report of house dust mite extract inducing 
IL-33  release  from  cultured  epithelial  cells(547).  Viral  infections  are  the 
commonest cause of exacerbations in asthma(5) and can induce the release of 
the related alarmin IL-1α from epithelial cells(565-567). It is possible that viral 
infection in asthmatic induces the release of IL-33 from infected epithelial cells 
which goes on to trigger eosinophilic inflammation and AHR as represented in 
Figure  6.2.  Once  inflammation  is  established  the  epithelial  damage  which 
characterises  asthma(57,69)  may  result  in  ongoing  IL-33  release  and  the 
perpetuation  of  asthma.  IL-33  has  recently  been  detected  at  elevated 
concentrations  from  the  lungs  in  an  model  of  asthma  seven  days  after  the 
antigen challenge(492). 
6.6 Future work 
IL-33  biology  is  a  fast  moving  area  of  research  at  present,  both  within  our 
laboratory  and  internationally,  but  there  are  a  number  of  specific  lines  of 
investigation which would advance the work presented here. 
-  In order to definitively establish whether or not the requirement for ST2 
in the alum free model is upon mast cells adoptive transfer experiments 
could  be  undertaken.  Mast  cells  can  be  restored  in  W–sh  mice  by  the 
adoptive  transfer  of  bone  marrow  derived  mast  cells(426).  It  would Chapter 6:  232 
therefore be possible to study the alum free model of asthma in W-sh 
mice  reconstituted  with  wild  type  or  ST2
-/-  mast  cells.  In  such 
reconstituted mice only the mast cells would lack ST2. 
-  Further work is required to establish the potential source and stimulus of 
IL-33  release in  the context  of  both  experimental  and clinical  asthma. 
Studies carried out in vitro on murine and human samples could establish 
whether triggers such as house dust mite and viral infection result in IL-33 
release  from  specific  cells,  particularly  epithelial  cells.  Further  animal 
studies could also establish whether these triggers resulted in the release 
of IL-33 in vivo. 
-  To begin to establish a role for IL-33 in clinical asthma it is important to 
demonstrate  that IL-33  is  elevated  in  asthma.  We  have  recently  found 
that IL-33 expression is enhanced within the epithelial cells of asthmatic 
patients(568). An important next step would be to assay the extracellular 
IL-33 in clinical samples, particularly sputum or BAL. If IL-33 is released 
from  epithelial  cells  in  response  to  allergens  or  infections  it would  be 
useful to measure IL-33 in samples collected during asthma exacerbations. 
-  Building on the data presented in Chapter 3 and some preliminary data 
not shown, others within the group have characterised the role of IL-33 
activation  in  other  models  of  allergic  inflammation(449).  IL-33  could 
induce both passive cutaneous anaphylaxis and systemic anaphylaxis in IgE 
sensitised  mice  in  the  absence  of  antigen.  This  was  mediated  by 
degranulation  of  IgE  sensitised  mast  cells.  We  have  also  demonstrated 
that the activation of mast cells by IL-33 can play a role in experimental 
arthritis(548). Chapter 6:  233 
6.7 Conclusions 
At the outset of this work there was only a single published report on IL-33 and 
very little information on the biological function of this novel cytokine. The data 
presented in this thesis is among the earliest work on IL-33. I have demonstrated 
that IL-33 administration induces pulmonary eosinophilia and AHR, that IL-33 is a 
potent activator of mast cells, and that ST2 is crucial in an adjuvant free mast 
cell dependent model of asthma, perhaps more akin to human asthma. These 
data position IL-33 as a central cytokine in allergic airways inflammation and 
hence a novel therapeutic target in clinical asthma. 
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